Multiple Cutaneous (pre)-Malignancies by Leest, R.J.T. (Robert) van der


Multiple Cutaneous (pre)-Malignancies
Robert J.T. van der Leest
The Netherlands Cancer Registry, managed by ‘Netherlands comprehensive cancer 
organisation’, was an important data source of the chapters 4, 5, 7, 9 and 10 in this thesis.
ISBN: 978-94-6169-674-8
Cover design: Marcel Ruijters
Cover Font: Puppeteer (copyright 2008 by Tjarda Koster, www.dafont.com, capital letters 
adapted by Sjoerd Hoeks).
Lay-out and Printing: Optima Grafische Communicatie, Rotterdam, The Netherlands
© R.J.T. van der Leest, 2015
All rights reserved. No part of this thesis may be reproduced, stored in a retrieval system 
or transmitted in any form or by any means, electronically or mechanically, including 
photo-copying, recording, or otherwise, without permission of the author, or when ap-
propriate, of the publishers of the publications.
Download this thesis from: http://www.e-pubs.nl/?epub=r.vanderleest
Username: r.vanderleest
Password: multiple
Multiple Cutaneous (pre)-Malignancies
Multipele cutane (pre)-maligniteiten
Proefschrift
ter verkrijging van de graad van doctor
aan de Erasmus Universiteit Rotterdam
op gezag van de rector magnificus
Prof.dr. H.A.P. Pols
en volgens besluit van het College voor Promoties.
De openbare verdediging zal plaatsvinden op
woensdag 24 juni 2015 om 11.30 uur
door
Robertus Josephus Theodorus van der Leest
geboren te Oss
PRoMoTieCoMMissie
Promotor: Prof.dr. T.E.C. Nijsten
Overige leden: Prof.dr. H.A.M. Neumann
Prof.dr. C. Verhoef
Prof.dr. H.J. de Koning
Copromotoren: Dr. E. de Vries
Dr. L.M. Hollestein
‘Voor T&T’

 7
ConTenTs
Chapter 1 Introduction 11
Part i Multiple
Chapter 2 Risk of subsequent cutaneous malignancy in patients with prior 
melanoma: a systematic review and meta-analysis.
J Eur Acad Dermatol Venereol. 2014 Dec 10.
29
Chapter 3 Risk of subsequent cutaneous malignancy in patients with prior 
keratinocyte carcinoma: a systematic review and meta-analysis.
Eur J Cancer. 2013 Jul;49(10):2365-75.
65
Chapter 4 Risk of second primary in situ and invasive melanoma in a Dutch 
population-based cohort: 1989-2008.
Br J Dermatol. 2012 Dec;167(6):1321-30.
93
Screening for second primary melanomas: is it efficient? Reply from 
authors.
Br J Dermatol. 2013 May;168(5):1135.
113
Chapter 5 Risks of different skin tumor combinations after a first melanoma, 
squamous cell carcinoma and basal cell carcinoma in Dutch 
population-based cohorts: 1989-2009.
(submitted)
119
Chapter 6 Cohort studies (and skin cancer) never come alone.
J Invest Dermatol. 2015 Mar;135(3):649-51.
137
Part ii early / Pre
Chapter 7 Time trends of thin melanomas in The Netherlands, 1994 – 2010.
(submitted)
145
Chapter 8 Prevalence of actinic keratosis and its risk factors in the general 
population: the Rotterdam Study.
J Invest Dermatol. 2013 Aug;133(8):1971-8.
167
Part iii survival
Chapter 9 Conditional survival of malignant melanoma in The Netherlands: 
1994-2008.
Eur J Cancer. 2014 Feb;50(3):602-10.
189
Chapter 10 Comparing survival of patients with single or multiple primary 
melanoma in the Netherlands: 1994-2009
(in preparation)
209
8Part iV
Chapter 11 Discussion 219
Chapter 12 Summary, Samenvatting 237
Part V Appendices
A List of abbreviations 253
B List of co-authors 255
C List of publications 259
D Curriculum Vitae 263
E Dankwoord 265
F PhD Portfolio 269
G Color section 276
 9
10
¶
1 | 11
Chapter 1
Introduction
1 | 12
1 | 13
Skin cancer, the most commonly occurring cancer in Caucasian populations, includes 
a large number of types of malignancies deriving from a myriad of different cells. The 
three most common cutaneous malignancies are derived from melanocytes and kera-
tinocytes (ordered in decreasing aggressiveness): melanoma, squamous cell carcinoma 
(SCC) and basal cell carcinoma (BCC). This thesis focuses only on these three types of 
cancer and their precursors. The majority of skin cancer patients have a relatively good 
prognosis, which has implications for treatment, follow-up strategies and risks of devel-
oping multiple cutaneous (pre)-malignancies.
Melanoma, the most aggressive type of skin cancer, develops from the pigment mela-
nin producing melanocytes, derived from the neural crest in origin, which are located in 
the stratum basale of the skin’s epidermis. Melanocytes are also present in eyes, ears, the 
heart and the central nervous system, but in these organs melanocytes rarely develop 
into malignant melanomas. Under the influence of ultraviolet radiation melanocytes 
secrete melanin pigment to numerous keratinocytes by dendritic processes and in 
this way provide some degree of solar-induced protection of genetic damage to the 
keratinocytes.
Keratinocyte carcinoma (KC)1, comprising of SCC and BCC, develops from the epithelial 
keratinocytes and usually occurs on sun-exposed skin. These cancers are often referred 
to as non-melanoma skin cancer (NMSC), although technically the non-melanoma skin 
cancers also encompass cutaneous lymphomas, sarcomas, Merkel cell carcinomas and 
other rare types of skin cancer2. Therefore, in this thesis I will refer to KCs rather than 
NMSC. BCC, by far the most commonly occurring skin cancer, hardly ever metastasizes 
(a literature search yielded in total 172 metastatic BCC cases based on criteria of Lattes 
and Kessler3, reported between 1981 and 2011, of which 100 metastatic BCC cases 
included information on follow-up time4) and is therefore the most ‘benign’ type of skin 
cancer. The majority of BCCs occur on facial skin where their surgical treatment might 
have a large impact on functional and cosmetic outcome. Cutaneous SCC is known to 
metastasize if left untreated (proportion of stage III and IV SCC in The Netherlands: 1.5%; 
1989-20085). SCC might arise from precursors such as actinic keratosis (AK) and in situ 
variants (Bowen’s disease).
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ePideMioLogy
The incidence rates of the three most common skin cancers are rising and show large 
variations between countries. Recently a stabilization or decline was found for mela-
noma patients (mainly younger patients) in Australia, New Zealand, the U.S.A., Canada, 
Israel and Norway6,7. The decline in Australia might have been artificial, due to immigra-
tion of people with dark skin types, which have a lower risk of developing skin cancer8. In 
Table 1 trends of incidence rates of The Netherlands, the U.S.A. and Australia were listed, 
direct comparisons are not possible because age standardized rates were adjusted to 
different populations (no recent world standardized rates available for U.S.A.). Besides, 
incidence rates of SCC and BCC in the U.S.A. and Australia were based on surveys9,10.
In general, the survival of melanoma improved markedly in recent decades (5-year 
relative survival in The Netherlands; 1989-1993: 81% and 2008-2012: 89%11), probably 
because of improved awareness and early detection of melanoma. The last two decades 
mortality rates of melanoma were rising, but recent mortality data seem to indicate a 
stabilizing or decreasing trend (Figure 1; age-standardized mortality rates (per 100,000 
person-years) in respectively 1989, 2000, 2010, 2011, 2012 and 2013 were 2.24, 2.71, 3.75, 
3.64, 3.63 and 3.7211). In the Netherlands, 821 patients died due to melanoma in 201311. 
Important prognostic factors for melanoma are Breslow thickness, nodal involvement 
(sentinel node procedure), histologically recognized ulceration, mitotic rate (number of 
mitosis per mm square)12, and gender13.
The survival of SCC was relatively stable (5-year relative survival in The Netherlands; 
1989-1993: 91% and 2008-2012: 95%). The relative survival may have been influenced 
by the increased mortality risk of SCC patients with a history of solid organ transplanta-
tion and immunosuppressive drug use. Therefore the relative survival of SCC patients 
without these conditions may even be higher. Mortality rates remained stable between 
Table 1. Incidence of skin cancer in The Netherlands, the U.S.A. and Australia (age standardized rate / 
100,000 person-years for males (M) and females (F)).
The netherlands U.s.A. Australia
Melanoma 1989 (M,F): 7.4, 10.8 1950-1954 (M,F): 1.9, 2.6 1982 (M,F): 22.9, 22.5
2013 (M,F): 18.9, 21.811* 2003-2007 (M,F): 33.5, 25.316** 2010 (M,F): 44.9, 31.217*
Basal cell carcinoma 1973 (M,F): 27, 22 1977-1978 (M,F): 618.7, 930.3 1985 (M,F): 735, 593
2008 (M,F): 101, 10118* 1998-1999 (M,F): 930.3, 485.59** 2002 (M,F): 1041, 74510*
squamous cell 
carcinoma
1989 (M,F): 13.7, 5.5 1977-1978 (M,F): 187.5, 356.2 1985 (M,F): 209, 122
2013 (M,F): 24.1, 16.411* 1998-1999 (M,F): 71.8, 150.49** 2002 (M,F): 499, 29110*
Abbreviations: ‘M’= males, ‘F’= females.
*adjusted to the World Standard Population.
**adjusted to the U.S.A. census Standard Population.
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1989 (Mortality rates per 100,000 person-years, adjusted for the European standard 
population [ESR] 0.45) and 2013 (ESR 0.35). In 2013, an estimated 98 patients died due 
to SCC in The Netherlands11.
The survival of BCC is most likely almost 100%, exact numbers are not available for 
The Netherlands. However, the high incidence of BCC (Table 1), increasing incidence in 
younger patients14 and high risks of developing multiple BCCs (5-year cumulative risk of 
developing one or more subsequent BCCs in The Netherlands is 29.2%15) make this type 
of skin cancer a major public health concern.
The increasing incidence rates of skin cancer together with a small change of mortal-
ity rates suggest cancer overdiagnosis of skin cancer. Cancer overdiagnosis may have 
two explanations: a) the cancer never progresses (or regresses); or b) the cancer pro-
gresses slowly enough that the patient dies of other causes before the cancer becomes 
symptomatic19. Three variables are important for the second explanation: cancer size at 
detection, its growth rate and the patient’s competing risks for mortality19. Besides, an 
overdiagnosed patient has a tumor that fulfills the pathological criteria for cancer19. Der-
matologists are not able to know which patients are overdiagnosed at time of diagnosis 
and therefore treat all of them. Thus, overdiagnosis contributes to the problem of esca-
lating health-care costs19. Besides, overdiagnosis stimulates overdiagnosis and screening 
because an increasing proportion of the population knows someone who ‘owes their life’ 
to early cancer detection, some have labeled this the popularity paradox of screening19.
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Figure 1. Mortality rates of melanoma in The Netherlands between 1989 and 2013, adjusted for the Europe-
an standard population (ESR / 100,000 person-years), source: www.dutchcancerfigures.nl/www.statline.nl.
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CLiniCAL PResenTATion, hisToPAThoLogy, diAgnosis And TReATMenT 
(see CoLoR seCTion)
Melanoma and melanoma in situ
The majority of melanoma patients do not present with full-blown melanomas but 
with precursor forms, thin melanomas (proportion invasive melanomas with a Breslow 
thickness of <1mm: 50%20) or with concerns about pigmented lesions. It is important 
to be able to recognize various forms of melanocytic lesions to prevent unnecessary 
excisions or treatment delay. Melanocytes are found as single dendritic cells surrounded 
by keratinocytes in the basal layer. In neoplasms melanocytes are found as a group of 
cells or a nest and then are called nevus cells. Neoplasms of melanocytic origin can be 
benign, borderline, or malignant. The borderline group is represented by dysplastic 
nevi. Diagnosis requires multiple architectural and cytologic criteria and is difficult for 
pathologists because some features can be found in both benign nevi and melano-
mas21. Superficial spreading melanoma (approximately 60% of melanomas in Caucasian 
populations20) usually originates from an atypical melanocytic nevus, but it might arise 
from normal skin. It has a radial and vertical growth phase and starts with the radial 
phase. After months to years vertical growth follows. Histology shows large melanocytic 
cells with nest formation in the dermo-epidermal junction, atypical mitoses, a pagetoid 
growth pattern and invasion of the dermis by atypical melanocytes. Nodular mela-
noma (around 15% of melanomas among Caucasians20) is a more aggressive form and 
develops without a radial growth phase de novo or from atypical nevi. Highly atypical 
melanocytes infiltrate the deep dermis. The less common acral lentiginous melanoma is 
seen on the palms and soles and under the nails. This form is most prevalent in darker-
skinned individuals and Asians. Clinically, lentigo maligna is an irregularly pigmented 
brownish macule, usually in older patients, which grows radially. Histologically it is a 
melanoma in situ with atypical melanocytes in the basal layers of the epidermis. After 
some time the macule can thicken and become an invasive lentigo maligna melanoma 
(around 3% of melanomas among Caucasians22). Melanoma in situ are cancer cells in 
the epidermis without growth into deeper layers of the skin. It is treated surgically and 
the life expectancy of patients with melanomas in situ is similar to that of the general 
population.
Different aspects of a pigmented lesion can be visualized with a dermatoscope evalu-
ating Asymmetry, Border, Color and Differential structures (ABCD rule), pattern analysis, 
the 7-point checklist, the Menzies method or the revised pattern analysis23. A high 
dermoscopy score leads to a suspicion of malignancy and the lesion should be excised 
with 2 mm margins and examined histopathologically.
The Breslow thickness is the depth that the melanoma reaches measured from 
the granular layer in the epidermis and is incorporated in the T staging of the TNM 
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system24. Recommended re-excision margins are determined by Breslow thickness, 
ranging from 5 mm for in situ melanoma to 20 mm for melanomas with a Breslow 
thickness higher than 2 mm25. In The Netherlands, patients with a melanoma with stage 
1B or higher can be referred to a surgical oncologist for a sentinel node procedure25. 
Having a positive sentinel node influences survival greatly and is therefore a major 
prognostic value, but the sentinel node procedure is considered a prognostic rather 
than a therapeutic intervention, as the influence of the sentinel node procedure on 
disease free survival remains subject of debate26. Imaging diagnostics are also mainly 
of prognostic value.
In the past approved agents for advanced melanomas were dacarbazine chemo-
therapy (1976) and high-dose Interleukin-2 (1998). Recently, several new therapies 
became available for advanced melanoma patients. In 2011, the immunotherapy ipilim-
umab (antibody to cytotoxic T-lymphocyte-associated antigen-4) and targeted therapy 
vemurafenib (BRAF inhibitor) were approved. The BRAF inhibitor dabrafenib and MEK 
inhibitor trametinib were approved in 2013. Pembrolizumab (antibody to programmed 
cell death-1, PD-1) was approved in 2014 and nivolumab (antibody to PD-1) may be ap-
proved in the near future27. Acquired resistance to therapy and efficacy of combination 
therapies are currently being investigated.
squamous cell carcinoma, Bowen’s disease and actinic keratosis
SCCs have a polymorph-presenting pattern from ulceration to invasive tumors, usually 
with the presence of hyperkeratosis. The highly prevalent actinic keratoses are precur-
sors of SCC and are found on sun-exposed sites of the body. The risk of progression of 
a single actinic keratosis to SCC is approximately 0.1% and 60% of SCCs arise from a 
preexistent actinic keratosis28, but the problem for clinicians is that the risk of progres-
sion of an individual lesion is unknown29.
AKs may also develop into BCCs, but it is also possible that BCCs are misdiagnosed as 
AK30. Bowen’s disease, or squamous cell carcinoma in situ, manifests as a sharply circum-
scribed erythematous plaque sometimes covered with scales (resembling eczema and 
psoriasis). The disorder involves full thickness of the epidermis where different degrees 
of dysplasia can be seen. In contrast with actinic keratosis, atypical squamous cells are 
present in the whole thickness of the epidermis, but no invasion of the dermis is present. 
In SCC the basement membrane is destroyed and atypical cells form keratinous pearls 
invading the dermis with a reduced surrounding stroma containing an inflammatory 
infiltrate. The majority of SCCs are found on the head. SCCs on ears, lips and anogential 
region are more likely to produce metastases than tumors on the scalp or face5,31. Most 
metastases are in-transit metastasis (unknown proportion) or draining lymph node 
metastasis (approximately 10%)32.
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Conventional surgical excision is the first choice in treatment of primary cutaneous 
SCC (surgical margins depending on tumor size and location)32. Mohs micrographic 
surgery is more appropriate at difficult sites where wide margins could result in func-
tional impairment. Treatment preferences for advanced SCCs should be discussed within 
multidisciplinary teams. Radiotherapy is a good treatment option for patients with a 
contra-indication for surgery. AK and Bowen’s disease can be treated with nonsurgical 
treatments like topical 5% 5-fluorouracil cream, imiquimod 5% cream, ingenol mebutate 
gel, cryotherapy or photodynamic therapy.
Basal cell carcinoma
Early BCCs can be recognized as small, translucent, light-colored papules or nodules of 
the skin, completely covered by a thin epidermis through which teleangiectasias are no-
ticeable. The tumor slowly evolves into a nodus with a typical pearly aspect and telean-
giectasias (nodular type), subsequently ulceration appears. Sometimes the lesion can be 
pigmented and confusion with a melanoma is possible. The classical ulcus rodens is an 
extensive nodo-ulcerative BCC. Furthermore, there is a red, scaly superficial type (often 
misdiagnosed as eczema) and thickened or scar tissue-like infiltrative (morpheaform or 
micronodular) type. Dermoscopy features of non-pigmented BCCs are arborizing ves-
sels, superficial fine telangiectasia, ulceration, multiple small erosions, shiny white-red 
structureless areas and short white streaks; pigmented BCCs may also display one or 
more of the following features: blue-gray ovoid nests, multiple blue-gray dots/globules, 
in-focus dots, maple leaf-like areas, spoke wheel areas and concentric structures33. 
Diagnosis requires a skin biopsy (diameter 2-3 mm) for histopathological examination, 
however, in clinical practice some lesions with typical aspects (mainly superficial basal 
cell carcinoma) are treated without a previous biopsy34. Histopathological examination 
shows epithelial islands, characterized by dark cells with a small volume of cytoplasm 
surrounded by cells in a palisade arrangement. The cells look similar to the cells of the 
basal lamina in the epidermis and matrix cells of the adnexa. Superficial BCCs can be 
treated with imiquimod, 5-fluorouracil, cryosurgery or photodynamic therapy. Other 
BCCs can be treated with surgical excision (SE), Mohs’ micrographic surgery (MMS), ra-
diotherapy, cryosurgery, curettage and electrocoagulation. SE and MMS have the ad-
vantage of margin control (MMS aims an almost 100% margin control), other treatment 
options should be reserved for patients who cannot undergo surgery35. Indications for 
MMS are tumour site localized to the H zone (central face, around the eyes, nose, lips and 
ears, cosmetically and functionally important areas), tumour size larger than 2 cm, ag-
gressive histopathological subtype (especially morphoeic, infiltrative, micronodular and 
basosquamous subtypes), poor clinical definition of tumour margins, recurrent lesions, 
perineural or perivascular involvement36. Recently, the long term results of MMS versus 
surgical excision in patients with respectively high risk facial BCCs or recurrent facial 
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BCCs were reported with 10-year cumulative recurrence probabilities of 4.4% vs. 12.2% 
and 3.9% vs. 13.5%37.
For the small group of patients with locally advanced or metastatic BCC and patients 
with the basal cell nevus syndrome the new therapy option vismodegib (oral capsules) 
is available38,39. Almost all BCCs have genetic alterations in the hedgehog signaling path-
way which causes loss of function of patched homologue 1 (PTCH1), which normally 
inhibits the signaling activity of smoothened homologue (SMO). Vismodegib is a small-
molecule inhibitor of SMO. Response rates in respectively metastatic BCC and locally 
advanced BCC were 30% and 43% with a median duration of response of 7.6 months 
in both groups. Approximately 30% had adverse events like muscle spasms, alopecia, 
dysgeusia, weight loss, and fatigue and 25% reported serious adverse events39.
CARCinogenesis
The understanding of the genetic basis of melanoma has increased markedly in recent 
years. The well-known BRAF p.V600E classical oncogene has activating mutations in 
approximately 50% of melanomas and 15-20% have activating mutations in NRAS, in a 
mutually exclusive way40. These oncogenes lead to activation of the RAS RAF MEK ERK 
mitogen-activated protein kinase (MAPK) pathway. BRAF mutations are characteristic 
for melanomas which develop on non-chronically sun-exposed skin; in melanomas 
developed on chronically sun exposed sites BRAF and NRAS mutations are equally 
distributed. However, 80% of benign nevi have BRAF p.V600E mutations, so other 
mechanisms are also important in melanoma genesis. Besides, the majority of mela-
noma patients treated with BRAF inhibitors and an initial response became resistant to 
therapy. Several mechanisms for these recurrences were suggested and combination 
therapies are currently investigated40. A variety of KIT mutations are found in 2% of skin 
melanomas (21% in acral melanomas), clinical responses were only observed in patients 
with specific KIT mutations40. New oncogene candidates based on recent studies are 
MAP2K1/2, MAP3K5, MAP3K9, ERBB4, TRRAP, GRIN2A, GRM3, RAC1, PREX2, HRAS and 
BRAF amplification40. Mutations in the tumor suppressor gene CDKN2A (p16-Leiden) 
and melanocortin-1 receptor gene (MC1R) variants are also associated with high risks of 
melanoma41. Mutations in CDKN2A (40%) and CDK4 (3%) are present in familial atypical 
mole melanoma (FAMMM) syndrome patients. These patients have a 70% lifetime risk of 
developing melanoma, an increased risk of developing multiple melanomas (30%) and 
pancreatic cancer (15-20%)42.
SCC develops from keratinocytes and mainly UV-induced mutations in the p53 
gene are important in early events43. Chronic sun exposure leads to DNA damage, the 
accumulation of subsequent mutations causes progression from normal skin, to pre-
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cancerous lesion (actinic keratosis or squamous cell carcinoma in situ) and ultimately 
invasive cancer (SCC) and metastatic SCC. The most important gene mutation in the 
p53 tumor suppressor gene leads to further accumulation of DNA damage, because in 
a normal cell p53 causes cell cycle arrest after DNA damage, which removes DNA dam-
age before DNA synthesis and mitosis. Sun-exposed skin contains many p53 mutations 
(74% compared to 5% in normal skin)44. Other signaling pathways that may play a role 
in SCC development are epidermal growth factor receptor, RAS, Fyn, p16INK4a, c-myc, 
bcl-2, STAT-3, beta-1 integrin, MMP, Srcasm, Notch (p53), PKC delta, E-cadherin, MMP2, 
MMP7, MMP12 (ras), and P-cadherin44. Major genetic syndromes with increased risks of 
squamous cell carcinoma are Xeroderma pigmentosum, Oculocutaneous albinism and 
Epidermodysplasia verruciformis.
The nevoid BCC syndrome (Gorlin Goltz syndrome) is a hereditary syndrome in patients 
with a mutation in the Patched gene causing multiple BCCs at young age. The patched 
gene is part of the Hedgehog pathway and in sporadic BCCs also loss-of-function PTCH1 
mutations were found45. PTCH1 blocks the function of Smoothened (SMO) in the absence 
of Hedgehog ligands, signaling starts when Hedgehog ligands bind PTCH1 and block its 
function. The Hedgehog pathway is deregulated in the majority of BCCs by mutations of 
the signaling repressor PTCH1, but in a minority of tumors a mutation of SMO is present. 
Systemic and topical Hedgehog inhibitors are currently investigated and are important 
new therapies for advanced and metastatic BCC, however, the use in the more common 
less advanced BCC is yet unclear45.
FoLLow-UP
The three major reasons for follow-up are the detection of recurrent lesions (and pro-
gression of the disease), diagnosis of new malignant lesions and reassurance of the 
patient46. In the Netherlands melanoma patients with stage 1A require, according to 
the guidelines, one follow-up visit one month after treatment and patient education in 
order to detect new lesions or recurrence. Patients with stage ≥ 1B are advised to have 
5 years of follow-up with a decreasing frequency per year (four follow-up visits in the 
first year, two in the second year after diagnosis and annually in the next years)25. SCC 
patients require five years of follow-up23. According to the BCC guideline, only high risk 
BCC patients require annual follow-up visits (nevoid BCC syndrome, immunosuppres-
sive medication use and patients with extensive actinic damage), other BCC patients 
do not require follow-up22. In The Netherlands no clear follow-up schemes are available 
for patients with multiple cutaneous (pre)-malignancies. Internationally, no evidence-
based data is available concerning follow-up length and frequency, almost every other 
country advises lifelong annually follow-up visits47. There is also low evidence for skin 
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self-examination, although education about skin self-examination is widely advised48. 
In the Netherlands, 42% of the medical specialists think less follow-up is needed49. How-
ever, the frequency of follow-up visits of a large group of melanoma patients (mainly 
those with lower Breslow thickness) was higher than recommended by the current 
melanoma guideline in The Netherlands50, which may be due to patients preferences, 
and to a lesser extent physicians’ preferences.
Risk FACToRs
The most important risk factors associated with melanoma, BCC and SCC and multiple 
skin cancers are summed in Table 2. One of the most important risk factors of skin cancer 
is Ultraviolet radiation (UVR). UVR (a potent carcinogen) is subdivided into ultraviolet A 
(UVA, 315-400 nm), ultraviolet B (UVB, 280-315 nm) and ultraviolet C (UVC, 100-280 nm), 
around 90-99% of the solar UVR energy that reaches earth’s surface is UVA and 1-10% 
is UVB51. Solar skin damage and photoaging are thought to be caused by direct DNA 
damage (formation of cyclobutane pyrimidine dimers), gene mutations, immunosup-
Table 2. Risk factors of melanoma, squamous cell carcinoma, basal cell carcinoma53 and multiple skin cancers.
Melanoma sCC BCC Multiple skin cancers
exogenous Risk Factors
Acute UV exposure ++ + ++ ++
Intermittent UV exposure +++ + ++ ++
Cumulative UV exposure + +++ + ++
Sun-damaged skin (e.g. AK) + +++ ++ +++
Smoking n.a. ++ n.a. n.a.
Ionizing radiation n.a. ++ + +
Human papillomavirus n.a. +++ + ++
Immunosuppression (e.g. medication, organ transplant) n.a. +++ + +++
endogenous Risk Factors
Sex n.a. +++ ++ +
Age + +++ ++ ++
Pigmentation status (light skin, eyes and hair) +++ +++ +++ +++
Increasing number of nevi +++ n.a. + ++
Atypical nevi +++ n.a. + ++
Positive history of skin cancer + ++ +++ +++
Chronic inflammation n.a. +++ + +
Scarring n.a. +++ + +
Genetics ++ + + +++
Abbreviations: ‘UV’= ultraviolet; ‘AK’= actinic keratosis; ‘n.a.’ =not applicable.
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pression, oxidative stress, and inflammatory responses51. UVR leads to mutations of p53 
tumor suppressor genes. These genes are involved in DNA repair or the apoptosis of cells 
with high levels of DNA damage51. Skin color, the ozone layer, life style changes (outdoor 
activities and worsening sunbathing habits), sunburns during childhood, phototherapy 
and tanning beds are all influencing the individual risk of skin cancer51.
In 1953, Slaughter et al. described ‘field cancerization’ in oral epithelium as a regional 
carcinogenic activity of some kind, in which a preconditioned epithelium has been 
activated over an area in which multiple cell groups undergo a process of irreversible 
change toward cancer52. Skin cancer and actinic keratosis are strongly associated with 
sun exposure and therefore field cancerization is an important concept in the occur-
rence of multiple cutaneous (pre)-malignancies.
AiMs oF This Thesis
Important topics like follow-up and early detection of skin cancer remain a subject of 
debate. In this thesis I describe the burden of multiple cutaneous malignancies and their 
consequences for patients, doctors and health care systems.
The main questions addressed in this thesis are:
Part I: What are the risks of multiple cutaneous (pre)-malignancies (melanoma, SCC 
and BCC) in The Netherlands and worldwide (Europe, North America and Australia)?
Part II: What are the trends in incidence of thin melanomas and what is the prevalence 
of actinic keratosis in The Netherlands?
Part III: What is the conditional relative survival of lymph node negative and positive 
melanoma patients and patients with multiple melanoma?
Part I: To answer the first research question we performed a large systematic review and 
meta-analysis to pool current available data concerning risks of a subsequent cutaneous 
malignancy (including KC or melanoma) in patients with a prior melanoma or KC. The 
results of this review are presented in chapters 2 and 3. In chapter 4 we used data of 
the Netherlands Cancer Registry to investigate risks of a second primary melanoma (in 
situ or invasive) after a first in situ or invasive melanoma and discuss effectiveness and 
efficiency of screening of second primary melanomas. In chapter 5 we analyzed risks of 
a subsequent different cutaneous malignancy (melanoma, SCC or BCC) in patients with 
a prior melanoma or KC. Data from the Eindhoven Cancer Registry includes data on BCC 
and was used to estimate BCC – melanoma, BCC – SCC, melanoma – BCC and SCC – BCC 
risks. Data from the Netherlands Cancer Registry includes the Eindhoven Cancer Regis-
try and was used to estimate nationwide melanoma – SCC and SCC – melanoma risks. In 
chapter 6 we discuss occurrence of exclusive development of keratinocyte carcinoma.
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Part II: In chapter 7 we used data of the Netherlands Cancer Registry to investigate 
time trends of thin melanomas. Incidence rates and estimated annual percentage 
changes were investigated for in situ melanomas and thin melanomas and trends were 
compared with thicker melanomas to find signs for overdiagnosis and increased aware-
ness. In chapter 8 we calculated the prevalence of actinic keratosis amongst participants 
of the Rotterdam Study, a population-based cohort, and also investigated risk factors 
and detection rates of skin cancer.
Part III: In chapter 9, data of the Netherlands Cancer Registry was used to investigate 
5-year conditional relative survival for lymph node negative melanoma patients and 
1-year conditional relative survival for lymph node positive and negative patients. In 
chapter 10, survival of patients with multiple melanoma was investigated using data of 
the Netherlands Cancer Registry. A Cox proportional hazard model was used to describe 
the differences between multiple melanoma patients and single primary melanoma 
patients.
In this thesis different aspects of the epidemiology of multiple cutaneous (pre)-malig-
nancies are described in order to investigate the risks for different skin cancer patients 
and to provide insight for clinicians and health care management policy makers. I also 
describe epidemiology of early cutaneous malignancies with data of the Netherlands 
Cancer Registry and The Rotterdam Study to respectively find signs of overdiagnosis 
and to emphasize the enormous burden of cutaneous (pre)-malignancies for health care 
providers. Finally, I will describe the conditional relative survival of melanoma in The 
Netherlands in order to give a more optimistic message to melanoma survivors than the 
traditional relative survival rates and the survival of patients with multiple melanoma.
MeThods
In order to answer the research questions described above, I used several methods to 
estimate pooled risks, risks, incidence, prevalence and survival of skin cancer in the 
general population. More details are provided in the individual chapters and statistics 
and/or epidemiology textbooks. In this thesis, I used three types of datasources:
Literature search engines
For the separated systematic review and meta-analysis a comprehensive literature search 
strategy was performed assisted by a medical librarian of the Erasmus MC University 
Medical Center, Rotterdam, the Netherlands. PubMed, Embase, Web of Science and the 
Cochrane library were searched with database-specific search strings. To have insight in 
grey literature internet search engines (www.google.nl) were also searched. These data 
were the base of chapters 2 and 3.
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Population-based cancer registry data
Population-based cancer registry data of the Netherlands Cancer Registry (NCR) and 
Eindhoven Cancer Registry (ECR) (www.iknl.nl)were the base of chapters 4, 5, 7, 9 and 
10. The nationwide NCR combines data from all comprehensive cancer centers in the 
Netherlands since 1989. The NCR is based on all newly diagnosed malignancies in the 
Netherlands by the automated pathological archive (PALGA). Additional sources are 
the national registry of hospital discharge diagnosis, haematology departments and 
radiotherapy institutions. Information on patients diagnosed with basal cell carcinoma 
was obtained from the Eindhoven Cancer Registry, which is the only comprehensive 
cancer center in the Netherlands that registers BCCs routinely and systematically. The in-
formation on vital status was initially obtained from municipal registries and from 1995 
onwards from the nationwide population registries network. Population-based cancer 
registries collect data on all new cases of cancer occurring in a well-defined population 
(usually a particular geographical region). Main objective of this type of cancer registry 
is to produce statistics on the occurrence of cancer in a defined population and to pro-
vide a framework for assessing and controlling the impact of cancer in the community54. 
Information on the Dutch population size in the past were obtained from Statistics 
Netherlands (CBS, Centraal Bureau voor de Statistiek, www.cbs.nl).
The Rotterdam study
The Rotterdam Study is a large prospective population-based cohort study in the Om-
moord district in the city of Rotterdam, the Netherlands55, with recruitment starting in 
January 1990. Up to 2008, 14,926 subjects aged 45 years or over comprise the Rotterdam 
Study cohort56. Participants were followed for the most common diseases in the elderly. 
Since 2010 dermatological diseases were examined in the Rotterdam study56. Several 
items were added to the home interview, including questions concerning ultraviolet ex-
posure and history of skin diseases. A full body skin examination by physicians trained in 
dermatology with a focus on the most common skin diseases including actinic keratosis 
and cutaneous malignancies at time of examination is assessed in a standardized way56. 
The first dermato-oncological cross-sectional data was the base of chapter 8.
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Chapter 2
Risk of subsequent cutaneous malignancy 
in patients with prior melanoma: 
A systematic review and meta-analysis
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ABsTRACT
Melanoma patients are known to be at risk of developing multiple cutaneous (pre-) 
malignancies, however the exact dimensions of these risks are unknown. In this meta-
analysis risks of developing a melanoma, basal cell carcinoma (BCC) or squamous cell 
carcinoma (SCC) after a melanoma were investigated. An extensive systematic literature 
search was conducted (last performed on January 18, 2012). Studies reporting risks, i.e. 
proportions, standardized incidence ratios [SIR] and cumulative risks were included. Fifty, 
of 233 fully read articles, met selection criteria. Two independent reviewers extracted 
data on study characteristics and risks measurements. Random-effects meta-analyses 
were used to pool the risk estimates for the three tumour combinations. In melanoma 
patients, pooled proportions for a subsequent melanoma, BCC or SCC were respectively 
3.8% (n=47), 2.8% (n=5) and 1.0% (n=6). The pooled SIRs for a subsequent melanoma, 
BCC or SCC in melanoma patients were respectively 10.4 (n=12), 4.6 (n=2) and 2.8 (n=2). 
Mean 20-year cumulative risks of a subsequent melanoma, BCC or SCC in melanoma 
patients were respectively 5.4% (n=3), 14.0% (n=1) and 4.0% (n=1). Subgroup analyses 
showed substantial differences in reported risks between continents and study design. 
In conclusion, a history of a prior melanoma is a strong predictor for development of 
a subsequent melanoma (approximately 10-fold increased risk) and to a lesser extent 
BCC or SCC. This information could serve as information for health care systems. Further, 
secondary prevention seems pivotal in this patient group.
Funding:
The Netherlands Organization for Health Research and Development (ZonMw), project 
numbers 152001013/VIDI 91711315.
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inTRodUCTion
The three most common cutaneous malignancies are basal cell carcinoma (BCC), 
squamous cell carcinoma (SCC) and melanoma and their incidence rates are increas-
ing worldwide.1,2 Skin cancer patients are known to be at risk of developing multiple 
cutaneous (pre-)malignancies (supplemental Table  1).3 This is associated with patient 
morbidity and to a lesser extent mortality, and the management of these malignancies 
has a high impact on current health care systems and costs. In a recent systematic review 
and meta-analysis high risk estimates of subsequent skin cancers after a first keratino-
cyte carcinoma (KC; including BCC and SCC) were found for all tumour combinations, 
especially for similar subsequent skin cancer (almost 30% for BCC after a BCC).3
Melanoma causes most skin cancer related deaths4, because of its much higher case-
fatality rate compared to KC. Fortunately, survival of melanoma has improved, probably 
because of earlier detection (due to increased skin cancer awareness in the population 
and early detection by patients and doctors5). This improved survival implies that more 
patients live a long time after diagnosis and therefore likelihood of subsequent (skin) 
cancers becomes important. Subsequent melanomas appear to be thinner than first 
melanomas6, probably due to clinical examinations during follow-up. A structured re-
view in 2005 summarised twelve studies that investigated the risk of a melanoma after a 
prior melanoma (without systematic search strategy and meta-analysis) to find evidence 
for melanoma follow-up strategies and stated that more high-quality methodological 
research is needed as input for follow-up guidelines.7 Since then, a substantial number 
of population- and hospital-based studies reported their risk estimates of subsequent 
melanoma.
Melanoma and KC share many risk factors, such as exposure to ultraviolet radiation, 
genetic (e.g. ASIP and TYR8) and phenotypic characteristics (e.g. hair and skin colour) 
and indeed, melanoma patients are thought to be at increased risk for both melanoma 
and KC development.9-12
In this systematic review and meta-analysis, the risks of developing a subsequent mela-
noma or KC were investigated in patients diagnosed with a cutaneous melanoma, strati-
fied for study quality, study design and geographical location. This information could 
be valuable for patient education, secondary prevention and health care policy makers.
MeThods
We aimed to provide estimates for the development of a subsequent melanoma, BCC or 
SCC in patients with a history of melanoma. We recently published the risks of these cu-
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taneous malignancies amongst KC patients in a separate article.3 Results were reported 
according to the PRISMA statement for reporting systematic reviews and meta-analyses 
of epidemiological studies.13
search strategy
The search strategy is depicted schematically in Supplemental Table 2.
inclusion and exclusion criteria
The inclusion and exclusion criteria were identical to those of our recent review on pa-
tients with a first KC3, but applied to patients with a first melanoma. In short, if a publica-
tion fulfilled the following inclusion criteria it was eligible for inclusion: (1) patients with 
a previous melanoma were followed over time for the development of a subsequent 
melanoma, BCC or SCC and an associated proportion, standardized incidence ratio (SIR) 
or cumulative risk (CR) was provided; (2) more than 80% of the skin cancer cases were 
histopathologically confirmed; (3) findings reported in English.
Of the above mentioned eligible risk estimates, the proportion was the most frequently 
reported in the literature. However, this estimate is not very informative as it increases 
with follow-up time, but does not correct for it, does not account for the competing risk 
‘death’ and does not compare to the risk in the non-melanoma population, unlike the 
preferable CR and SIR.
The following exclusion criteria were used: (1) specific patient populations who 
were at extreme risk of developing cutaneous malignancies (e.g. transplant patients or 
genodermatoses); (2) more than 10% of the first or subsequent cutaneous malignancies 
were recurrences or no adequate case definition was made (e.g. no distinction between 
recurrences and first or subsequent cutaneous malignancies); (3) animal studies; (4) 
review, editorial, meta-analysis, consensus, guideline, case-reports or case – series; (5) 
only reporting cutaneous malignancies on specific anatomical sites.
study selection
The following three tumour combinations of interest were investigated: melanoma after 
melanoma, BCC after melanoma and SCC after melanoma (see part II of Figure 1). Some 
included studies reported separate observations for multiple tumour combinations. If 
identical populations were described in several publications within the same or over-
lapping time period, these publications were compared and the study with the most 
detailed results was included.
data extraction
The study characteristics are listed in Supplemental Table 1.
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Quality assessment
The study quality was assessed by using adapted criteria (Supplemental Table 3) from 
the Newcastle-Ottawa quality assessment scale (NOS) which is a quality assessment tool 
for cohort and case-control studies in systematic reviews and meta-analyses.14 The NOS 
is divided within three grouping items: selection (4 points), comparability (2 points) and 
outcome (3 points). The maximum score of an article was 9 points. The risk of bias was 
considered moderate or low when the overall sum was 5 points or higher.15
statistical methods
Despite its disadvantages compared to SIR and CR, the primary outcome of this meta-
analysis was the proportion of melanoma patients that developed a subsequent cutane-
ous malignancy (i.e., melanoma, BCC or SCC) because it was by far the most commonly 
used estimate. This proportion was calculated by dividing the number of patients with 
a subsequent skin cancer by the total number of followed patients. The second, more 
informative, outcome of interest was SIR, calculated as the observed number of patients 
that developed a subsequent cutaneous malignancy divided by the expected number 
of patients in the general population (i.e. background incidence). Thirdly, the CR was 
calculated by dividing the number of patients that developed a subsequent cutaneous 
malignancy by the total number of patients alive after a certain time period.
Pooled estimates for proportion and SIR with 95% confidence intervals (95%CI) were 
calculated with a random effects model as proposed by DerSimonian and Laird because 
of high study heterogeneity (I2 index>75%).16,17 In this model, the inverse of standard 
errors of proportion and SIR from the individual studies combined with the between 
study variation were used as weights. Only a limited number of studies provided a CR 
and most of them provided a 5–year or 10-year CR. Moreover, CI and life tables were 
often lacking, making it impossible to calculate a pooled CR. However, to provide an 
overview of the available CR data, the available 1-year, 5–year, 10-year, 15-year and 20-
year cumulative risks were averaged.
Subgroup analyses (only performed when number of separate observations per 
tumour combination ≥5) and sensitivity analyses were performed to understand the 
‘robustness’ of the data and to find possible sources for study heterogeneity.18 In the 
subgroup analyses the following study characteristics were compared, overall NOS score 
<5 versus ≥5, population- versus hospital-based, in- versus exclusion of in situ cutane-
ous malignancies, studies that explicitly stated to follow patients with a ‘first’ melanoma 
versus studies without this statement (i.e., unknown if the patients under study were 
‘new’ skin cancer patients or not). Stratification by study continent (i.e., Australia, North 
America and Europe) was also performed. Publication bias was statistically assessed by 
funnel plots and the Eggers’ test (Supplemental Figure 1).19
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All statistical analyses were performed using the software package Comprehensive 
meta-analysis (version 2.2) and SPSS statistical software (version 18 and 21 for Windows, 
SPCC Inc, Chicago, Illinois).
ResULTs
The literature search identified 10,147 articles of which 233 were found potentially 
eligible based on title or abstract. Of the 233 fully read articles, 50 were eligible in the 
prior melanoma analysis (Figure 1). In these 50 articles (Supplemental Table 1), a total of 
61 separate observations (i.e., a part of the articles contained information on multiple 
tumour combinations) were reported for the three eligible tumour combinations. Of 
these 61 separate observations, 48 had melanoma as subsequent tumour, 7 BCC, and 6 
SCC. The 61 observations in this meta-analysis included 55 cohort and 6 case – control 
studies. Almost thirty percent of the articles were population-based (n=16), of which 
13 used cancer registry data. In total, 9 observations had a prospective, while 52 had a 
retrospective study design. Of 55 observations the full text was available, whereas for 6 
only abstracts could be retrieved.20-25 Sixteen countries were represented in the studies, 
corresponding to three continents (i.e. Australia, North America and Europe). Of the 55 
full articles, 70% of the observations were appraised with a high quality score (≥5 NOS 
score).
Pooled proportion
In Figure 2 A-C, the pooled proportions for respectively a subsequent melanoma, BCC 
or SCC after a melanoma are shown; 3.8% (95%CI 3.3-4.4%; n=47), 2.8% (2.0-3.7%; n=5) 
and 1.0% (0.6–1.8%; n=6).
Pooled estimates within the subgroup analyses showed higher pooled proportions in 
the melanoma after melanoma tumour combination for hospital based studies versus 
population based studies (respectively 4.3% versus 2.6% [Table 1]). Further, studies 
including in situ melanomas versus excluding in situ melanomas showed a higher pro-
portion (respectively 4.9% versus 3.2%), as well as Australian studies in comparison with 
European and USA studies (respectively 5.6% versus 3.5% and 3.5% [Table 1]).
After stratifying for sex, the pooled proportions for subsequent skin tumours after a 
melanoma were higher for men compared to women (men: melanoma 3.9% [95% CI 
2.9 – 5.2], n=15; BCC 4.9% [95% CI 3.7 – 6.4], n=2; SCC 1.2% [95% CI 0.3 – 4.7], n=2; and, 
women: melanoma 3.3% [95% CI 2.5 – 4.4], n=15, BCC 2.7% [95% CI 1.5-4.7], n=2, SCC 
(0.6% [95% CI 0.1 – 2.8], n=2).
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Figure 1. Selection process of included articles
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Pooled siR
Pooled SIRs, Figure 3 A-C, which compare the observed incidence to the expected inci-
dence in the general population, showed that patients with a melanoma had a 10-fold 
(SIR 10.4 [8.5–12.3; n=12]) increased risk of a subsequent melanoma compared to the 
general population. The pooled SIRs of BCC after melanoma was 4.6 (95% CI 3.9-5.4; n=2) 
and SCC after melanoma 2.8 (95% CI 1.9-3.7; n=2) (Table 2).
Subgroup analyses were only performed for the melanoma after melanoma tumour 
combination (n ≥ 5). Pooled estimates within the subgroup analyses showed higher 
pooled SIRs for hospital-based studies versus population-based studies (respectively 
17.8 versus 7.9, Table 2) and studies including in situ melanomas versus excluding in 
situ melanoma (respectively 21.3 versus 7.8) and first tumour no versus first tumour 
yes (respectively 84.0 versus 10.6). The other subgroups had overlapping confidence 
intervals (Table 2).
Mean cumulative risks
Supplemental Table 4 describes mean CR of a subsequent melanoma, BCC or SCC for 1, 
5, 10, 15 and 20 years after the first primary melanoma. The highest mean CR was found 
after 20 years in the BCC after melanoma group with 14%, followed by melanoma (5.4%) 
and SCC (4.0%).
B
C
Figure 2. Risk (%) of subsequent cutaneous malignancy in patients with prior melanoma
A Melanoma after melanoma
B Basal cell carcinoma (BCC) after melanoma
C Squamous cell carcinoma (SCC) after melanoma
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sensitivity analyses
Five outliers were observed in the pooled proportion forest plot of melanoma after 
melanoma leading to substantial variation of proportions ranging from 0.64 to 20.4%. 
Three of these outliers included studies with high risk patients: Marghoob et al.26 
analysed a cohort of patients of which 27.7% had a classical atypical mole syndrome, 
Table 1. Overview of pooled estimates of proportion with subgroup analyses for all observations
Melanoma after
Melanoma
(%, 95% Ci)
BCC after melanoma
(%, 95% Ci)
sCC after melanoma
(%, 95% Ci)
n studies 47 5 6
Pooled estimate proportion 3.8 (3.3-4.4) 2.8 (2.0-3.7) 1.0 (0.6-1.8)
n studies 13 1 1
nos ≥5 3.8 (2.9-4.9) 4.1 (2.7-6.1) 1.3 (0.3-6.5)
n studies 34 4 5
nos <5 3.8 (3.2-4.6) 2.5 (1.9-3.2) 0.9 (0.4-2.0)
n studies 11 1 1
Population-based 2.6 (1.9-3.5) 4.1 (2.7-6.1) 1.3 (0.3-6.5)
n studies 36 4 5
hospital-based 4.3 (3.7-5.2) 2.5 (1.9-3.2) 0.9 (0.4-2.0)
n studies 14 3 3
In situ not included 3.2 (2.5-4.2) 2.8 (1.8-4.3) 1.0 (0.5-1.9)
n studies 20 1 1
In situ included 4.9 (3.9-6.0) 2.7 (1.1-6.3) 0.2 (0.0-1.5)
n studies 13 1 2
In situ included unknown 3.1 (2.3-4.1) 2.7 (1.1-6.4) 1.7 (0.7-4.2)
n studies 26 1 1
First tumour yes 4.0 (3.3-4.9) 4.1 (2.7-6.1) 1.3 (0.4-4.5)
n studies 8 0 1
First tumour no 4.4 (3.0-6.4) NA 3.4 (0.9-11.6)
n studies 13 4 4
First tumour unknown 3.1 (2.3-4.2) 2.5 (1.9-3.2) 0.6 (0.3-1.3)
n studies 21 2 2
europe 3.5 (2.8-4.3) 3.5 (2.4-5.2) 0.7 (0.2-2.8)
n studies 18 3 4
UsA 3.5 (2.8-4.5) 2.4 (1.7-3.3) 1.1 (0.5-2.6)
n studies 8 0 0
Australia 5.6 (4.0-7.8) NA NA
Abbreviations: BCC, basal cell carcinoma; CI, confidence interval; NA, not applicable, NOS, Newcastle – Ot-
tawa scale; SCC, squamous cell carcinoma; USA, United States of America.
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Salava et al.21 described patients with more than 100 naevi or more than 5 clinical 
atypical naevi and Siskind et al.27 included patients with high familial melanoma risk. 
The other two outliers were relatively small hospital-based studies, which could have 
inflated the observed proportions.25,28 After excluding these five outliers in a sensitivity 
Table 2. Overview of pooled estimates of standardised incidence ratios with subgroup analyses for all ob-
servations
Melanoma after 
Melanoma
(siR, 95% Ci)
BCC after melanoma
(siR, 95% Ci)*
sCC after melanoma
(siR, 95% Ci)*
n studies 12 2 2
Pooled estimate proportion 10.4 (8.5-12.3) 4.6 (3.9-5.4) 2.8 (1.9-3.7)
n studies 7
nos ≥5 8.7 (6.3-11.0)
n studies 5
nos <5 14.1 (10.7-17.5)
n studies 7
Population-based 7.9 (5.7-10.1)
n studies 5
hospital-based 17.8 (14.1-21.7)
n studies 6
In situ not included 7.8 (5.4-10.1)
n studies 3
In situ included 21.3 (16.5-26.0)
n studies 3
In situ included unknown 10.1 (5.6-14.6)
n studies 8
First tumour yes 10.6 (8.5-12.8)
n studies 1
First tumour no 84.0 (64.3-103.7)
n studies 3
First tumour unknown 7.1 (3.7-10.6)
n studies 6
europe 14.0 (9.5-18.6)
n studies 5
UsA 11.8 (6.7-16.9)
n studies 1
Australia 7.3 (0.0-17.4)
Abbreviations: BCC, basal cell carcinoma; CI, confidence interval; KSC, keratinocytic skin cancer; n, number; 
NA, not applicable; NOS, Newcastle – Ottawa scale; SCC, squamous cell carcinoma; SIR, standardised inci-
dence ratio; USA, United States of America.
*Too low number for subanalyses.
I | 2 | 40
analysis the pooled proportion of developing a second melanoma decreased from 3.8 
to 3.3% (95%CI 2.9-3.7). In the other tumour combinations only one outlier was found 
in the SCC after melanoma group, however this was the smallest study (n=352) with a 
relatively small weight in the pooled proportion.29 In the SIR forest plots, three outliers 
were present in the melanoma after melanoma group. In these three studies, hospital 
based incidences were divided by cancer registry based expected incidences to roughly 
estimate the SIRs.26,30,31 After excluding these studies in a sensitivity analysis, the pooled 
SIR decreased from 10.4 to 7.7 (95%CI 6.3-9.2).
A
B
C
Figure 3. Standardised incidence ratio (SIR) of subsequent cutaneous malignancy in patients with prior 
melanoma
A Melanoma after melanoma
B Basal cell carcinoma (BCC) after melanoma
C Squamous cell carcinoma (SCC) after melanoma
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disCUssion
This systematic review and meta-analysis emphasizes that a melanoma history is among 
the strongest risk factors of developing a subsequent primary melanoma and to a lesser 
extent subsequent BCC or SCC. The highest SIR was found for melanoma after melanoma, 
implying that despite shared risk factors, there are carcinogenetic differences between 
the three cutaneous malignancies.3
However, the increased risk of developing a subsequent BCC or SCC after a first 
melanoma suggests a partially common aetiology of UV-induced field cancerization and 
genetic predisposition among these three types of skin cancer.8,32 The risk was a twofold 
higher for people to develop a subsequent BCC than a SCC after their melanoma. An ex-
planation for this phenomenon could be the fact that BCC and melanoma share sunburn 
and intermittent UV exposure as a common risk factor, while the development of SCC is 
associated with cumulative UV exposure.10,33,34 Genetically, ASIP and TYR pigmentation 
variants have been associated with both cutaneous melanoma and BCC.8 Unfortunately, 
it was not possible to stratify for histological subtype of melanoma. Most probably 
the increased risk of developing a SCC after a melanoma may be driven by the lentigo 
maligna melanoma subtype, which is most often located on the face and also associated 
with chronic and high levels of UV – exposure.
A positive melanoma history is related to a tenfold increased risk to develop a subse-
quent melanoma. This high risk is almost comparable to the risk of patients that have 
hundreds or more common naevi or those that have more than five atypical moles 
(pooled RR 6.9 or 6.4 respectively) to develop a melanoma35, and is much higher than 
other known melanoma risk factors such as increased UV exposure, sun bed use, family 
history of melanoma, light skin and hair colour, pre-malignant and skin cancer lesions 
and actinic damage indicators (pooled elevated relative risks between 1.3 – 4.3) em-
phasizing the need for secondary prevention in this patient population.10,11 Therefore, 
melanoma patients need to be informed about their persistent future risk, motivated to 
perform self-examinations and, if feasible, have annual total body skin examinations for 
at least five years or even lifelong (duration of follow-up remains debatable and differs 
across countries) by trained physicians or nurse practitioners in order to detect second 
melanomas early.
subgroup analyses
Incidence rates of a primary skin cancer depend on geographic latitude.10,36 Stratifica-
tion for continent showed, as expected by decreasing UV-levels, that effect sizes of 
developing subsequent skin cancers after a first melanoma were the highest for Aus-
tralia, followed by North America and Europe. This is in accordance with the incidence 
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rates of a first skin cancer for these regions at different geographic latitudes. Therefore, 
the pooled risk estimates of all studies combined should be interpreted with caution 
because they are biased by geographic location limiting the generalizability of the 
results. Australian studies tended to show lower pooled SIRs compared to European and 
USA studies (respectively 7.3 versus 14.0 and 11.8), which may be explained by the high 
background incidence of melanoma in Australia (Table 2). Unfortunately, only a limited 
number of countries (n= 16) and continents (n= 3) were available and the number of 
studies in some geographic areas was low. Although we performed subgroup analyses 
by continents, differences in the distribution of people’s characteristics such as pigmen-
tation status (i.e. eye-, hair- and skin colour) were not accounted for further affecting the 
generalizability. No pooled estimates could be calculated for Africa, Asia, South-America 
and inhabitants of the Middle-East, but considering the darker pigmentation status of 
these inhabitants, cutaneous malignancies are a smaller public health issue in these 
regions.37
Consequences and follow-up
The US preventative task force recommended a case-finding approach in the screen-
ing of skin cancer.38 Although total body skin examinations of all patients visiting a 
physician may not be feasible in clinical practice, it should be mandatory in patients 
with a history of skin cancer (i.e. melanoma, BCC and SCC) because of their extremely 
high risk for subsequent malignancies.3 Other important reasons of following patients 
with cutaneous malignancies are for psychosocial support, (early) detection of a local 
recurrence and progression of SCC and melanoma to the draining lymph nodes and 
visceral organs.39 Frequency and duration of follow-up of skin cancer patients remains 
controversial, but purely from the perspective of developing subsequent cutaneous 
malignancies lifelong follow-up seems desirable. However, lifelong follow-up visits will 
also increase the number of subsequent cutaneous malignancies by possible ‘overdiag-
nosis’, as is hypothesized for the thinner subsequent melanomas.40 Besides, health care 
systems differ across countries and increased follow-up might induce a partial switch of 
skin cancer care to general practitioners and psychological effects of follow-up differ in 
patients.39,41
strengths and limitations
This is the largest systematic review and meta-analysis available on risk of subsequent 
skin cancer after a melanoma. To ensure high quality reporting, the PRISMA guidelines 
were used.13 The pooled risk estimates presented for a BCC after a melanoma are 
probably underestimated, because some BCCs may be diagnosed clinically without 
histological confirmation.42 This problem is almost non-existent for melanoma and SCC, 
because these cutaneous malignancies have a higher metastatic potential than BCC 
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and are usually surgically treated and histologically confirmed. A recent European study 
observed that only 0.7 – 24.1% of the subsequent BCCs in patients with a prior BCC 
were clinically diagnosed, indicating that the degree of underestimation of our data 
is relatively limited, but country-specific.42 The risk estimate proportion was the most 
frequently reported estimate in the literature describing risks of subsequent cutaneous 
malignancies, but has the disadvantage that it does not control for the background 
incidence in the general population and it is not time-specific nor does it account for 
the competing risk ‘death’. Therefore, we strongly recommend the use of relative risks 
(SIR) and CR in future subsequent (cutaneous) malignancy research.43 Unfortunately, the 
number of studies providing SIRs of the tumour combinations of interest was low, which 
may be a KC specific problem. Most cancer registries do not register BCCs and those that 
do usually only reliably report the first histologically confirmed BCCs only. Therefore, the 
risk of a subsequent BCC or SCC was primarily based on smaller studies that may have 
underestimated the pooled proportions by shorter follow-up. Also, the younger age at 
inclusion of melanoma patients (on average 50 years) together with limited follow-up 
time could have influenced the pooled BCC or SCC risk negatively, because these tu-
mours mainly appear at older ages. Further, only a small group of studies presented CRs 
in their results and therefore these averaged CRs should be interpreted with caution.
Publication bias due to negative findings is likely to be minimal because the risk esti-
mates of developing a subsequent cutaneous malignancy are probably increased in all 
studies, as illustrated in this review, minimizing negative findings and thus publication 
bias.44 This was supported by symmetrical funnel plots and non-significant Egger’s tests 
showing no signs of publication bias (Supplemental Figure 1). The systematic literature 
search was done by a medical librarian using a search string and included congress 
abstracts and monographs (i.e., ‘grey literature’).45 However, language bias may have had 
an effect because only studies reported in English were eligible. To control for multiple 
publication bias, only the study that presented the most extensive results or had the 
longest follow-up was included.
ConCLUsion
A history of a prior melanoma is among the strongest predictors for developing a sub-
sequent melanoma and to a lesser extent BCC or SCC. Therefore, secondary prevention 
is pivotal in patients with a prior melanoma and patients should be well informed about 
future risk of subsequent skin cancers and sun protection.
I | 2 | 44
ACknowLedgeMenTs
We would like to thank Louis Volkers (medical librarian) from the Erasmus MC University 
Medical Center Rotterdam, the Netherlands for assistance in developing an accurate 
search strategy and Emmilia Dowlatshahi for her help with statistical analyses.
I | 2 | 45
ReFeRenCes
 1. Lomas A, Leonardi-Bee J,Bath-Hextall F. A Systematic Review of worldwide incidence of Non-
melanoma skin cancer. Br J Dermatol. 2012; 166: 1069-1080.
 2. Erdmann F, Lortet-Tieulent J, Schuz J et al. International trends in the incidence of malignant 
melanoma 1953-2008-are recent generations at higher or lower risk? Int J Cancer. 2013; 132: 385-
400.
 3. Flohil SC, van der Leest RJ, Arends LR, de Vries E,Nijsten T. Risk of subsequent cutaneous malig-
nancy in patients with prior keratinocyte carcinoma: a systematic review and meta-analysis. Eur J 
Cancer. 2013; 49: 2365-75.
 4. Hollestein LM, van den Akker SA, Nijsten T et al. Trends of cutaneous melanoma in The Neth-
erlands: increasing incidence rates among all Breslow thickness categories and rising mortality 
rates since 1989. Ann Oncol. 2012; 23: 524-30.
 5. Baade P, Meng X, Youlden D, Aitken J,Youl P. Time trends and latitudinal differences in melanoma 
thickness distribution in Australia, 1990-2006. Int J Cancer. 2012; 130: 170-8.
 6. Murali R, Goumas C, Kricker A et al. Clinicopathologic features of incident and subsequent tumors 
in patients with multiple primary cutaneous melanomas. Ann Surg Oncol. 2012; 19: 1024-33.
 7. Francken AB, Bastiaannet E,Hoekstra HJ. Follow-up in patients with localised primary cutaneous 
melanoma. Lancet Oncol. 2005; 6: 608-21.
 8. Gudbjartsson DF, Sulem P, Stacey SN et al. ASIP and TYR pigmentation variants associate with 
cutaneous melanoma and basal cell carcinoma. Nat Genet. 2008; 40: 886-91.
 9. Wehner MR, Shive ML, Chren MM et al. Indoor tanning and non-melanoma skin cancer: systematic 
review and meta-analysis. BMJ. 2012; 345: e5909.
 10. Gandini S, Sera F, Cattaruzza MS et al. Meta-analysis of risk factors for cutaneous melanoma: II. 
Sun exposure. Eur J Cancer. 2005; 41: 45-60.
 11. Gandini S, Sera F, Cattaruzza MS et al. Meta-analysis of risk factors for cutaneous melanoma: III. 
Family history, actinic damage and phenotypic factors. Eur J Cancer. 2005; 41: 2040-59.
 12. Khalesi M, Whiteman DC, Tran B et al. A meta-analysis of pigmentary characteristics, sun sensitiv-
ity, freckling and melanocytic nevi and risk of basal cell carcinoma of the skin. Cancer Epidemiol. 
2013; 37: 534-43.
 13. Moher D, Liberati A, Tetzlaff J, Altman DG,Group P. Preferred reporting items for systematic re-
views and meta-analyses: the PRISMA statement. BMJ. 2009; 339: b2535.
 14. Wells GA, Shea B, O’Connell D et al. The Newcastla-Ottawa Scale (NOS) for assessing the quality 
if nonrandomized studies in meta-analyses. . Available from URL: http://www.ohri.ca/programs/
clinical_epidemiology/oxford.asp, accessed February 26th 2014.
 15. Aung K,Htay T. Thiazide diuretics and the risk of hip fracture. Cochrane Database Syst Rev. 2011: 
CD005185.
 16. DerSimonian R,Laird N. Meta-analysis in clinical trials. Control Clin Trials. 1986; 7: 177-88.
 17. Higgins JP, Thompson SG, Deeks JJ,Altman DG. Measuring inconsistency in meta-analyses. BMJ. 
2003; 327: 557-60.
 18. van Houwelingen HC, Arends LR,Stijnen T. Advanced methods in meta-analysis: multivariate ap-
proach and meta-regression. Stat Med. 2002; 21: 589-624.
 19. Egger M, Davey Smith G, Schneider M,Minder C. Bias in meta-analysis detected by a simple, 
graphical test. BMJ. 1997; 315: 629-34.
 20. Ray MC, Gately LE,Krementz ET. INCIDENCE OF MULTIPLE PRIMARY MALIGNANT MELANOMAS 
(MPM). Clinical Research. 1985; 33: A457-A.
I | 2 | 46
 21. Salava A, Ranki A,Saksela O. Risk for a second primary melanoma in patients with a history of 
melanoma and multiple melanocytic nevi: A 5 year follow up study. J Invest Dermatol. 2010; 130: 
S99.
 22. Savoia P, Quaglino P, Verrone A,Bernengo MG. Multiple primary melanomas: analysis of 49 cases. 
Melanoma Res. 1998; 8: 361-6.
 23. Schoellhammer HF, Torisu-Itakura H, Huynh Y et al. Second primary melanoma: Risk factors, 
histopathologic features, and survival. J Clin Oncol. 2009; 27: 9073.
 24. Titus-Ernstoff L, Perry AE, Spencer SK et al. Multiple primary melanoma: two-year results from a 
population-based study. Arch Dermatol. 2006; 142: 433-8.
 25. Wendt J, Schanab O, Binder M, Pehamberger H,Okamoto I. Factors contributing to subsequent 
melanoma in a central European cohort. Melanoma Research. 2010; June 2011 - Volume 21 - e-
Supplement Abstracts of the 7th European Association of Dermato-Oncology Congress (EADO)
 26. Marghoob AA, Slade J, Kopf AW et al. Risk of developing multiple primary cutaneous melanomas 
in patients with the classic atypical-mole syndrome: a case-control study. Br J Dermatol. 1996; 
135: 704-11.
 27. Siskind V, Hughes MC, Palmer JM et al. Nevi, family history, and fair skin increase the risk of second 
primary melanoma. J Invest Dermatol. 2011; 131: 461-7.
 28. Uliasz A,Lebwohl M. Patient education and regular surveillance results in earlier diagnosis of 
second primary melanoma. Int J Dermatol. 2007; 46: 575-7.
 29. Helm KF, Bittenbender S,Localio R. Coexisting malignancies in patients with malignant mela-
noma. Arch Dermatol. 1996; 132: 471-2.
 30. de Giorgi V, Rossari S, Papi F et al. Risk of second primary melanoma: how should be long follow-
up? Ratio of observed and expected cases. J Eur Acad Dermatol Venereol. 2012; 26: 1454-1455.
 31. Schmid-Wendtner MH, Baumert J, Wendtner CM, Plewig G,Volkenandt M. Risk of second primary 
malignancies in patients with cutaneous melanoma. Br J Dermatol. 2001; 145: 981-5.
 32. Stacey SN, Gudbjartsson DF, Sulem P et al. Common variants on 1p36 and 1q42 are associated 
with cutaneous basal cell carcinoma but not with melanoma or pigmentation traits. Nat Genet. 
2008; 40: 1313-8.
 33. Rosso S, Zanetti R, Martinez C et al. The multicentre south European study ‘Helios’. II: Different sun 
exposure patterns in the aetiology of basal cell and squamous cell carcinomas of the skin. Br J 
Cancer. 1996; 73: 1447-54.
 34. Kricker A, Armstrong BK, English DR,Heenan PJ. Does intermittent sun exposure cause basal cell 
carcinoma? a case-control study in Western Australia. Int J Cancer. 1995; 60: 489-94.
 35. Gandini S, Sera F, Cattaruzza MS et al. Meta-analysis of risk factors for cutaneous melanoma: I. 
Common and atypical naevi. Eur J Cancer. 2005; 41: 28-44.
 36. Madan V, Lear JT,Szeimies RM. Non-melanoma skin cancer. Lancet. 2010; 375: 673-85.
 37. Hay RJ, Johns NE, Williams HC et al. The Global Burden of Skin Disease in 2010: An Analysis of the 
Prevalence and Impact of Skin Conditions. J Invest Dermatol. 2013.
 38. United States Preventative Services Task Force. skincanrs.pdf. http://www.uspreventiveservices-
taskforce.org/Page/Topic/recommendationsummary/skin-cancer-screening (last accessed: 13 
November 2014).
 39. Holterhues C, van de Poll-Franse LV, de Vries E, Neumann HA,Nijsten TE. Melanoma patients 
receive more follow-up care than current guideline recommendations: a study of 546 patients 
from the general Dutch population. J Eur Acad Dermatol Venereol. 2012; 26: 1389-95.
 40. Glusac EJ. The melanoma ‘epidemic’: lessons from prostate cancer. J Cutan Pathol. 2012; 39: 17-20.
I | 2 | 47
 41. Mols F, Holterhues C, Nijsten T,van de Poll-Franse LV. Personality is associated with health status 
and impact of cancer among melanoma survivors. Eur J Cancer. 2010; 46: 573-80.
 42. Flohil SC, Proby CM, Forrest AD et al. Basal cell carcinomas without histological confirmation and 
their treatment: an audit in four European regions. Br J Dermatol. 2012; 167 Suppl 2: 22-8.
 43. Boyle P,Parkin DM. Chapter 11 Statistical methods for registries. In: Cancer registration: principles 
and methods (IARC Scientific Publication no 95) Lyone, France: International Agency for Research 
on Cancer. 1991: 126-58.
 44. Egger M, Smith GD,Sterne JA. Uses and abuses of meta-analysis. Clin Med. 2001; 1: 478-84.
 45. Ahmed I, Sutton AJ,Riley RD. Assessment of publication bias, selection bias, and unavailable data 
in meta-analyses using individual participant data: a database survey. BMJ. 2012; 344: d7762.
I | 2 | 48
sUPPLeMenTAL TABLes And FigURes
-6 -5 -4 -3 -2 -1 0 1 2 3 4 5 6
0.0
0.5
1.0
1.5
2.0
S
ta
n
d
ar
d
 E
rr
o
r
Logit event rate
Funnel Plot of Standard Error by Logit event rateA
-5 -4 -3 -2 -1 0 1 2 3 4 5
0.0
0.1
0.2
0.3
0.4
S
ta
n
d
ar
d
 E
rr
o
r
Logit event rate
Funnel Plot of Standard Error by Logit event rateB
I | 2 | 49
-7 -6 -5 -4 -3 -2 -1 0 1 2 3 4 5 6 7
0.0
0.5
1.0
1.5
2.0
S
ta
n
d
ar
d
 E
rr
o
r
Logit event rate
Funnel Plot of Standard Error by Logit event rateC
supplemental Figure 1. Funnel plot with Egger’s test of studies reporting a proportion (%)
A Melanoma after melanoma (p-value 0.76)
B Basal cell carcinoma (BCC) after melanoma (p-value 0.30)
C Squamous cell carcinoma (SCC) after melanoma (p-value 0.30)
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supplemental Table 2. Search strategy and strings
Search strategy
database search stringa number of 
articles 
(first search 
performed 
on May 5th 
2012)
number of 
articles 
(update from 
May 1st until 
January 1st 
2012)b
Pubmed  (cancer*[tw] OR tumour[tw] OR tumours[tw] OR tumou*[tw] 
OR carcinom*[tw] OR neoplas*[tw] OR squam*[tw] OR 
epitheliom*[tw] OR melanom*[tw]) AND (multiple[tw] OR 
subsequen*[tw] OR second*[tw] OR metachron*[tw]) AND 
(skin*[tw] OR dermatol*[tw] OR basal[tw] OR baso*[tw] 
OR cutan*[tw] OR cutis*[tw] OR rodent ulcer*[tw] OR 
melanom*[tw]) AND (risk[mesh] OR risk*[tw] OR incidence*[tw] 
OR prevalence*[tw] OR epidemiol*[tw]) AND eng[la] NOT 
(animals[mesh] NOT humans[mesh])
7,076 409
EMbase  (((cancer* OR tumo* OR carcinom* OR neoplas* OR melanom*) 
NEAR/3 (multiple OR subsequen* OR another OR further OR 
more OR second* OR metachron*)):ti,ab,de OR ‘second cancer’/
syn) AND (((cancer* OR tumo* OR carcinom* OR neoplas* OR 
squam* OR epitheliom*) NEAR/3 (skin* OR derma* OR basal 
OR baso* OR cutan* OR cutis*)):ti,ab,de OR ‘skin tumour’/syn 
OR (rodent NEAR/1 ulcer*):ti,ab,de OR melanom*:ti,ab,de) AND 
(risk* OR incidence* OR prevalence* OR epidemiol*):ti,ab,de AND 
[english]/lim NOT ([animals]/lim NOT [humans]/lim)
3,155 304
Web of 
Science
 ((cancer* OR tumo* OR carcinom* OR neoplas* OR melanom*) 
SAME (multiple OR subsequen* OR another OR further OR more 
OR second* OR metachron*)) AND (((cancer* OR tumo* OR 
carcinom* OR neoplas* OR squam* OR epitheliom*) SAME (skin* 
OR derma* OR basal OR baso* OR cutan* OR cutis*)) OR rodent-
ulcer* OR melanom*) AND (risk* OR incidence* OR prevalence* 
OR epidemiol*)
2,299
Web of 
Sciencea
((cancer* OR tumo* OR carcinom* OR neoplas* OR melanom*) 
NEAR/1 (multiple OR subsequen* OR another OR further OR 
more OR second* OR metachron*)) AND (((cancer* OR tumo* 
OR carcinom* OR neoplas* OR squam* OR epitheliom*) NEAR/3 
(skin* OR derma* OR basal OR baso* OR cutan* OR cutis*)) OR 
(rodent NEAR/1 ulcer*) OR melanom*) AND (risk* OR incidence* 
OR prevalence* OR epidemiol*)
200
Total 12,530 913
Deduplication -3,151 -148
Total (after deduplication) 9,379 765
A comprehensive literature search strategy was performed assisted by a medical librarian of the Erasmus 
MC University Medical Center, Rotterdam, the Netherlands. On May 5th 2011, Pubmed, Embase, Web of Sci-
ence and the Cochrane library were searched with database-specific search strings (Supplemental Table 2). 
On January 18th 2012, an update of the search query (May 1st 2011 until January 1st 2012) was performed. 
In Figure 1, the selection process of included articles is shown. No relevant articles were found within the 
Cochrane database. To have insight in grey literature internet search engines were also searched and one 
additional article was included.21 Two other articles were handpicked; one after manually checking cross-
references17 and another recent study conducted within our department.44
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supplemental Table 2. Search strategy and strings (continued)
Two authors (S.F., MD, PhD and R.L., MD) reviewed independently all titles and/or abstracts (n= 10,147, 
including 3 handpicked). When an article fulfilled the inclusion criteria, data extraction and quality assess-
ment were independently performed by S.F. and R.L. Disagreements were discussed and solved together in 
consensus with authors E.V. and T.N..
Legend:
a Identical search strings were used for the update within Pubmed and Embase databases. The search string 
for Web of Science was adjusted due to changes of this database and time was restricted to 2011 and 2012.
b Literature search was updated until January 1st 2012, but was performed on January 18th 2012.
supplemental Table 3A. Adapted Newcastle – Ottawa quality assessment scale for cohort studies
nosa Adapted nosb
selection
1 Representativeness of the exposed cohort Representativeness of the cohort
a) truly representative of the average … 
(describe) in the community
* population-based study **
b) somewhat representative of the average … in 
the community
* population-based study with restrictions 
(e.g. age limits)
*
c) selected group of users eg nurses, volunteers - hospital-based study -
d) no description of the derivation of the cohort - no description of the derivation of the 
cohort
-
2 selection of the non exposed cohort Question removed, not applicable in our 
research question
a) drawn from the same community as the 
exposed cohort
* NA
b) drawn from a different source -
c) no description of the derivation of the non 
exposed cohort
-
3 Ascertainment of exposure Ascertainment of completeness of the 
studied cohort
a) secure record (eg surgical records) * nationwide pathology lab, Cancer Registry *
b) structured interview * hospital-based -
c) written self report - written self report -
d) no description - no description -
4 demonstration that outcome of interest was 
not present at start of study
Certainty of the first skin cancer
a) yes * yes, truly first skin cancer, explicitly 
mentioned in text
*
b) no - no / unknown -
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supplemental Table 3A. (continued)
Comparability
1 Comparability of cohorts on the basis of the 
design or analysis
Comparability of cohorts on the basis of 
the design or analysis
a) study controls for … (select the most important 
factor)
* risk of developing another skin cancer is 
stratified for sex
*
b) study controls for any additional factor (This 
criteria could be modified to indicate specific 
control for a second important factor.)
* study controls for any additional factor (e.g. 
follow-up, age)
*
outcome
1 Assessment of outcome Ascertainment of another skin cancer
a) independent blind assessment * record linkage (e.g. cancer registry, 
nationwide pathology database)
*
b) record linkage * hospital pathology database *
c) self report - NA (exclusion criteria) -
d) no description - no description -
2 was follow-up long enough for outcomes 
to occur
was follow-up long enough for outcomes 
to occur
a) yes (select an adequate follow up period for 
outcome of interest)
* yes (mean/median follow-up time is at least 
3 years)
*
b) no - no or unknown -
3 Adequacy of follow up of cohorts Adequacy of follow up of cohorts
a) complete follow up - all subjects accounted for * complete follow up - all subjects accounted 
for
*
b) subjects lost to follow up unlikely to introduce 
bias - small number lost - > … % (select an 
adequate %) follow up, or description provided 
of those lost)
* subjects lost to follow up unlikely to 
introduce bias - small number lost - > 
80% (select an adequate %) follow up, or 
description provided of those lost)
*
c) follow up rate < … % (select an adequate %) 
and no description of those lost
- follow up rate < 80% (select an adequate %) 
and no description of those lost
-
d) no statement - no statement -
a A study can be awarded a maximum of one star for each numbered item within the Selection and Out-
come categories. A maximum of two stars can be given for Comparability.
b A study can be awarded a maximum of one star for each numbered item within the Selection and Out-
come categories (except Selection question 1, two stars can be given to population-based studies). A maxi-
mum of two stars can be given for Comparability.
Abbreviations: ‘NOS’=Newcastle - Ottawa Scale; ‘NA’= not applicable
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supplemental Table 3B. Adapted Newcastle – Ottawa quality assessment scale for case-control studies
nosa Adapted nosb
selection
1 is the case definition adequate is the case definition (skin cancer patients 
who developed another skin cancer) 
adequate
a) yes, with independent validation * secure record (e.g. cancer registry, nationwide 
pathology database)
*
b) yes, e.g. record linkage or based on self 
reports
- hospital-based database -
c) no description - no description -
2 Representativeness of the cases Representativeness of the cases (skin 
cancer patients who developed another 
skin cancer)
a) consecutive or obviously representative 
series of cases
* population-based study *
b) potential for selection biases or not stated - population-based study with restrictions (e.g. 
age limits)
*
c) hospital-based study -
d) no description of the derivation of the cohort -
3 selection of Controls selection of Controls (skin cancer patients 
who did not develop another skin cancer)
a) community controls * population-based study *
b) hospital controls * population-based study with restrictions (e.g. 
age limits)
*
c) no description - hospital-based study -
d) no description of the derivation of the cohort -
4 definition of Controls definition of Controls (skin cancer patients 
who did not develop another skin cancer)
a) no history of disease (endpoint) * no development of another skin cancer *
b) no description of source - not described / unknown -
Comparability
1 Comparability of cases and controls on 
the basis of the design or analysis
Comparability of cases and controls on the 
basis of the design or analysis
a) study controls for … (Select the most 
important factor.)
* study controls for age *
b) study controls for any additional factor 
(This criteria could be modified to indicate 
specific control for a second important 
factor.)
* study controls for any additional factor (e.g. 
sex)
*
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supplemental Table 3B. (continued)
exposure
1 Assessment of outcome Ascertainment of another skin cancer
a) secure record (e.g. surgical records) * secure record (e.g. cancer registry, nationwide 
pathology database)
**
b) structured interview where blind to case/
control status
* hospital pathology database *
c) interview not blinded to case/control status - NA -
d) written self report or medical record only - NA -
e) no description - no description -
2 same method of ascertainment for cases 
and controls
Question removed, not applicable in our 
research question
a) yes * NA
b) no -
3 non-Response rate non-Response rate
a) same rate for both groups * same rate for both groups *
b) non respondents described - non respondents described -
c) rate different and no designation - rate different and no designation -
a A study can be awarded a maximum of one star for each numbered item within the Selection and Expo-
sure categories. A maximum of two stars can be given for Comparability.
b A study can be awarded a maximum of one star for each numbered item within the Selection and Expo-
sure categories (except Exposure question 1, two stars can be given to a secure record). A maximum of two 
stars can be given for Comparability.
Abbreviations: ‘NOS’=Newcastle - Ottawa Scale; ‘NA’= not applicable
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ABsTRACT
In this systematic review and meta-analysis the risk of a subsequent basal cell carci-
noma (BCC), squamous cell carcinoma (SCC) or melanoma in patients with a previous 
keratinocyte carcinoma (KC) was investigated. PubMed, Embase, Web of Science and 
the Cochrane library were searched for studies published before 1st January 2012 that 
reported risks (i.e. proportions, cumulative risks or standardised incidence ratios [SIR]) of 
developing a subsequent BCC, SCC or melanoma in patients with prior KC. 45 articles ful-
filled the inclusion criteria. In BCC patients, the pooled proportion for a subsequent BCC, 
SCC or melanoma was respectively 29.2% (95% confidence interval (CI) 24.6–34.3%), 
4.3% (1.7–10.1%) and 0.5% (0.4–0.8%). The pooled proportion of a subsequent SCC, 
BCC or melanoma in SCC patients was respectively 13.3% (95% CI 7.4–22.8%), 15.9% 
(5.6–37.6%) and 0.5% (0.3–0.6%). The pooled SIRs for a subsequent BCC, SCC or mela-
noma were respectively 17.4 (95% CI 0.0–37.4), 3.2 (0.0–6.5) and 2.4 (2.3–2.6) in BCC and 
4.2 (95% CI 2.0–6.5), 15.0 (14.0–16.0) and 2.7 (2.3–3.2) in SCC patients. In the subgroup 
analyses, strongest differences in risks were found in the continent strata (risks Australia 
> North America > Europe).
Funding
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inTRodUCTion
Keratinocyte carcinoma (KC), comprising basal cell carcinoma (BCC) and squamous cell 
carcinoma (SCC) of the skin, is the most common cancer in Caucasian populations with 
increasing incidence rates across North America, Australia and Europe.1
Patients with prior KC are at increased risk of developing subsequent cutaneous 
(pre)-malignancies (Supplemental Table  1). The number of population-based studies 
investigating risks of subsequent KC is low, because KC is often not or partially included 
in national or regional cancer registries. Marcil and Stern, 2000 estimated the risk of a 
subsequent BCC and SCC in patients with a history of KC in a meta-analysis including 17 
studies.2 A 3-year cumulative risk of 44% for BCC after BCC and 18% for SCC after SCC was 
observed. However, these analyses were not based on a systematic review, studies were 
not critically appraised and melanoma was excluded. After 2000, multiple new studies 
on the risk of subsequent cutaneous malignancies among patients with prior cutaneous 
malignancies have been published.
In this systematic review and meta-analysis the risk of developing a subsequent BCC, 
SCC or melanoma in patients with previous KC was investigated to give a complete view 
on the currently available data regarding this topic. It may serve as a guide for patients 
and clinicians and form a basis for (future) skin cancer care and guidelines, health care 
policy makers and public health campaigns.
MeThods
This study was conducted to examine risk estimates of developing a subsequent BCC, 
SCC or melanoma in patients with a history of BCC, SCC or melanoma. This systematic 
review and meta-analysis is limited to the risk of developing a subsequent BCC, SCC 
or melanoma in patients with previous KC. In this study, the risks of these cutaneous 
malignancies amongst melanoma patients were excluded due to the large amount of 
eligible papers. Risks of a subsequent BCC, SCC or melanoma after a melanoma will be 
described in a separate study. Results were reported according to the PRISMA statement 
for reporting systematic reviews and meta-analyses of epidemiological studies.3
search strategy
See Supplemental Table 2.
inclusion and exclusion criteria
Studies were included when meeting the following inclusion criteria: (1) patients with a 
previous BCC or SCC were followed over time for the development of a subsequent BCC, 
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SCC or melanoma and an associated proportion, standardised incidence ratio (SIR) or 
cumulative risk (CR) was provided; (2) skin cancer diagnoses were histopathologically 
confirmed in more than 80% of the cases; (3) reported in English.
Of the above mentioned eligible risk estimates, proportion was the most frequently 
reported in the literature, however, in contrast with CR and SIR, this estimate is little 
informative as it is not time-specific, does not account for the competing risk ‘death’ and 
does not compare to the risk in the non-KC population.
Studies were excluded when meeting the following exclusion criteria: (1) specific pa-
tient populations who were at extreme risk of developing cutaneous malignancies (e.g. 
transplant patients or genodermatoses); (2) more than 10% of the first or subsequent 
cutaneous malignancies were recurrences or no adequate case definition was made (e.g. 
no distinction between recurrences and first or subsequent cutaneous malignancies); 
(3) animal studies; (4) review, editorial, meta-analysis, consensus, guideline, case-reports 
or case-series; (5) only reporting cutaneous malignancies on specific anatomical sites.
study selection
The following seven tumour combinations of interest were extracted: BCC after BCC, SCC 
after BCC, melanoma after BCC, BCC after SCC, SCC after SCC, melanoma after SCC and 
KC after KC.
The majority of the included articles reported separate observations for multiple 
tumour combinations.
If identical populations were described in several publications within the same or 
overlapping time period, these publications were compared and the study with the 
most extensive results was included. An exception was made for two studies with an 
overlapping study population, which provided different risk measurements.4 ,5
data extraction
See Supplemental Table 1.
Quality assessment
The study quality was assessed by using adapted criteria (Supplemental Table 3) from 
the Newcastle–Ottawa quality assessment scale (NOS) which is a quality assessment 
tool for cohort and case–control studies in systematic reviews and meta-analyses.6 The 
NOS is divided within three grouping items: selection (four points), comparability (two 
points) and outcome (three points). The maximum score of an article was 9 points. The 
risk of bias was considered moderate or low when the overall sum was five points or 
higher.7
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statistical methods
The primary outcome of interest of this meta-analysis was the proportion of BCC, SCC 
or KC patients that developed a subsequent cutaneous malignancy (i.e. BCC, SCC, 
melanoma or KC separately). This proportion was calculated by dividing the number of 
patients with a subsequent skin cancer by the total number of followed patients. The 
second outcome of interest was SIR, calculated as the observed number of patients that 
developed a subsequent cutaneous malignancy by the expected number of patients in 
the general population (i.e. background incidence). CR was calculated by dividing the 
number of patients that developed a subsequent cutaneous maliganancy by the total 
number of patients alive after a certain time period.
Pooled estimates for proportion and SIR with 95% confidence intervals (95% CI) were 
calculated with a random effects model as proposed by DerSimonian and Laird because 
of high study heterogeneity (I2 index > 75%).8,9 In this model, the inverse of standard 
errors of proportion and SIR from the individual studies combined with the between 
study variation were used as weights. Only a limited number of studies provided a CR 
and most of them provided a 5-year CR. In addition, confidence intervals and life tables 
were often lacking. Therefore, it was not possible to calculate a pooled CR. However, to 
give an overview of the available CR data, the available 5-year CR was averaged.
Subgroup analyses (only performed when number of separate observations per 
tumour combination ≥5) and sensitivity analyses were performed to understand the 
‘robustness’ of the data and to find possible sources for study heterogeneity.10 In the 
subgroup analyses the following study characteristics were compared, overall NOS 
score <5 versus ≥5, population- versus hospital-based, in- versus exclusion of in situ 
cutaneous malignancies, studies that explicitly stated to follow patients with a ‘first’ 
BCC, SCC or KC versus studies without this statement (i.e. unknown if the patients under 
study were ‘new’ skin cancer patients or not). Stratification by study continent (i.e. Aus-
tralia, North America and Europe) was also performed. Publication bias was statistically 
assessed by funnel plots and the Eggers’ test (Supplemental Figure 1).11 All statistical 
analyses were performed using the software package Comprehensive meta-analysis 
(version 2.2) and SPSS statistical software (version 18 for Windows, SPCC Inc, Chicago, 
Illinois).
ResULTs
The literature search identified 10,147 articles of which 233 were found potentially eli-
gible based on title or abstract. Of the 233 fully read articles, 45 were eligible in the prior 
KC analysis (Figure 1). In these 45 articles (Supplemental Table 1), a total of 74 separate 
observations (i.e. in most cases one article contained information on multiple tumour 
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Figure 1. Selection process of included articles
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combinations) were reported for the seven possible tumour combinations. Of these 74 
separate observations, 39 had BCC as index tumour, 27 SCC and eight KC.
The 45 articles in this meta-analysis included 43 cohort and two case–control studies. 
More than half of the articles were population-based (n = 24), of which 15 included 
cancer registry data. In total, 11 articles had a prospective, while 34 had a retrospective 
study design. For 41 articles the full text was available, whereas for four only abstracts12-15 
were retrieved. Fourteen countries were represented in the articles, corresponding to 
three continents (i.e. Australia, North America and Europe). Of the full articles, 44% was 
appraised with a high quality score (≥5 NOS score); 47% of the 74 separate observations 
also received this score.
BCC as index tumour
29 articles (Supplemental Table  1A), corresponding to 39 separate observations, in-
cluded patients with a BCC as the index tumour. In these patients, the pooled proportion 
for a subsequent BCC, SCC or melanoma was respectively 29.2% (95% CI 24.6–34.3%; n = 
19), 4.3% (1.7–10.1%; n = 7) and 0.5% (0.4–0.8%; n = 11) (Figure 2A–C). Pooled estimates 
within the subgroup analyses (i.e. study quality, study design, in situ cutaneous malig-
nancies in- or excluded, ‘first’ cutaneous malignancy yes/no, continents) showed similar 
results with overlapping confidence intervals (Table 1).
In the forest plots, the Australian study by Richmond-Sinclair16 was an outlier, with 
almost 58% of the BCC patients developing another BCC, compared to the other 18 
studies (Figure 2A). Two studies conducted in North America17,18 presented relatively 
high proportions of patients developing a subsequent SCC (after BCC) compared to the 
other European studies (Figure 2B). Also, melanoma risk after BCC was higher in United 
States (US) studies,18,19 compared to the European and one Canadian study20 (Figure 2C).
The previous observations were confirmed within the subgroup analyses by continent 
(Table 1). For BCC after BCC, the highest pooled proportion for BCC after BCC was found 
in Australia (n = 1, 57.9%), followed by North America (n = 6, 32.5%) and Europe (n = 12, 
27.3%). For SCC and melanoma after BCC the highest pooled proportion was observed 
in North America followed by Europe (Table 1). In the latter two tumour combinations, 
no data from Australia were available.
In addition, two studies explicitly stated to have age restrictions, Cox21 and Kiiski et 
al.22 and two studies only contained data on low risk BCC (Mc Loone et al.23 and Pulido et 
al.14). After excluding these four articles in a sensitivity analysis, the pooled proportion 
increased to 32.5% (95% CI 27.2–38.3).
Pooled SIRs, which compares the observed incidence to the expected incidence in 
the general population, showed that patients with a BCC had a seventeen fold (SIR 17.4 
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Figure 2. Risk (%) of subsequent cutaneous malignancy in patients with prior keratinocyte carcino-
ma4, 5, 12-29, 49, 51-53, 56-72
A Basal cell carcinoma (BCC) after BCC
B Squamous cell carcinoma (SCC) after BCC
C Melanoma after BCC
d SCC after SCC
e BCC after SCC
F Melanoma after SCC
g Keratinocyte carcinoma (KC) after KC
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[0.0–37.4; n = 2] increased risk of a subsequent BCC compared to the general population. 
This was followed by SCC (3.2 [0.0–6.5]; n = 3) and melanoma (2.4 [2.3–2.6]; n = 5) after 
BCC (Table 2).
The mean 5-year cumulative risk (CR) for BCC after BCC was 36.2% (n = 7, range 
11.0–49.9%). No 5-year CR was available for the other tumour combinations with BCC as 
the index tumour (Table 3).
sCC as index tumour
17 articles (Supplemental Table  1B), corresponding to 27 separate observations, de-
scribed patients with SCC as the index tumour. The pooled proportion of a subsequent 
SCC, BCC or melanoma in SCC patients was respectively, 13.3% (95% CI 7.4–22.8; n = 
5), 15.9% (5.6–37.6; n = 6) and 0.5% (0.3–0.6; n = 9) (Figure 2D–F). In the five subgroup 
analyses, similar results with overlapping CI compared to the overall pooled proportions 
were observed (Table 1). The continent with the highest pooled proportion for SCC, BCC 
and melanoma after SCC was North America [15.3% (11.7–19.7; n = 3), 29.1% (11.0–57.7; 
n = 3) and 1.3% (0.8–2.2; n = 2), respectively]. No data were available for Australia.
The studies performed in the USA, Schreiber et al.17 and Chuang et al.24, except the 
study by Efird et al.25 had with 43% the highest proportions for BCC after SCC and seemed 
outliers compared to the other four studies in this tumour combination. After excluding 
these two studies in a sensitivity analysis, the pooled proportion for BCC after SCC de-
creased to 8.0% (5.8–11.4). In melanoma after SCC, the highest proportions were found by 
relatively small studies such as Chuang et al.24 (n = 189) and Efird et al.25 (n = 822), whereas 
others had study sizes of more than 1,000 patients, except Troyanova et al.12 (n = 741) 
(Supplemental Table 3B). After excluding Chuang et al.24 and Efird et al.25 in the sensitivity 
analysis, the pooled proportion for melanoma after SCC decreased to 0.4% (0.3–0.5).
A high SIR of 15.0 (14.0–16.0) was observed for SCC after SCC, however based on 
just one study (Table 2). The SIRs for BCC and melanoma after SCC were also increased, 
respectively 4.2 ([95% CI 2.0–6.5]; n = 3) and 2.7 ([95% CI 2.3–3.2]; n = 5).
The mean 5-year CR for SCC after SCC was 37.0% (n = 3, range 30.0–50.0%) and compa-
rable to the mean 5-year CR of BCC after SCC (39.3% [n = 2, range 6.0–72.5%]). No 5-year 
CR was available for tumour combination melanoma after SCC (Table 3).
kC as index tumour
Seven articles (Supplemental Table  1C), including eight separate observations, inves-
tigated KC (BCC and SCC combined) after KC. This resulted in a pooled proportion of 
37.0% (95% CI 29.0–45.8; n = 7). Czarnecki et al.26 from Australia, the study with the lon-
gest mean follow-up time (i.e. 10 years), had with 67.8% a high proportion of KC patients 
developing another KC compared to another Australian study with 38.5% (Raasch and 
Buettner27) and studies from North America and Europe (Figure 2G).
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Although based on one study, subgroup analysis by continent (Table 1) showed that 
the highest pooled proportion was found in Australia with 53.3% (n = 2), followed by 
North America (44.8%; n = 2) and Europe (23.3%; n = 3). No studies reported SIR as risk 
measurement for KC after KC.
The mean 5-year CR for KC after KC was 36.2% (n = 2, range 22.4–50.0%).28,29
disCUssion
This systematic review and meta-analysis emphasises that a KC history is among the 
strongest risk factors for developing another BCC, SCC or melanoma. The highest 
risk estimates were found for subsequent cutaneous malignancies of the same type, 
especially for BCC in which 29% of patients had subsequent BCCs. The increased risk 
of developing subsequent BCC, SCC and melanoma after a first KC suggests a par-
tially common aetiology of UV-induced field cancerisation and genetic predisposition 
among these three types of skin cancer.30,31 In contrast, the observation that people 
were most likely to develop an identical type of malignancy suggests that there are 
differences in carcinogenesis and associated risk factors among the three most com-
mon skin cancers.
Table 2. Overview of pooled estimates of standardised incidence ratios (SIR)
BCC after 
BCC 
(95%Ci)
sCC after 
BCC 
(95%Ci)
Mel after 
BCC 
(95%Ci)
BCC after 
sCC 
(95%Ci)
sCC after 
sCC 
(95%Ci)
Mel after 
sCC 
(95%Ci)
kC after 
kC 
(95%Ci)
n studies 2 3 6 3 1 5 0
Pooled 
estimate siR
17.4
(0.0-37.4)
3.2
(0.0-6.5)
2.4
(2.3-2.6)
4.2
(2.0-6.5)
15.0
(14.0-16.0)
2.8
(2.3-3.2)
nA
Abbreviations: BCC, basal cell carcinoma; CI, confidence interval; KC, keratinocyte carcinoma; Mel, mela-
noma; NA, not applicable; N, number; SCC, squamous cell carcinoma; SIR, standardised incidence ratio.
Table 3. Mean 5 – year cumulative risks (CR)
number of studies Mean 5-year cumulative risk (range)
BCC after BCC 7;5,15,28,49-52 36.2% (11.0 – 49.9)
SCC after BCC 0 NA
Mel after BCC 0 NA
BCC after SCC 2;53-54 39.3% (6.0 – 72.5)
SCC after SCC 3;28,54-55 37.0% (30.0 – 50.0)
Mel after SCC 0 NA
KC after KC 2;28,29 36.2% (22.4 – 50.0)
Abbreviations: BCC, basal cell carcinoma; CR, cumulative risk; Mel, melanoma; NA, not applicable; SCC, 
squamous cell carcinoma
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A KC history seems to be among the highest risk factors for developing a subsequent 
KC, and almost comparable to the risk of transplant recipients, radiotherapy treated 
patients and those exposed to high doses of psoralen combined with ultraviolet A 
(PUVA).32-36 Compared to these specific patient populations with an iatrogenic risk of 
developing skin cancer, the number of patients with a history of KC is enormous and 
constantly increasing implying a huge impact on health care services. Since primary 
prevention appears to be unsuccessful in reducing the incidence of skin cancer, second-
ary prevention strategies in which patients with a KC are informed about future risk, 
motivated to perform self examinations and have annual total body skin examinations 
for 3–5 years by trained physicians or nurse practitioners in order to detect new lesions 
early seems appropriate.
Both BCC and SCC patients also had increased SIRs for developing melanoma (2.4 and 
2.7 respectively), which is in accordance with a previous systematic review.37 Unfortu-
nately, in this review, KC was not included as second primary cancers. These increased 
risks should alert clinicians and KC patients because early detection of a subsequent 
melanoma may decrease melanoma-associated mortality.
subgroup analyses
BCC, SCC and melanoma are all strongly associated with UV exposure and the incidence 
rates of a primary skin cancer depends on geographic latitude.38,39 After stratifying 
for continent, effect sizes of developing subsequent skin cancers after a first KC were 
the highest for Australia, followed by North America and Europe as expected by the 
decreasing UV-levels among primarily Caucasian populations. Therefore, the pooled 
risk estimates of all studies combined should be interpreted with caution because it is 
biased by geographic location limiting the generalisability of the results. To maximise 
external validity of this meta-analysis, ideally, it would be necessary to include many 
studies with identical study designs and large study populations for each tumour com-
bination in each continent to provide location-specific estimates.40 Here, only a limited 
number of countries (n = 14) and continents (n = 3) were available and the number of 
studies in some geographic areas was low. Although we performed subgroup analyses 
by continents, differences in the distribution of people’s characteristics such as pigmen-
tation status (i.e. eye-, hair- and skin-colour) were not accounted for further affecting 
the generalizibility. No pooled estimates could be calculated for Africa, Asia and inhabit-
ants of the Middle-East. However, considering the darker pigmentation status of these 
inhabitants, primary and multiple cutaneous malignancies might be a smaller public 
health problem in these regions.
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Consequences and follow-up
Recently, the US preventative task force recommended a case-finding approach in the 
screening of skin cancer.41 Although total body skin examinations of all patients visiting a 
physician may not be feasible in clinical practice, it is warranted in patients with a history 
of KC because of their extremely high risk. Other important reasons for following patients 
with cutaneous malignancies are for psychosocial support, (early) detection of a local 
recurrence for BCC and to a lesser extent of SCC and progression of SCC and melanoma 
to the draining lymph nodes and visceral organs.42 Frequency and duration of follow-up 
of KC patients remains controversial, but from the perspective of developing subsequent 
cutaneous malignancies follow-up seems desirable for at least 3–5 years annually.43
strengths and limitations
This is the largest systematic review and meta-analysis available on risk of subsequent 
skin cancer after a BCC or SCC. To ensure high quality reporting, the PRISMA guidelines 
were used.3 The pooled risk estimates presented for all tumour combinations are prob-
ably underestimated, because some BCCs may be diagnosed clinically without histologi-
cal confirmation.44 This problem is almost non-existent for melanoma and SCC, because 
these cutaneous malignancies have a higher metastatic potential than BCC and are usu-
ally surgically treated and histologically confirmed. A recent Dutch study observed that 
during a mean follow-up of 6 years only 7% of the subsequent BCC in patients with a 
prior histologically confirmed BCC were clinically diagnosed, indicating that the degree 
of underestimation of our data is relatively limited.45
The risk estimate proportion was the most frequently reported estimate in the litera-
ture describing risks of subsequent cutaneous malignancies, but has the disadvantage 
that it is not time-specific nor does it account for the competing risk ‘death’. A relative risk 
that is much more informative about the risk in the study population compared to the 
general population (SIR) and an unbiased risk over time (CR) that controls for the number 
of patients that died during follow-up (i.e. competing risks) are preferred in subsequent 
(cutaneous) malignancy research.46 Unfortunately, the number of studies providing SIRs 
of the tumour combinations of interest was low, which may be a KC specific problem. 
Most cancer registries do not register BCCs and those that do reliably report the first but 
not the subsequent BCCs because of the required resources and ‘coding’ difficulties.43,47 
Therefore, the risk of a subsequent BCC or SCC was mostly based on smaller studies 
that may have inflated the pooled proportions by selection bias. Also, no pooled CR 
estimates were calculated because only a few studies reporting the risk of BCC and SCC 
after a first KC provided this risk measurement. In contrast, studies investigating the risks 
of subsequent melanomas were more often larger cancer registry studies than studies 
investigating the risk of a subsequent BCC or SCC in patients with prior KC limiting the 
aforementioned limitations.
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Publication bias is likely to be minimal because the risk estimates of developing a 
subsequent cutaneous malignancy are probably increased in all studies, as illustrated in 
this review, minimising negative findings and thus publication bias.40 Furthermore, pub-
lication bias was unlikely due to symmetrical funnel plots and non-significant Egger’s 
tests. The systematic literature search was done by a medical librarian using a string and 
included congress abstracts and monographs (i.e. ‘grey literature’).48 However, language 
bias may have had an effect because only studies reported in English were eligible. To 
control for multiple publication bias, only the study that presented the most extensive 
results or had the longest follow-up was included.
ConCLUsion
A history of a prior KC is a very strong predictor for developing a subsequent BCC and 
SCC and to a lesser extent melanoma. Secondary prevention (early detection of subse-
quent episodes of the disease) is pivotal in patients with a prior KC. Patients should be 
well informed about future risk and require adequate follow-up by physicians.
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sUPPLeMenTAL TABLes And FigURes
supplemental Figure 1. Funnel plot with Egger’s test of studies reporting a proportion (%)
A Basal cell carcinoma (BCC) after BCC (p-value 0.06)
B Squamous cell carcinoma (SCC) after BCC (p-value 0.6)
C Melanoma after BCC (p-value 0.7)
d SCC after SCC (p-value 0.4)
e BCC after SCC (p-value 0.8)
F Melanoma after SCC (p-value 0.3)
g Keratinocyte carcinoma (KC) after KC (p-value 0.4)
See http://www.sciencedirect.com/science/article/pii/S0959804913002128 .
I | 3 | 86 I | 3 | 87
su
pp
le
m
en
ta
l T
ab
le
 1
. S
tu
dy
 c
ha
ra
ct
er
is
tic
sa
A
 B
as
al
 c
el
l c
ar
ci
no
m
a 
(B
CC
) a
s 
in
de
x 
tu
m
or
Re
fe
r-
en
ce
 
nu
m
be
r
Ye
ar
Co
un
tr
y
Ti
m
e 
pe
rio
d
St
ud
y 
de
si
gn
Ca
nc
er
re
gi
st
ry
H
os
pi
ta
l -
(H
) 
or
 p
op
ul
at
io
n 
(P
) -
ba
se
d
Su
bg
ro
up
N
o.
 o
f 
pa
tie
nt
s
%
 s
ub
-
se
qu
en
t 
tu
m
or
M
ea
n 
ag
e
(y
ea
rs
)
M
ea
n
fo
llo
w
-u
p
(y
ea
rs
)
Pe
rs
on
ye
ar
s
(t
ot
al
)
N
O
S
S 
C 
O
 T
BC
C 
af
te
r B
CC
56
19
75
U
SA
19
66
 - 
19
71
Re
tr
os
pe
ct
iv
e
Co
ho
rt
N
o
H
-
62
8
21
.5
-
-
-
0
0
0
0
(n
= 
19
)
18
19
90
U
SA
19
76
 - 
19
84
Re
tr
os
pe
ct
iv
e
Co
ho
rt
N
o
P
-
65
7
26
.0
65
5
-
4
0
2
6
21
19
92
U
K
19
79
 - 
19
89
Re
tr
os
pe
ct
iv
e
Co
ho
rt
Ye
s
H
15
 - 
34
 y
ea
r 
of
 a
ge
54
7.
4
30
1
-
3
0
1
4
57
20
04
Ita
ly
19
94
 - 
20
02
Re
tr
os
pe
ct
iv
e
Co
ho
rt
N
o
H
-
32
2
37
.6
68
6
-
0
1
1
2
51
20
11
N
et
he
rla
nd
s
20
04
 - 
20
09
Re
tr
os
pe
ct
iv
e
Co
ho
rt
N
o
P
-
2,
48
3
27
.7
65
5
12
,2
97
4
2
3
9
28
19
92
U
SA
19
80
 - 
19
89
Pr
os
pe
ct
iv
e
Co
ho
rt
N
o
H
M
ul
ti 
- 
ce
nt
er
 tr
ia
l
1,
73
5
37
.5
-
5
-
0
2
1
3
22
20
10
N
et
he
rla
nd
s
19
90
 - 
20
07
Pr
os
pe
ct
iv
e
Co
ho
rt
N
o
P
> 
55
 y
ea
r 
of
 a
ge
52
4
31
.1
69
12
6,
27
4
3
2
2
7
52
19
97
U
K
19
91
 - 
19
95
Re
tr
os
pe
ct
iv
e
Co
ho
rt
N
o
H
-
85
6
33
.9
68
-
-
1
0
0
1
49
20
06
Sw
itz
er
la
nd
19
76
 - 
20
03
Re
tr
os
pe
ct
iv
e
Co
ho
rt
Ye
s
P
-
1,
86
8
27
.1
69
-
20
,2
61
4
2
2
8
15
19
93
U
SA
-
Re
tr
os
pe
ct
iv
e
Co
ho
rt
N
o
H
W
hi
te
s
26
0
52
.7
59
7
-
0
1
2
3
23
20
06
U
K
19
99
 - 
20
00
Re
tr
os
pe
ct
iv
e
Co
ho
rt
N
o
H
O
nl
y 
lo
w
 
ris
k 
BC
C
11
4
16
.7
67
-
19
6
0
0
1
1
14
20
10
Sp
ai
n
19
97
 - 
20
07
Re
tr
os
pe
ct
iv
e
Co
ho
rt
N
o
H
O
nl
y 
so
lid
 
BC
C
10
6
10
.4
66
10
-
0
0
2
2
4
20
01
U
K
19
91
 - 
19
98
Pr
os
pe
ct
iv
e
Co
ho
rt
N
o
H
-
92
6
27
.8
-
-
-
0
0
0
0
5
20
09
U
K
19
91
 - 
19
98
Pr
os
pe
ct
iv
e
Co
ho
rt
N
o
H
-
17
4
48
.9
-
5
-
0
0
2
2
58
19
93
U
SA
19
83
 - 
19
87
Pr
os
pe
ct
iv
e
Co
ho
rt
N
o
P
-
24
2
16
.9
57
5
71
,8
88
2
0
1
3
59
20
04
Sp
ai
n
19
98
 - 
20
01
Pr
os
pe
ct
iv
e
Co
ho
rt
N
o
H
-
85
5.
9
3
-
1
0
2
3
16
20
10
Au
st
ra
lia
19
92
 - 
20
07
Pr
os
pe
ct
iv
e
Co
ho
rt
N
o
P 
/ fi
el
d 
tr
ia
l
-
40
1
57
.9
60
-
-
1
1
1
3
17
19
90
U
SA
19
85
 - 
19
88
Re
tr
os
pe
ct
iv
e
Co
ho
rt
Ye
s
P
-
4,
67
0
46
.9
-
-
-
3
1
1
5
50
20
05
N
et
he
rla
nd
s
19
93
 - 
19
98
Re
tr
os
pe
ct
iv
e
Co
ho
rt
N
o
H
-
23
7
29
.5
-
3.
1
-
1
2
2
5
I | 3 | 86 I | 3 | 87
su
pp
le
m
en
ta
l T
ab
le
 1
. (
co
nt
in
ue
d)
Re
fe
r-
en
ce
 
nu
m
be
r
Ye
ar
Co
un
tr
y
Ti
m
e 
pe
rio
d
St
ud
y 
de
si
gn
Ca
nc
er
re
gi
st
ry
H
os
pi
ta
l -
(H
) 
or
 p
op
ul
at
io
n 
(P
) -
ba
se
d
Su
bg
ro
up
N
o.
 o
f 
pa
tie
nt
s
%
 s
ub
-
se
qu
en
t 
tu
m
or
M
ea
n 
ag
e
(y
ea
rs
)
M
ea
n
fo
llo
w
-u
p
(y
ea
rs
)
Pe
rs
on
ye
ar
s
(t
ot
al
)
N
O
S
S 
C 
O
 T
sC
C 
af
te
r B
CC
60
20
09
Ire
la
nd
19
93
 - 
20
02
Re
tr
os
pe
ct
iv
e
Co
ho
rt
Ye
s
P
-
14
,4
42
2.
4
68
4
-
4
1
3
8
(n
= 
8)
18
19
90
U
SA
19
76
 - 
19
84
Re
tr
os
pe
ct
iv
e
Co
ho
rt
N
o
P
-
65
7
11
.0
65
-
-
4
0
1
5
57
20
04
Ita
ly
19
94
 - 
20
02
Re
tr
os
pe
ct
iv
e
Co
ho
rt
N
o
H
-
32
2
0.
9
68
6
-
0
1
1
2
61
19
98
Sw
itz
er
la
nd
19
74
 - 
19
94
Re
tr
os
pe
ct
iv
e
Co
ho
rt
Ye
s
P
-
11
,8
78
4.
2
68
-
76
,5
10
4
2
2
8
23
20
06
U
K
19
99
 - 
20
00
Re
tr
os
pe
ct
iv
e
Co
ho
rt
N
o
H
O
nl
y 
lo
w
 
ris
k 
BC
C
11
4
2.
6
67
-
19
6
0
0
1
1
76
20
10
U
K
19
98
 - 
20
07
Re
tr
os
pe
ct
iv
e
Co
ho
rt
Ye
s
P
-
-
-
-
-
-
2
0
1
3
59
20
04
Sp
ai
n
19
98
 - 
20
01
Pr
os
pe
ct
iv
e
Co
ho
rt
N
o
H
-
85
2.
4
-
3
-
1
0
2
3
17
19
90
U
SA
19
85
 - 
19
88
Re
tr
os
pe
ct
iv
e
Co
ho
rt
Ye
s
P
-
4,
67
0
19
.4
-
-
-
3
1
1
5
M
el
an
om
a
62
20
00
U
K
19
81
 - 
19
95
Re
tr
os
pe
ct
iv
e
Co
ho
rt
Ye
s
P
-
13
,9
61
0.
5
-
-
11
7,
93
9
4
1
2
7
af
te
r B
CC
60
20
09
Ire
la
nd
19
93
 - 
20
02
Re
tr
os
pe
ct
iv
e
Co
ho
rt
Ye
s
P
-
14
,4
42
0.
3
68
4
-
4
1
3
8
(n
= 
12
)
18
19
90
U
SA
19
76
 - 
19
84
Re
tr
os
pe
ct
iv
e
Co
ho
rt
N
o
P
-
65
7
1.
1
65
-
-
4
0
1
5
57
20
04
Ita
ly
19
94
 - 
20
02
Re
tr
os
pe
ct
iv
e
Co
ho
rt
N
o
H
-
32
2
0.
6
68
6
-
0
1
1
2
19
20
00
U
SA
19
74
 - 
19
97
Re
tr
os
pe
ct
iv
e
Ca
se
 - 
co
nt
ro
l
N
o
P
-
3,
16
4
2.
4
-
11
-
2
2
2
6
63
19
96
D
en
m
ar
k
19
78
 - 
19
91
Re
tr
os
pe
ct
iv
e
Co
ho
rt
Ye
s
P
-
37
,6
74
0.
4
68
4
19
0,
94
5
4
2
3
9
61
19
98
Sw
itz
er
la
nd
19
74
 - 
19
94
Re
tr
os
pe
ct
iv
e
Co
ho
rt
Ye
s
P
-
11
,8
78
0.
5
68
76
,5
10
4
2
2
8
64
19
91
Sw
ed
en
19
71
 - 
19
83
Re
tr
os
pe
ct
iv
e
Co
ho
rt
Pa
rt
ly
H
-
1,
97
3
0.
8
68
7
12
,8
67
1
1
2
4
65
20
00
Fi
nl
an
d
19
53
 - 
19
95
Re
tr
os
pe
ct
iv
e
Co
ho
rt
Ye
s
P
-
71
,9
24
0.
4
-
-
62
5,
14
4
4
2
2
8
20
20
05
Ca
na
da
 1
95
6 
- 2
00
0
Re
tr
os
pe
ct
iv
e
Co
ho
rt
Ye
s
P
-
28
,9
56
0.
5
67
-
28
2,
81
4
4
2
1
7
76
20
10
U
K
19
98
 - 
20
07
Re
tr
os
pe
ct
iv
e
Co
ho
rt
Ye
s
P
-
-
-
-
-
-
2
0
1
3
12
20
02
Bu
lg
ar
ia
19
93
 - 
20
00
Re
tr
os
pe
ct
iv
e
Co
ho
rt
Ye
s
P
-
1,
82
0
0.
1
-
-
15
,8
56
4
1
2
7
I | 3 | 88
su
pp
le
m
en
ta
l T
ab
le
 1
. (
co
nt
in
ue
d)
B 
Sq
ua
m
ou
s 
ce
ll 
ca
rc
in
om
a 
(S
CC
) a
s 
in
de
x 
tu
m
or
Re
fe
r-
en
ce
 
nu
m
be
r
Ye
ar
Co
un
tr
y
Ti
m
e
pe
rio
d
St
ud
y 
de
si
gn
Ca
nc
er
re
gi
st
ry
H
os
pi
ta
l -
(H
) 
or
 p
op
ul
at
io
n 
(P
) -
ba
se
d
Su
bg
ro
up
N
o.
 o
f 
pa
tie
nt
s
%
 s
ub
-
se
qu
en
t 
tu
m
or
M
ea
n 
ag
e
(y
ea
rs
)
M
ea
n
fo
llo
w
-u
p
(y
ea
rs
)
Pe
rs
on
ye
ar
s
(t
ot
al
)
N
O
S
S 
C 
O
 T
sC
C 
af
te
r s
CC
24
19
90
U
SA
19
76
 - 
19
84
Re
tr
os
pe
ct
iv
e
Co
ho
rt
N
o
P
-
16
9
11
.8
71
4
-
4
0
1
5
(n
=8
)
66
19
95
U
SA
19
83
 - 
19
87
Pr
os
pe
ct
iv
e
Co
ho
rt
N
o
P
-
58
13
.8
66
5
71
,8
88
2
0
1
3
67
20
01
Sw
ed
en
19
58
 - 
19
96
Re
tr
os
pe
ct
iv
e
Co
ho
rt
Ye
s
P
-
17
,4
38
6.
9
72
-
-
4
2
1
7
55
19
92
U
SA
19
80
 - 
19
88
Re
tr
os
pe
ct
iv
e
Co
ho
rt
N
o
H
O
nl
y 
th
os
e 
w
ho
 h
ad
 
M
M
S
10
1
-
67
5
-
0
2
1
3
28
19
92
U
SA
19
80
 - 
19
89
Pr
os
pe
ct
iv
e
Co
ho
rt
N
o
H
M
ul
ti-
ce
nt
er
 tr
ia
l
18
9
-
-
5
-
0
2
1
3
13
20
04
Sc
ot
la
nd
19
99
 - 
20
03
Re
tr
os
pe
ct
iv
e
Co
ho
rt
N
o
H
-
10
4
21
.2
77
4
-
0
1
1
2
17
19
90
U
SA
19
85
 - 
19
88
Re
tr
os
pe
ct
iv
e
Co
ho
rt
Ye
s
P
-
2,
19
2
17
.3
-
-
-
3
1
1
5
54
20
09
Au
st
ra
lia
19
96
 - 
20
06
Re
tr
os
pe
ct
iv
e
Co
ho
rt
N
o
H
-
40
-
65
8
-
0
0
3
3
BC
C 
af
te
r s
CC
60
20
09
Ire
la
nd
19
93
 - 
20
02
Re
tr
os
pe
ct
iv
e
Co
ho
rt
Ye
s
P
-
6,
40
1
5.
2
74
4
-
4
1
3
8
(n
=8
)
24
19
90
U
SA
19
76
 - 
19
84
Re
tr
os
pe
ct
iv
e
Co
ho
rt
N
o
P
-
16
9
43
.2
71
-
-
4
0
1
5
25
20
02
U
SA
19
74
 - 
19
89
Re
tr
os
pe
ct
iv
e
Ca
se
 - 
co
nt
ro
l
N
o
H
-
82
2
10
.8
-
8
-
2
0
2
4
13
20
04
Sc
ot
la
nd
19
99
 - 
20
03
Re
tr
os
pe
ct
iv
e
Co
ho
rt
N
o
H
-
10
4
14
.4
77
4
-
0
1
1
2
53
19
97
Sw
itz
er
la
nd
19
74
 - 
19
94
Re
tr
os
pe
ct
iv
e
Co
ho
rt
Ye
s
P
-
4,
63
9
6.
8
74
-
23
,1
52
4
2
2
8
76
20
10
U
K
19
98
 - 
20
07
Re
tr
os
pe
ct
iv
e
Co
ho
rt
Ye
s
P
-
-
-
-
-
-
2
0
1
3
17
19
90
U
SA
19
85
 - 
19
88
Re
tr
os
pe
ct
iv
e
Co
ho
rt
Ye
s
P
-
2,
19
2
43
.0
-
-
-
3
1
1
5
54
20
09
Au
st
ra
lia
19
96
 - 
20
06
Re
tr
os
pe
ct
iv
e
Co
ho
rt
N
o
H
-
40
-
65
8
-
0
0
3
3
M
el
an
om
a
60
20
09
Ire
la
nd
19
93
 - 
20
02
Re
tr
os
pe
ct
iv
e
Co
ho
rt
Ye
s
P
-
6,
40
1
0.
2
74
4
-
4
1
3
8
af
te
r s
CC
24
19
90
U
SA
19
76
 - 
19
84
Re
tr
os
pe
ct
iv
e
Co
ho
rt
N
o
P
-
16
9
1.
8
71
-
-
4
0
1
5
(n
=1
1)
25
20
02
U
SA
19
74
 - 
19
97
Re
tr
os
pe
ct
iv
e
Ca
se
 - 
co
nt
ro
l
N
o
H
-
82
2
1.
2
-
8
-
2
0
2
4
68
19
95
D
en
m
ar
k
19
78
 - 
19
89
Re
tr
os
pe
ct
iv
e
Co
ho
rt
Ye
s
P
-
5,
10
0
0.
3
75
-
22
,9
16
4
2
2
8
53
19
97
Sw
itz
er
la
nd
19
74
 - 
19
94
Re
tr
os
pe
ct
iv
e
Co
ho
rt
Ye
s
P
-
4,
63
9
0.
5
74
-
23
,1
52
4
2
2
8
69
20
05
U
K
19
61
 - 
20
00
Re
tr
os
pe
ct
iv
e
Co
ho
rt
Ye
s
P
-
25
,7
31
0.
3
-
4
1
1
6
20
20
05
Ca
na
da
19
56
 - 
20
00
Re
tr
os
pe
ct
iv
e
Co
ho
rt
Ye
s
P
-
7,
83
3
0.
5
73
-
61
,4
16
4
2
1
7
76
20
10
U
K
19
98
 - 
20
07
Re
tr
os
pe
ct
iv
e
Co
ho
rt
Ye
s
P
-
-
-
-
-
2
0
1
3
I | 3 | 89
su
pp
le
m
en
ta
l T
ab
le
 1
. (
co
nt
in
ue
d)
Re
fe
r-
en
ce
 
nu
m
be
r
Ye
ar
Co
un
tr
y
Ti
m
e
pe
rio
d
St
ud
y 
de
si
gn
Ca
nc
er
re
gi
st
ry
H
os
pi
ta
l -
(H
) 
or
 p
op
ul
at
io
n 
(P
) -
ba
se
d
Su
bg
ro
up
N
o.
 o
f 
pa
tie
nt
s
%
 s
ub
-
se
qu
en
t 
tu
m
or
M
ea
n 
ag
e
(y
ea
rs
)
M
ea
n
fo
llo
w
-u
p
(y
ea
rs
)
Pe
rs
on
ye
ar
s
(t
ot
al
)
N
O
S
S 
C 
O
 T
12
20
02
Bu
lg
ar
ia
19
93
 - 
20
00
Re
tr
os
pe
ct
iv
e
Co
ho
rt
Ye
s
P
-
74
1
0.
5
-
-
15
,8
56
4
1
2
7
70
19
99
Sw
ed
en
19
85
 - 
19
92
Re
tr
os
pe
ct
iv
e
Co
ho
rt
Ye
s
P
-
25
,9
47
0.
4
75
5
13
7,
31
2
4
2
3
9
54
20
09
Au
st
ra
lia
19
96
 - 
20
06
Re
tr
os
pe
ct
iv
e
Co
ho
rt
N
o
H
-
40
-
65
8
-
0
0
3
3
C.
 K
er
at
in
oc
yt
e 
ca
rc
in
om
a 
(K
C)
 a
s 
in
de
x 
tu
m
or
Re
fe
r-
en
ce
 
nu
m
be
r
Ye
ar
Co
un
tr
y
Ti
m
e
pe
rio
d
St
ud
y 
de
si
gn
Ca
nc
er
re
gi
st
ry
H
os
pi
ta
l -
(H
) 
or
 p
op
ul
at
io
n 
(P
) -
ba
se
d
Su
bg
ro
up
N
o.
 o
f 
pa
tie
nt
s
%
 s
ub
-
se
qu
en
t
tu
m
or
M
ea
n 
ag
e
(y
ea
rs
)
M
ea
n
fo
llo
w
-u
p
(y
ea
rs
)
Pe
rs
on
ye
ar
s
(t
ot
al
)
N
O
S
S 
C 
O
 T
kC
 a
ft
er
 k
C
26
20
02
Au
st
ra
lia
19
88
 - 
19
89
Pr
os
pe
ct
iv
e
Co
ho
rt
N
o
H
-
48
1
67
.8
-
10
-
0
1
2
3
(n
= 
8)
29
20
04
Sp
ai
n
19
95
 - 
20
01
Re
tr
os
pe
ct
iv
e
Co
ho
rt
N
o
H
-
53
5
22
.4
68
2
-
0
0
1
1
28
19
92
U
SA
19
80
 - 
19
89
Pr
os
pe
ct
iv
e
Co
ho
rt
N
o
H
M
ul
ti-
 
ce
nt
er
 tr
ia
l
1,
80
5
-
-
5
-
0
2
1
3
27
20
02
Au
st
ra
lia
19
97
 - 
19
99
Pr
os
pe
ct
iv
e
Co
ho
rt
N
o
P
-
6,
70
8
38
.5
-
-
-
2
0
1
3
71
20
01
U
SA
19
96
 - 
19
98
Re
tr
os
pe
ct
iv
e
Co
ho
rt
N
o
H
96
%
 o
n 
he
ad
 a
nd
 
ne
ck
44
0
39
.3
-
2
-
1
0
2
3
17
19
90
U
SA
19
85
 - 
19
88
Re
tr
os
pe
ct
iv
e
Co
ho
rt
Ye
s
P
-
6,
31
0
50
.0
69
-
-
3
1
1
5
72
20
01
D
en
m
ar
k
19
95
 - 
19
98
Pr
os
pe
ct
iv
e
Co
ho
rt
N
o
H
-
63
8
27
.1
-
2
-
0
0
0
0
72
20
01
D
en
m
ar
k
19
90
 - 
19
93
Pr
os
pe
ct
iv
e
Co
ho
rt
N
o
H
-
52
6
20
.3
-
2
-
0
0
0
0
A
bb
re
vi
at
io
ns
: B
CC
, b
as
al
 c
el
l c
ar
ci
no
m
a;
 H
, h
os
pi
ta
l-b
as
ed
; K
C,
 k
er
at
in
oc
yt
e 
ca
rc
in
om
a;
 N
, n
um
be
r; 
N
A
, n
ot
 a
pp
lic
ab
le
; N
O
S,
 N
ew
ca
st
le
 –
 O
tt
aw
a 
sc
al
e;
 P
, P
op
ul
at
io
n-
ba
se
d;
 
SC
C,
 s
qu
am
ou
s 
ce
ll 
ca
rc
in
om
a;
 S
CO
T,
 S
el
ec
tio
n 
Co
m
pa
ra
bi
lit
y 
O
ut
co
m
e 
To
ta
l N
O
S;
 U
SA
, U
ni
te
d 
St
at
es
 o
f A
m
er
ic
a.
a  T
he
 fo
llo
w
in
g 
in
fo
rm
at
io
n 
w
as
 e
xt
ra
ct
ed
 fr
om
 e
ac
h 
st
ud
y:
 (1
) s
tu
dy
 d
es
ig
n;
 (2
) i
n 
- a
nd
 e
xc
lu
si
on
 c
rit
er
ia
 o
f t
he
 s
tu
dy
; (
3)
 a
bs
tr
ac
t o
r f
ul
l t
ex
t; 
(4
) t
he
 n
um
be
r o
f f
ol
lo
w
ed
 
pa
tie
nt
s 
w
ith
 a
 (fi
rs
t)
 B
CC
, S
CC
 o
r K
C 
(t
he
 la
tt
er
, w
he
n 
on
ly
 c
om
bi
ne
d 
da
ta
 o
n 
BC
C 
an
d 
SC
C 
w
er
e 
av
ai
la
bl
e)
; (
5)
 c
ha
ra
ct
er
is
tic
s 
of
 s
tu
dy
 p
op
ul
at
io
n 
(s
ex
, m
ea
n 
[S
D
; s
ta
nd
ar
d 
de
vi
at
io
n]
 o
r m
ed
ia
n 
ag
e 
in
 y
ea
rs
, m
ea
n 
[S
D
] o
r m
ed
ia
n 
fo
llo
w
-u
p 
tim
e 
in
 y
ea
rs
, t
ot
al
 n
um
be
r o
f p
er
so
n-
ye
ar
s)
; (
6)
 ri
sk
 e
st
im
at
e 
of
 d
ev
el
op
in
g 
a 
se
co
nd
 o
r s
ub
se
qu
en
t B
CC
, 
SC
C,
 m
el
an
om
a 
or
 K
C 
(i.
e.
 p
ro
po
rt
io
n,
 c
um
ul
at
iv
e 
ris
k 
[C
R]
, s
ta
nd
ar
di
ze
d 
in
ci
de
nc
e 
ra
tio
 [S
IR
]);
 (7
) fi
rs
t c
ut
an
eo
us
 m
al
ig
na
nc
y 
w
ith
in
 p
at
ie
nt
 (y
es
, n
o 
or
 u
nk
no
w
n)
; (
8)
 in
cl
us
io
n 
of
 in
 s
itu
 c
ut
an
eo
us
 m
al
ig
na
nc
ie
s 
(y
es
, n
o 
or
 u
nk
no
w
n)
; (
9)
 s
tu
dy
 lo
ca
tio
n 
an
d 
co
nt
in
en
t; 
(1
0)
 y
ea
r o
f p
ub
lic
at
io
n.
In
 st
ud
ie
s p
ro
vi
di
ng
 a
 C
R 
fo
r m
en
 a
nd
 w
om
en
 se
pa
ra
te
ly
 w
ith
ou
t a
n 
ov
er
al
l C
R,
 th
es
e 
nu
m
be
rs
 w
er
e 
av
er
ag
ed
. D
iff
er
en
t n
om
en
cl
at
ur
e 
in
 m
ed
ic
al
 li
te
ra
tu
re
 is
 u
se
d 
fo
r t
he
 ri
sk
 
m
ea
su
re
 ‘S
ta
nd
ar
di
se
d 
In
ci
de
nc
e 
Ra
tio
’ (
SI
R)
, t
he
re
fo
re
 ‘r
el
at
iv
e 
ris
k’
 (R
R)
 a
nd
 o
bs
er
ve
d 
di
vi
de
d 
by
 e
xp
ec
te
d 
(O
:E
) w
er
e 
al
so
 c
on
si
de
re
d 
a 
SI
R.
I | 3 | 90
supplemental Table 2. Search strategy and strings
See chapter 2 and http://www.sciencedirect.com/science/article/pii/S0959804913002128 .
supplemental Table 3A. Adapted Newcastle – Ottawa quality assessment scale for cohort studies
See chapter 2 and http://www.sciencedirect.com/science/article/pii/S0959804913002128 .
supplemental Table 3B. Adapted Newcastle – Ottawa quality assessment scale for case-control studies
See chapter 2 and http://www.sciencedirect.com/science/article/pii/S0959804913002128 .
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Chapter 4
Risk of second primary in situ and invasive 
melanoma in Dutch population-based cohort: 
1989 – 2008
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L. Liu
J.W.W. Coebergh
H.A.M. Neumann
W.J. Mooi
T. Nijsten
E. de Vries
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sUMMARy
Background
Patients with melanoma are at increased risk of developing a subsequent melanoma.
objectives
To estimate the risks of developing a second primary in situ or invasive cutaneous mela-
noma after a first melanoma, between 1989 and 2008.
Methods
Patients were followed until diagnosis of a second melanoma, date of death or end of 
study. Cumulative risks, standardized incidence ratio (SIR, observed second melanomas 
divided by background age-, calendar- and sex-specific incidence rates of melanoma, as 
recorded in the Netherlands Cancer Registry) and absolute excess risk (AER, observed 
minus expected per 10,000 person-years) of second melanomas were calculated.
Results
In total, 10 765 patients with in situ melanoma and 46 700 with invasive melanoma were 
included. Cumulative risks of a second invasive melanoma after a first in situ or invasive 
melanoma at 20 years of follow-up were 6.2% and 5.0%, respectively. Relative risk of 
developing any melanoma (in situ or invasive) after any first melanoma (SIR) was 12.4 
[invasive after invasive melanoma; 95% Confidence Interval (CI) = 11.6–13.2] to 26.4 [in 
situ after in situ melanoma; 95% CI = 22.6–30.7] fold increased compared to the general 
population. SIRs and AERs remained elevated up to 20 years after the first melanoma.
Conclusions
This study shows significantly increased long-term risks (both relative and absolute) of 
developing a second invasive melanoma after a first melanoma (invasive and in situ), 
and might serve as a basis for follow-up guidelines.
Funding sources: This study is funded by the Dutch Cancer Society (KWF): The increasing 
burden of second primary cancers in the Netherlands: trend in incidence, survival and 
causes-of-death since 1970 (EMCR 2008-4132).
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inTRodUCTion
The incidence rate of cutaneous melanoma (melanoma) in Europe has increased annually 
over the last 50 years.1 In the Netherlands, the European standardized incidence rate has 
almost doubled between 1989 and 2008 from 11 per 100,000 person-years to 22 with an 
Estimated Annual Percentage Change of 4.1% (95% Confidence Interval: 3.6 – 4.5).2 This 
rising trend has been reported previously in several studies1,3-5, and is usually attributed 
to increased sun exposure in the general population, especially at young ages. The ma-
jority of melanomas are detected in early stages2, when simple excision often results in 
cure. Consequentially, survival rates are relatively high (in the time period 2004-2008 the 
10-year relative survival of melanoma in the Netherlands was 77% and 88% for males 
and females, respectively).2 Thirty percent of melanoma patients report symptoms of 
psychological distress.6 Second melanomas detected among melanoma patients who 
were not under active follow-up had a higher Breslow thickness compared with those 
in follow-up7, suggesting a beneficial effect, although methodological difficulties in that 
study preclude an unequivocal conclusion.
The melanoma guideline in the Netherlands advises different follow-up schemes for cu-
taneous melanoma patients depending on Breslow thickness: patients with melanomas 
with a Breslow thickness of less than 1 millimeter (mm) require a single control visit, 
one month after treatment; those with 1 to 2 mm thickness are advised a follow-up 
time of 5 years and those with more than 2 mm thickness are advised to be in follow-up 
for 10 years (www.cbo.nl, accessed 1 February 2012; Guideline Melanoma of the skin, 
2005). Internationally, follow-up guidelines vary considerably, from one control visit one 
month after treatment in the Netherlands, to lifelong annual follow-up visits for all stage 
I melanomas in Australia / New Zealand8, which suggests a perception of the underlying 
risk. Follow-up schemes for in situ melanoma patients have not been formulated in the 
Dutch guideline.
In this study we investigated the risk pattern of second primary cutaneous melanomas 
among patients with melanoma (both invasive and in situ) in the Netherlands, by dura-
tion of follow-up, in order to provide information for optimal follow-up guidelines.
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MeThods
data
The population-based Netherlands Cancer Registry (NCR) provided incidence data of all 
patients diagnosed with in situ (International Classification of Diseases (ICD)-10 D.03) and 
invasive (ICD-10 C.43) cutaneous melanoma between 1989 and 2008. Information on vital 
status was obtained by linkage with the Dutch Municipality Register. Recurrence data were 
not collected. Detailed description of data has been described elsewhere.2 The locations 
of the in situ and invasive melanomas were subdivided in the categories head and neck, 
trunk, arms, legs, other (including genital region) and unknown. The most common histo-
pathological subtypes of melanoma were categorized as superficial spreading melanoma 
(SSM), nodular melanoma, acrolentiginous melanoma (ALM), lentigo maligna melanoma 
(LMM), lentigo maligna, melanoma in situ and other. Breslow thickness was categorized 
into 5 categories: lower than or equal to 1 mm, 1.01 – 2.0 mm, 2.01 – 4.0 mm, higher than 
4 mm and unknown. The tumour stage was not used, as the criteria have changed repeat-
edly in the past.
Patient selection
Patients diagnosed with an either in situ or invasive cutaneous melanoma between 
1989 and 2008 were included. Person-years at risk were calculated as time from first 
cancer diagnosis until the diagnosis of a second primary melanoma (for invasive and 
in situ, separately), date of death or end of follow-up (December 31 2008), whichever 
came first. It is of note that all the second melanomas were included. For instance, after a 
first melanoma diagnosis, if the second cancer is non-melanoma cancer and the third is 
melanoma, this melanoma is included, and so forth for other rank cancers. Patients were 
excluded if other invasive cancers were diagnosed before the first primary melanoma.
statistical analysis
To analyze heterogeneity in characteristics (sex, tumour location, Breslow thickness and 
histopathological subtype) between first primary invasive melanomas and second pri-
mary melanomas the Chi-square test was used. The cumulative risk of second melanoma 
up to 20 years after diagnosis of the first melanoma was calculated taking the competing 
risks invasive cancers (other than melanoma) and death into account.9 The standardized 
incidence ratio (SIR) is the ratio between the observed number of second melanomas and 
the expected number from the general population. It is a useful multiplicative measure 
for determining excess risk of second melanoma relative to the background risk in the 
general population. To derive the expected numbers, person-years under age-specific 
(5-year band), calendar-specific (1-year band) and sex-specific strata were multiplied with 
the corresponding background incidence rate from the general Dutch population. SIR > 
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1 indicates that the risk of developing a second melanoma is higher among melanoma 
patients than among the general population. Absolute excess risk (AER) is an additive 
measure for determining additional incidence beyond background incidence due to oc-
currence of a second melanoma. It is expressed as the difference between the observed 
number and the expected number per 10,000 person-years (i.e. (O-E) / person-years at 
risk x 10,000). Both SIR and AER were illustrated under follow-up periods of 0-1 year, 2-5 
years, 6-10 years, 10-15 years and 16-20 years after the first melanoma diagnosis. The 95% 
CI was under Poisson distribution and the statistical significance level was estimated as 
two-sided at 0.05.
ResULTs
Cohort characteristics
Of the 57,465 patients with a first primary melanoma (10,765 in situ and 46,700 invasive 
conditions), 3.2% (n=1,840) developed a second primary melanoma between 1989 and 
2008. The majority of second melanomas (71%) were invasive (n=1,301). Median follow-
up time for in situ melanoma patients was 5.4 years (Interquartile range (IQR) = 2.3-9.9 
years; male) and 6.1 years (IQR = 2.7-10.7 years; female) and for invasive melanoma 
patients 4.2 years (IQR = 1.7-8.9 years; male) and 5.6 years (IQR = 2.3-10.8 years; female).
Table 1 shows the characteristics of the first and second melanomas among the in situ 
and invasive melanoma patients with second primary melanomas. The median age of 
patients with a first in situ melanoma was 64 years (Interquartile range (IQR) = 52–74 
years) and with a first invasive melanoma 52 years (IQR = 40–64 years). First in situ mela-
nomas were most frequently (61%) located in the head or neck area, whereas first inva-
sive melanomas were most frequently located on the trunk (36%). The most frequently 
occurring histopathological subtypes of the first and second invasive melanomas were 
SSM (57% and 67% respectively) and nodular melanoma (13% and 9%, respectively). 
First and second in situ melanomas were predominantly lentigo maligna (62% and 76%, 
respectively). On average, second melanomas were thinner than the first invasive mela-
nomas (Table 1). In the majority of the cases second melanomas occurred in the first 5 
years after the first melanoma diagnosis (Table 1). The differences in sex of patients with 
a second primary melanoma are shown in Supplementary Table 1 (Table S1).
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Table 1. Characteristics of patients with second melanomas after a first in situ or invasive melanoma, 1989-
2008
1st in situ melanomaa 1st invasive melanomab
n % Median age
(yr) (iQR)
n % Median age
(yr) (iQR)
number patients with 
2nd melanoma
Total 471 4.4 64 (52 - 74) 1,369 2.9 52 (40 - 64)
Second in situ 173 36.7 70 (60 - 79) 366 26.7 60 (46 - 72)
Second 
invasive
298 63.3 69 (55 - 78) 1,003 73.3 55 (43 - 66)
site of 1st melanoma Head 287 60.9 68 (61 - 77) 208 15.2 64 (50 - 75)
Trunk 74 15.7 52 (42 - 63) 498 36.4 49 (39 - 60)
Arms 56 11.9 53 (38 - 64) 285 20.8 54 (42 - 65)
Legs 50 10.6 50 (35 - 67) 359 26.2 48 (36 - 60)
unknown / 
other
4 0.8 67 (65 - 75) 19 1.4 55 (41 - 64)
site of 2nd in situ 
melanoma
Head 118 68.2 73 (64 - 81) 104 28.4 72 (62 - 80)
Trunk 11 6.4 60 (44 - 63) 98 26.8 54 (42 - 63)
Arms 17 9.8 61 (52 - 71) 85 23.2 62 (49 - 73)
Legs 25 14.5 55 (45 - 72) 78 21.3 50 (38 - 62)
unknown / 
other
2 1.2 76 (75 - 77) 1 0.3 63 (63 - 63)
site of 2nd invasive 
melanoma
Head 144 48.3 75 (67 - 82) 167 16.7 64 (48 - 77)
Trunk 60 20.1 57 (45 - 68) 361 36.0 54 (43 - 63)
Arms 41 13.8 67 (57 - 76) 216 21.5 56 (44 - 69)
Legs 47 15.8 59 (43 - 71) 254 25.3 52 (41 - 63)
unknown / 
other
6 2.0 51 (38 - 68) 5 0.5 65 (54 - 75)
histopathological 
subtype 1st melanoma
NMc 1 0.2 73 (73 - 73) NM 181 13.2 56 (41 - 66)
SSMc 47 10.0 50 (36 - 63) SSM 776 56.7 49 (38 - 60)
LM 291 61.8 68 (61 - 77) LMM 52 3.8 70 (62 - 78)
MEL IN SITU 113 24.0 49 (40 - 63) MM NOS 304 22.2 51 (41 - 65)
ALMc 1 0.2 54 (54 - 54) ALM 8 0.6 67 (59 - 78)
other 18 3.8 70 (62 - 73) other 48 3.5 60 (52 - 69)
histopathological 
subtype 2nd in situ 
melanoma
SSMc 11 6.4 65 (54 - 77) SSMc 29 7.9 56 (46 - 65)
LM 131 75.7 73 (63 – 80) LM 147 40.2 71 (59 - 78)
MEL IN SITU 29 16.8 56 (44 - 68) MEL IN SITU 185 50.5 51 (41 - 63)
ALMc 1 0.6 67 (67 - 67) ALMc 1 0.3 32 (32 - 32)
other 1 0.6 52 (52 - 52) other 4 1.1 70 (62 - 80)
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Table 1 (continued)
1st in situ melanomaa 1st invasive melanomab
n % Median age
(yr) (iQR)
n % Median age
(yr) (iQR)
histopathological 
subtype 2nd invasive 
melanoma
NM 29 9.7 72 (62 - 81) NM 91 9.1 54 (40 - 69)
SSM 134 45.0 62 (46 - 72) SSM 667 66.5 54 (42 - 64)
LMM 59 19.8 75 (64 - 80) LMM 42 4.2 69 (62 - 79)
MM NOS 59 19.8 68 (52 - 81) MM NOS 164 16.4 54 (43 - 70)
ALM 0 0.0 NA ALM 4 0.4 59 (52 - 71)
other 17 5.7 71 (69 - 78) other 35 3.5 62 (55 - 74)
Breslow thickness 1st 
invasive melanomad
≤ 1 mm 586 55.5 49 (39 - 61)
1.01 - 2.0 mm 230 21.8 54 (46 - 66)
2.01 - 4.0 mm 142 13.5 59 (46 - 70)
> 4 mm 62 5.9 65 (56 - 72)
Unknown 35 3.3 54 (40 - 73)
Breslow thickness 2nd 
invasive melanomad
≤ 1mm 176 61.8 64 (49 - 75) ≤ 1mm 660 70.3 54 (43 - 65)
1.01 - 2.0 mm 42 14.7 73 (59 - 82) 1.01 - 2.0 mm 160 17.0 56 (44 - 67)
2.01 - 4.0 mm 34 11.9 77 (69 - 81) 2.01 - 4.0 mm 55 5.9 64 (51 - 77)
> 4 mm 14 4.9 79 (67 - 93) > 4 mm 34 3.6 72 (57 - 82)
unknown 19 6.7 71 (63 - 80) Unknown 30 3.2 57 (46 - 71)
Time to 2nd in situ 
melanoma
0 – 1 year 40 23.1 NA 134 36.6 NA
2 – 5 years 75 43.4 NA 134 36.6 NA
6 – 10 years 43 24.9 NA 61 16.7 NA
11 – 14 years 12 6.9 NA 28 7.7 NA
15 – 20 years 3 1.7 NA 9 2.5 NA
Time to 2nd invasive 
melanoma
0 – 1 year 53 17.8 NA 312 31.1 NA
2 – 5 years 125 41.9 NA 347 34.6 NA
6 – 10 years 74 24.8 NA 221 22.0 NA
11 – 14 years 36 12.1 NA 94 9.4 NA
15 – 20 years 10 3.4 NA 29 2.9 NA
Source: Netherlands Cancer Registry
a Total cohort of 10,765 in situ melanoma patients at risk; Person-years at risk 73,743; Median follow-up time 
males 5.4 years [IQR 2.3-9.9] and females 6.1 years [2.7-10.7]. b Total cohort of 46,700 invasive melanoma 
patients at risk; Person-years at risk 301,758; Median follow-up time males 4.2 years [IQR 1.7 - 8.9] and fe-
males 5.6 years [2.3 – 10.8]. c In situ melanoma with (erroneous) invasive morphology code. d Only Breslow 
thickness available in time period 1993 – 2008. Abbreviations: ‘IQR’= Interquartile range, ‘NM’= Nodular 
melanoma, ‘SSM’= Superficial spreading melanoma, ‘LM’= Lentigo Maligna, ‘LMM’= Lentigo Maligna Mela-
noma, ‘MEL IN SITU’= Melanoma in situ, ‘MM NOS’= Malignant melanoma not otherwise specified, ‘ALM’= 
Acrolentiginous melanoma, ‘mm’= millimeter, ‘NA’= not applicable.
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In Table 2 the characteristics of the first and second invasive melanomas are compared. 
Patients’ sex distributions of the first and the second primary melanomas were com-
parable. The localisation distribution differed significantly; second melanomas were 
more likely to occur in the head region than the first melanomas (24% vs. 13%, p<0.0001 
with four degrees of freedom) as is confirmed by the significantly higher proportion 
of lentigo maligna melanoma (LMM) among the second melanomas (8% versus 3%). 
Second primary melanoma showed a higher frequency of superficial spreading mela-
noma (SSM) compared to the first melanoma (62% and 55% respectively, p<0.0001 with 
five degrees of freedom). The Breslow thickness of second melanomas was less than 
or equal to 2 mm in 85% of the cases compared to 75% in the first melanoma group. 
Table 2. Comparison of tumour characteristics of the first invasive melanoma and a second primary inva-
sive melanoma
1st melanoma
(n)a
% 2nd melanoma
(n)
% p-valueb (degrees
of freedom)
sex
Male 19,664 42.1 569 43.7 0.2407 (1)
Female 27,036 57.9 732 56.3
site of melanoma
Head 5,866 12.6 311 23.9 <0.0001 (4)
Trunk 16,156 34.6 421 32.4
Arms 8,865 19.0 257 19.8
Legs 13,864 29.7 301 23.1
unknown / other 1,949 4.2 11 0.9
histopathological subtype
NM 6,546 14.0 120 9.2 <0.0001 (5)
SSM 25,576 54.8 801 61.6
LMM 1,332 2.9 101 7.8
MM NOS 10,999 23.6 223 17.1
ALM 382 0.8 4 0.3
other 1,865 4.0 52 4.0
Breslow thickness
≤ 1 mm 21,276 54.9 836 68.3 <0.0001 (4)
1.01 - 2.0 mm 7,952 20.5 202 16.5
2.01 - 4.0 mm 5,061 13.0 89 7.3
> 4 mm 3,111 8.0 48 3.9
unknown 1,384 3.6 49 4.0
Source: Netherlands Cancer Registry
aAll first invasive melanomas in the database, regardless of occurrence of a second melanoma in the same 
patient. bChi-square test. Abbreviations: ‘SSM’= Superficial spreading melanoma, ‘NM’= Nodular melanoma, 
‘LMM’= Lentigo Maligna Melanoma, ‘ALM’= Acrolentiginous melanoma, ‘mm’= millimeter.
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Thick melanomas (>4 mm) were more common in the first invasive melanoma group 
(8% vs. 4%, p<0.0001 with four degrees of freedom).
Cumulative risk
The 5-year cumulative risk of getting a second invasive melanoma after a first in situ or 
first invasive melanoma was 2.1% and 1.8%, respectively, 10-year cumulative risk was 
3.7% and 3.0%, 15-year cumulative risk was 5.2% and 4.0% and 20-year cumulative risk 
was 6.2% and 5.0%. The cumulative risk of developing a second primary in situ or inva-
sive melanoma increased constantly with follow-up time (follow-up time 0–20 years) 
(Figure 1). Cumulative risk of an invasive melanoma after a first invasive melanoma was 
consistently higher for females than for males (Figure 2).
standardized incidence ratio (siR) and Absolute excess risk (AeR)
SIRs of developing a second primary melanoma after a first melanoma were highest 
in the first year after the first melanoma diagnosis for all groups (SIRs 16.5 [95% CI = 
11.0 – 24.0] – 53.7 [95% CI = 40.2 – 70.4]) but remained elevated up to 20 years after the 
first melanoma diagnosis (Table 3). Patients with an in situ melanoma were at increased 
risk of developing a second in situ melanoma (SIR 26.4 [95% CI = 22.6 – 30.7]) or second 
invasive melanoma compared to the general population (SIR 15.4 [13.7 – 17.3]). SIR of 
an invasive melanoma after an invasive melanoma was 12.4 [11.6 – 13.2] and SIRs of 
this group were consistently higher for male patients compared to female patients, 
regardless of time since diagnosis. AERs were highest in the first year after the first 
melanoma and decreased over follow-up time. The AERs of an invasive melanoma after 
a first invasive melanoma were 36.4 / 10,000 (males) and 27.0 / 10,000 (females) person-
years, and after a first in situ melanoma 44.0 / 10,000 (males) and 34.4 / 10,000 (females) 
person-years (Table 3).
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Figure 1(a). Cumulative risk of second melanomas after a first in situ melanoma
Figure 1(b). Cumulative risk of second melanomas after a first invasive melanoma
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disCUssion
This large, population based study investigating risks of developing second melano-
mas in cohorts of patients with both in situ and invasive melanoma showed markedly 
increased total relative (12 to 26 fold) and absolute risks (11 to 38 per 10,000 person-
years). These risks remained increased for more than 15 years after the first diagnosis of 
melanoma.
In our data, 2.1% of patients developed a second primary invasive melanoma after a first 
invasive melanoma and the average 20-year cumulative risk was 5.6%. Internationally, 
considerable variations in incidence figures of a second melanoma after a first melanoma 
(range proportions: 1.0% - 4.4% and cumulative risks: 5.0% - 8.1%) have been reported 
(Table 4).10-16 The SIRs in the Netherlands were high compared to relative risks reported 
in other countries which varied from 3.4 [95% CI = 1.9 – 5.6] to 38.5 [95% CI = 30.4 – 48.1] 
(Table 4).10-15,17 Explanations should be sought in underlying incidence rates (shared risk 
factors or detection), chance of survival after the first cancer18 or diagnostic bias / misclas-
sification. Besides, as the SIR is a ratio of incidence rates in the cohort under study and 
the background population, the level of SIR will be strongly influenced by background 
incidence rates, the high background incidence rates in Australia may explain the lower 
SIR from Victoria, Australia.11 A German study showed a high SIR of up to 38.513, probably 
Figure 2. Cumulative risk of second invasive melanomas in male and female patients with invasive mela-
nomas
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caused by high numbers of second melanomas detected in a selected hospital-based study 
population which were divided by cancer registry background incidence rates. Finally, 
estimates will be influenced by the length of follow-up and degree of completeness of the 
cancer registry.19 The Netherlands Cancer Registry is assumed to be 98.3% complete.20 At 
this moment only two studies have calculated SIRs after a first in situ melanoma in which 
increased risks for more than 10 years after the first in situ melanoma were reported as 
well.10,15 However, the Swedish data were relatively old and the sample size was low. AER 
was calculated in two previous studies and our findings are in agreement with theirs.10,21
A high incidence of melanoma in a group of melanoma patients might be related to 
high risk factor exposure, but also to increased patients’ and doctors’ awareness, diag-
nostic bias or registry artefacts. Slowly growing tumours are more likely to be discovered 
through this mechanism, illustrating length-time bias.19,22 Previous studies observed 
high relative risks of developing a second melanoma related to fair skin type, presence 
of many or atypical moles and family history / genetic susceptibility of the melanoma 
patients, and modestly increased risks for patients whose first melanoma was an in situ 
/ lentigo maligna or invasive melanoma23-25 suggesting biologically increased risks. The 
NCR does not have information on risk factors like phototype or sun exposure and there-
fore we performed univariate analysis for age, sex, histopathological subtype, Breslow 
thickness and tumour location to predict occurrence of second melanomas, however, 
none of the above-listed factors yielded statistical significance (data not shown).
The histological interpretation of very small and difficult to interpret melanocytic le-
sions from patients with a history of melanoma is likely to result in some melanoma 
overdiagnosis, and in enrichment of the total group of second primary melanomas 
with exceedingly small and thin lesions that have been inappropriately labelled as 
melanoma. Benign lesions that are misclassified as melanoma could be a cause of, or 
contribute to, the melanoma ‘epidemic’.26-28 A recent paper stated that follow-up visits 
are an effective method to increase early detection of melanoma.7 However, the second 
melanomas in the follow-up group of this study were extremely thin (mean Breslow 
thickness: 0.36 mm) or melanomas in situ, and could indeed have included overdiag-
nosed small melanoma simulators. So, intensive follow-up visits might increase the risk 
of an inappropriate additional diagnosis of melanoma. Indications for the occurrence of 
this phenomenon are also present in our data (Table 1); we found that the majority of 
the second melanomas were found in the first 5 years after the first melanoma diagnosis 
when the most follow-up visits are scheduled. However, whether or not patients follow 
the Dutch guideline follow-up visit scheme in our study is unknown.
Women could be at increased risk (Figure 2) of developing second melanomas compared 
to males because of higher awareness. This increased risk could also correspond to the 
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higher incidence of primary melanoma in women in most European countries5 and the 
better survival of women with melanoma29-30 allowing women more time to develop a 
subsequent melanoma.
The increased risk of developing a second primary melanoma up to 20 years after the 
first melanoma diagnosis might be an indication for more extensive follow-up programs, 
although the effectiveness of follow-up programs in improving prognosis is controver-
sial.8,31-32 Analyses on potential differences in survival of the group of multiple melanoma 
patients versus the group with only one melanoma could give further information on 
the prognostic importance of the diagnosis of a second melanoma. This data may shed 
light on importance of increased surveillance of patients with a first primary melanoma.
Currently, there is not enough available evidence to prove efficacy of skin cancer 
screening.33-35 Selecting and examining high-risk populations (for melanoma e.g., geno-
dermatosis including Familial Atypical Mole - Malignant Melanoma (FAMMM) syndrome) 
and performing full body skin examination of people visiting physicians (i.e., ‘case find-
ing’ by clinicians) might be the best strategy to decrease the burden of skin cancer.34 
Education of nurses or physiotherapists could also be an important method to improve 
early detection36, but large studies are lacking.
In addition to disease progression and psychological support, follow-up visits suggested 
by malignant melanoma guidelines should include total body skin examinations to 
exclude second primary melanoma, because this patient group is at a highly increased 
risk. A SIR greater than 10.0 with an AER of more than 5.0 per 10,000 person-years is, 
in our opinion, large enough to conclude that a history of either an in situ or invasive 
melanoma is a strong risk indicator for detection of subsequent invasive melanomas 
and that both in situ and invasive melanoma patients must be considered to be at high 
risk and patient education and full body skin examinations should be performed during 
follow-up visits. Since the excess risk is persistent in time (up to 20 years), the duration of 
current follow-up recommendations for this indication remains debatable. A melanoma 
follow-up study found a relatively low delay in diagnosis when a follow-up schedule 
with lower frequency than current guidelines was used.37 However, large randomized 
controlled trials investigating duration and frequency of follow-up visits and follow-up 
procedures are suggested.
In conclusion, the risk of developing a second primary melanoma is elevated for at 
least 20 years after the first melanoma diagnosis. The explanation of this increased risk 
is multifactorial and includes genetic predisposition, shared environmental risk factors 
and overdiagnosis. Nevertheless, patients and physicians need to be aware of the high 
and persistent risk of developing second primary melanomas.
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Screening for second primary melanomas: 
is it efficient? Reply from authors
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MADAM, Geurts et al1 estimated the expected impact of prolonged follow-up of pa-
tients with a history of invasive melanoma on health care services. They concluded that 
extension of the follow-up period will result in overdiagnosis, overtreatment, anxiety in 
patients and a tripled workload for dermatologists. We agree that prolonged follow-up 
may have negative side effects and associated costs. However, purely from the perspec-
tive of secondary tumours there does not seem to be an upper limit of follow-up time 
after which the incidence decreases.
Reasons for follow-up of patients with melanoma include detection of a recurrence, 
diagnosis of second primary melanomas (and other cutaneous malignancies) and 
psychosocial support / information provision. The majority of recurrences and second 
primary melanomas are found in the first 5 years after the first melanoma diagnosis. The 
risk of recurrences decreases rapidly after the first 5 years of follow-up2, but our results 
showed that the risk of a second primary melanoma remains constantly increased for at 
least 20 years in both in situ and invasive melanoma patients (probably lifelong).3
 The new Dutch melanoma guideline is quite conservative and recommends mela-
noma patients to come back once one month after treatment of the primary melanoma 
combined with instructions for self-diagnosis (stage IA) and up to 5 years after diagnosis 
of the first melanoma (≥stage IB).4 Studies concerning self-diagnosis showed that first 
recurrences of melanoma are most often detected by the patients themselves (76%).5 
The ability to auto-detect thin second primary melanomas seemed to be more difficult 
in patients with a history of melanoma (46%).6 The 5-year follow-up period after a pri-
mary melanoma is generally accepted by clinicians. However, the patients’ perspective 
has not been included in determining this cut off.
Geurts et al1 pointed to potential negative psychosocial consequences for the pa-
tients with melanoma, but did not mention the fact that a proportion of the patients 
with melanoma find it re-assuring to have full body skin examinations more often than 
strictly recommended, as shown in a recent Dutch population based survey. This survey 
showed that almost 80% of patients with a melanoma Breslow thickness of less than 1 
mm reported more follow-up visits than the guideline recommended and also patients 
with thicker melanomas showed ‘’overconsumption’’ of health care.7 This overconsump-
tion (from the perspective of the physician and health care policy maker) may be due 
to patients asking for additional information about different aspects of melanoma8 or 
another full body skin examination, and to a lesser extent due to physicians’ preference.
In our opinion the duration and frequency of follow-up visits remain debatable and 
more research is needed to clarify the influence of follow-up visit schemes on melanoma 
survival and quality of life of melanoma survivors.
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Cohort studies (and skin cancer) 
never come alone
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ABsTRACT
A previous keratinocyte carcinoma is probably the strongest predictor of developing 
new keratinocyte carcinomas, which makes these patients an interesting population for 
prevention interventions. Investing in large cohort studies and consortia might increase 
the validity of observational findings and should stimulate scientists to investigate the 
underlying mechanisms in detail.
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It is well known that the risk of a subsequent cutaneous malignancy is increased in pa-
tients with a previous keratinocyte carcinoma (KC). A recent meta-analysis showed that 
29% of patients with a history of basal cell carcinoma (BCC) developed a subsequent 
BCC and 4% a subsequent squamous cell carcinoma (SCC), whereas 13% of patients with 
a history of SCC developed a subsequent SCC and 16% a subsequent BCC1. The major-
ity of studies on multiple cutaneous malignancies calculated risks of a subsequent or 
second primary skin cancer but did not calculate risks of additional skin cancers. In this 
issue, Adèle Green’s research group selected a cohort of 1,191 white-skinned Australian 
residents from their Nambour skin cancer prevention trial, without KC, before or at the 
start of this trial, to determine the proportion who developed a BCC exclusively, SCC, or 
both2. The original cohort consisted of 1,621 residents of the subtropical city Nambour, 
who were selected at random in 1986, and therefore the cohort reflects a general popu-
lation sample from Australia followed prospectively between 1992 and 2007. Besides 
the type of skin cancer, the investigators also assessed anatomic site distributions and 
other clinical features such as pigmentary characteristics and signs of actinic damage. 
This study demonstrated that about 21% of the study population developed a first KC 
and 47% of this group developed at least a second KC. The majority of this latter group 
developed exclusively BCCs (56%), 28% developed both, and 16% developed SCCs 
exclusively, with age as the most important predictor of increasing incidence rates2. 
Participants who developed SCC exclusively were the most distinct group, because they 
had significantly higher prevalences of easily sunburned skin, propensity to tan without 
burning, and freckling of the back than did the BCC only and mixed groups. The skin, eye, 
and hair color characteristics showed no significant differences among the three groups. 
In those with BCCs exclusively or both BCC and SCC, the head and neck area were the 
predominant sites of development, whereas in the SCC only group the limbs were the 
predominant sites of development. These differences may be the result of differences 
in UVR exposure or genetic susceptibilities, and they suggest different tumor biologies.
Major strengths of this study are 16 years of follow-up, a clear case definition (i.e., 
histopathologically confirmed tumors), full-body skin examinations, and detailed 
information on clinical features. However, the main limitation lies in the small sample 
of patients with multiple cutaneous malignancies, especially the group who developed 
SCCs exclusively (n=28). Small sample sizes result in wide confidence intervals and a 
possible type II error (i.e., no power calculation shown). Although the cohort was fol-
lowed for 16 years, the study population was young (mean age 46 years) at enrollment, 
suggesting that the majority of the patients had not yet reached the age in which the 
incidence of cutaneous malignancy is highest.
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ACTiniC neoPLAsiA syndRoMe
Martin Weinstock coined the term “actinic neoplasia syndrome” to emphasize that cuta-
neous (pre-)malignancies are not a single event but often reflect a field dysplasia from 
which patients suffer chronically3. After the 1992 landmark study on this subject4, many 
observational studies of different populations demonstrated that almost half of patients 
with cutaneous malignancy will develop at least a second KC, and even more will show 
other signs of chronic actinic skin damage (e.g., actinic keratosis, solar elastosis) due to 
the relatively high levels of acute, intermittent, and/or cumulative UVR exposure during 
their lives. Therefore, a previous cutaneous malignancy is probably the strongest predic-
tor of developing subsequent malignancies, making this an interesting population for 
studies of prevention intervention. One might argue that the occurrence of multiple 
malignancies might pose a greater problem to both patients and health-care systems 
compared with disease progression or recurrence.
The benefits of primary prevention programs should become evident only after 
decades5. Even though people become more and more aware of the harmful effects 
of UVR, they do not seem to change their attitude toward it (i.e., knowledge–behavior 
gap6). For now, it seems that primary prevention is not meeting its expectations, as the 
incidence of skin cancer continues to increase worldwide, with the possible exception 
of Australia, which has a highly active public education campaign7. As primary preven-
tion falls short, secondary prevention offers a good alternative strategy. This prevention 
method will be most successful when high-risk populations are defined and screening 
strategies for specific patient groups constructed. Well-calibrated, discriminating, and 
validated prediction models could provide physicians with a tool to find high-risk pa-
tients, such as patients with histories of skin cancer, and give them appropriate right 
follow-up and tailored instructions. If there indeed exists a type-specific skin cancer 
susceptibility, as suggested by Keim et al2, different prediction models should be devel-
oped, combining environmental, phenotypic, and genotypic risk factors. However, there 
also exists a significant group of patients who develop both BCCs and SCCs, which is not 
surprising, as they share many risk factors (Figure 1). Although the risk factor profiles of 
the different cutaneous (pre-)malignancies are well documented, the extent to which 
these risk factors are applicable to subsequent tumors is not certain. On the basis of 
Rothman’s sufficient-component cause model, it could be argued that the contribution 
of the conventional risk factors for a first event is not applicable to subsequent events, 
defined as the index event bias8. In recent decades, huge steps have been made in un-
derstanding the genetic predisposition (germline and somatic mutations) for BCC and 
to a lesser extent for SCC and actinic keratosis. However, our genetic understanding of 
these very common keratinocyte malignancies lags behind melanoma. Except for a few 
candidate gene studies and a genome-wide association study, no studies have investi-
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gated the common or rare genetic variants found in patients with multiple keratinocyte 
malignanies. There is hope, because an international consortium has been established 
to explore the genetics of patients with multiple skin cancers and to develop prediction 
models that include genetic variation.
PRosPeCTiVe FoLLow-UP sTUdies
As dermato-epidemiologists, we noticed another important element in this study2, 
which is the enormous return on investment seen in this prospective Nambour skin 
cancer study. Clinical epidemiology includes experimental and observational research 
that might aid our understanding of diseases through a quantitative approach of clinical 
problems. The Nambour skin cancer trial started as an experimental study (a random-
ized field trial) but extended its follow-up as a prospective cohort study. The advantages 
of that type of design are the possibility of calculating risk measures (absolute and 
relative risk) and a relatively low risk of bias compared with other observational designs. 
The classical argument against cohort studies is that they are too expensive, but large 
(population-based) prospective cohort studies such as the Nambour Skin Cancer Study, 
the Rotterdam Study, Nurses’ Health Study, the Health Professionals Follow-up Study, 
and the PUVA Follow-up Study have a tremendous scientific return on investment in 
Figure 1. Risk factor profiles of basal cell carcinoma (BCC) and squamous cell carcinoma (SCC).
Abbreviations: BCNS, basal cell nevus syndrome; EV, epidermodysplasia verruciformis; XP, xeroderma pig-
mentosum.
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many diseases, including skin cancer2,9-11. We are strong advocates of investing in well-
designed and large cohort studies (including drug or disease specific registries), but at 
the same time we encourage investigators to form a consortia to increase sample size 
and to replicate each other’s findings. Collaborative efforts increase the validity of the 
observational findings and should stimulate laboratory scientists even more strongly to 
investigate the underlying mechanisms in detail.
In conclusion, good research raises more questions than it answers, and it lifts the bar 
for scientific progress.
CLiniCAL ReLeVAnCe:
• Development of multiple skin cancers may indicate the beginning of chronic disease.
• Basal cell carcinoma and squamous cell carcinoma do have risk factors in common, 
but they are distinct entities.
• Mechanistic studies will offer better understanding of the etiopathogenesis 
of skin cancer.
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Background
Actinic keratoses (AKs) are precursors of cutaneous squamous cell carcinomas (SCC). 
Limited data are available on the prevalence and risk factors of AK.
Methods
Within the Rotterdam Study, a Dutch population-based cohort study, full body skin ex-
aminations were performed among participants aged 45 years or older to estimate the 
age- and sex standardized prevalence of AK and its associated risk factors. A multinomial 
logistic regression model calculated adjusted odds ratios (OR) with 95% confidence 
intervals (95% CI) for associations between risk factors and the presence of 1 – 3, 4 – 9 
and ≥ 10 AK. Binary logistic regression compared participants without or with extensive 
actinic damage (≤ 9 AK versus ≥ 10 AK). By linking the participants to PALGA, the nation-
wide network and registry of histo- and cytopathology in The Netherlands, participants 
with a history of cutaneous malignancy were identified.
Results
Of the 2,061 inspected cohort members (mean age 72 years), 21% had 1 to 3, 9% 4 
to 9 and 8% ten or more AK. Prevalence of AK in the Rotterdam Study was 49% (95% 
CI 46%–52%) for men and 28% (26%–31%) for women. Extrapolation suggested that 
approximately 1.4 of the 16 million Dutch citizens are affected with AK. Male sex, older 
age, light pigmentation status, severe baldness, skin wrinkling and high tendency for 
sunburn were significantly associated with number of AKs and extensive actinic damage 
(≥10 AKs) in the multivariate analyses. Especially bald males were at an increased risk of 
severe actinic skin damage (adjusted OR= 7.0 [3.8 – 13.1]). The group with no AKs had a 
lower positive history for SCC than the group with 10 AKs (1.2% and 13.6%, respectively).
Conclusions
The prevalence of AK is very high, especially among elderly bald males, and the presence 
of severe actinic damage significantly increases a history of SCC. The prevention and 
management of AK is a true challenge for patients, physicians, and health care policy 
makers.
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inTRodUCTion
Actinic keratoses (AKs) are a common keratinocytic intra-epidermal neoplasia (KIN) 
often occurring on chronically sun-exposed skin of Caucasian individuals.1 Although 
AKs may persist or spontaneously regress, AKs may progress to invasive cutaneous 
squamous cell carcinoma (SCC) in approximately 0.1 to 20% of the lesions annually.2-4 
Recently, a study suggested AKs may progress to basal cell carcinoma (BCC) as well.5 AKs 
are often diagnosed clinically (i.e., rough red scaly patches on chronically sun-exposed 
skin) without histological confirmation and are, therefore, not recorded in pathology 
databases and cancer registries.
Population-based studies investigating AK prevalence and its associated risk factors6-10 
conclude that elderly subjects with European ancestry and high cumulative ultraviolet 
(UV) exposure have the highest risk of developing AKs. However these studies are few 
and report prevalences of AK varying from 1.4 to 59.2%. These differences in prevalences 
could be due to the geographic variability in UV radiation levels (Australia > United 
States of America > Europe) and the differences between the studied populations (e.g. 
high-risk patients, pigmentation status and age restrictions). Moreover skin examina-
tions and AK count were not conducted uniformly in these studies.6-11
Most national guidelines or consensus reports recommend the treatment of AKs, for 
which a variety of modalities are available, and follow up of these patients because of 
their invasive potential. Implementing these recommendations puts a further burden 
on general physicians and the dermatological care that is already strained by the care of 
cutaneous malignancies.12-13
More accurate insight into the prevalence of AK among the general population is 
pivotal for public health strategies and medical decision makers. For the first time in The 
Netherlands, the prevalence of AK and its associated risk factors were investigated in a 
population-based cohort study (i.e. Rotterdam Study) among 2,061 elderly participants.
MeThods
study population
The Rotterdam Study is an ongoing prospective population-based cohort study that fol-
lows inhabitants of the Ommoord district of Rotterdam, The Netherlands since 1990. The 
study design and objectives of the Rotterdam Study have been described elsewhere.14 
The Rotterdam Study was designed to study frequencies and risk factors associated with 
diseases of the elderly (e.g. coronary heart disease, Alzheimer disease and osteoporosis). 
Every 3 to 4 years, participants are interviewed at home and undergo an extensive set of 
examinations at the Rotterdam Study research facilities.
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In January 1990, the first cohort (RS-I) of 7,983 participants (78% of invitees) aged 55 
years or older was established (Figure 1). In 2000, a second cohort (RS-II) was added to 
the Rotterdam Study, including 3,011 participants (67% of invitees) who had turned 55 
years of age or had moved into the study district. The third cohort (RS-III) was estab-
lished in 2006, in which 3,932 participants (65% of invitees) aged 45 to 54 years were 
added to the cohort. Participants of the present study were all above 50 years of age. 
The Rotterdam Study is approved by the Medical Ethics Committee of the Erasmus MC 
University Medical Center and The Netherlands Ministry of Health, Welfare and Sports.
dermatology in the Rotterdam study
In August 2010, dermatology was introduced to the Rotterdam Study (Figure 1). Since 
then, full body skin examinations (FBSE; with the exception of the feet and the skin 
covered by socks and underwear, respectively) are being conducted by four trained 
physicians focussing on the most common skin diseases such as skin (pre-)malignancies, 
atopic dermatitis, hand eczema, psoriasis and varicose veins.
Actinic keratoses
An AK was diagnosed clinically and was defined as a rough (keratotic) lesion with ad-
herent scaling and erythema, not fitting another diagnosis.15 Since AK lesions are often 
confluent and located on sun- damaged skin, it is difficult to count the total number of 
individual lesions within a participant.15
Figure 1. Flowchart of the Rotterdam Study
Abbreviations: AK, actinic keratoses; FBSE, full body skin examination; RS, Rotterdam Study
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We counted overall number of AK per participant and subdivided this into the number 
of AK per localisation using the same categories: no presence of AK, 1 to 3, 4 to 9 or ≥ 
10 AK. The subdivision per anatomical localisation consisted of the most important sun-
exposed areas including scalp, face (excluding ears), ears, neck, back of hands, forearms, 
chest or other localisations.
Risk factors
Sex and age (in years) at date of skin examination were registered. Educational level 
(classified into 3 categories: low [primary education and primary education with a higher 
not completed education], medium [lower-level secondary education, lower-level voca-
tional education intermediate-level vocational education], and high [general secondary 
education, higher-level vocational education and university]), smoking (never versus 
ever), hair color at young age (red, fair / blond, dark blond / brown and black) and four 
questions assessing UV exposure were available from interview data. The questions on 
UV exposure included tendency for sunburns, history of more than 25 years of outdoor 
work, having lived more than one year in a sunny country and sun-protective behavior 
(i.e. wearing sunglasses and/or a rimmed hat in the sunshine). The first three UV items 
had binary responses and the latter was categorized into never / almost never, often / 
not always and always. Eye color (blue, intermediate, brown) was available from and 
scored by the ophthalmology department within the Rotterdam study.
During FBSE, the following potential phenotypic risk factors for AK were scored; skin 
color (very white [3.4%], white [79.1%], white to olive [14.5%], light brown [1.7%], brown 
[1.1%], dark brown / black [0.2%]), Glogau score (type 1 ‘no wrinkles’, type 2 ‘wrinkles 
in motion’, type 3 ‘wrinkles at rest’ and type 4 ‘only wrinkles’)16, number of naevi (< 25, 
25 – 50, 50 – 100, > 100) and baldness of the scalp based on the Norwood – Hamilton 
(NH)17-18 scale for men and the Ludwig scale (LS)19 for women. In the analyses, baldness 
of the scalp was divided into none or minimal (NH score A,B,C,I,J and LS score 1), mild 
(NH score D,E,F,K and LS score 2) and extensive baldness (NH score G,H,L and LS score 3).
Due to significant correlation (phi-test for correlation, p < 0.001) between the pheno-
typic characteristics hair color at young age, eye - and skin color, these three variables 
were combined into one variable ‘pigmentation status’ and classified by light, medium 
or dark pigmentation status.
skin cancer history
All RS participants were linked to PALGA, the Dutch nationwide network and registry 
of histo- and cytopathology in The Netherlands, which contains excerpts of all pathol-
ogy reports with nationwide coverage from 1991 onwards.20 A linkage between PALGA 
and our study population was made until September 23th 2011.21 An excerpt encloses 
encrypted patient data, a summary of the pathology report and a diagnosis line based 
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upon standard pathology terminology similar to the Systematized Nomenclamenture 
of Medicine (SNOMED) issues by the College of American Pathologists. Individuals in 
the database have an encrypted patient identification code which enables linkage with 
all available pathology data within PALGA. The search in PALGA was based on codes 
corresponding to all types of BCC (i.e. M80903, M80913, M80923, M80933, M80943, 
M80963, M80973, M80983), SCC (i.e. M80703, M80713, M80723, M80743, M80753, 
M80704, M85603, M80711) and melanoma (i.e. M87203, M87213, M87223, M87233, 
M87263, M87303, M87403, M87423, M87433, M87443, M87453, M87700, M87703, 
M87713, M87723, M87743, M87753, M87803). Participants were counted only once per 
cutaneous malignancy (Figure 1).
statistical analyses
The prevalence of AK within the 2,061 studied participants of the Rotterdam Study was 
standardized by age (5–year bands) and sex and 95% confidence intervals (95% CI) for 
proportion were calculated. The sex– and age-specific prevalences were multiplied by 
the sex- and age-specific population size in The Netherlands (5-year bands). Population 
size was obtained from Statistics Netherlands and estimated on the first of January 
2011.22 The extrapolated AK prevalence was calculated for the Dutch population aged 
50 years or more.
To investigate risk factors associated with the development of AK, uni- and multivari-
ate multinomial logistic regression analyses were performed and odds ratios (OR) with 
95% CI were calculated for each of the three outcome groups, 1 to 3, 4 to 9 and ≥ 10 AK.
In addition, considering the ordinal structure of the latter outcome groups, an ordinal 
logistic regression was used to provide a cumulative OR. A significant cumulative OR 
corresponds to a statistically significant trend of increase in risk across the AK strata.23-24 
A corresponding p-value for trend (based on the ordinal logistic regression) was calcu-
lated (Table 4). However, not all variables met the proportional odds assumption for this 
test and fitted therefore better in the multinomial logistic regression model.
To compare participants with extensive actinic damage (≥ 10 AK) to those with no or 
less actinic damage (0 to 9 AK), uni- and multivariate binary logistic regression analyses 
were used to calculate (adjusted) OR with 95% CI. All variables included in the univariate 
analyses were included in the multivariate analyses as possible confounders for AK risk. 
No significant interaction terms were observed. All statistical analyses were performed 
using SPSS for Windows version 17.0 (SPSS inc., Chicago, IL, USA). P-values were two–
sided and considered statistically significant if p–value < 0.05.
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ResULTs
In total, 2,061 (99.9%) of 2063 participants visiting the Rotterdam Study research facility 
between August 2010 and April 2012 agreed to undergo a FBSE. Hereof, 208 (10.1%) 
were from RS-I, 1,542 (74.8%) RS-II and 311 (15.1%) RS-III. The majority of the participants 
were women (55.0%; Table 1). Mean age at date of FBSE was 71.6 years (standard devia-
tion [SD] 7.1; ranging from 51 to 98 years).
Table 1. Study characteristics of 2,061 participants of the Rotterdam Study with a full body skin examination
Characteristics
Total study
population
(n=2,061)
no Ak
(%)
(n=1,288)
1 - 3 Aks 
(%)
(n=433)
4 - 9 Aks 
(%)
(n=177)
≥ 10 Aks 
(%)
(n=163)
sex
Women 1,134 (55.0) 815 (63.3) 220 (50.8) 58 (32.8) 41 (25.2)
Men 927 (45.0) 473 (36.7) 213 (49.2) 119 (67.2) 122 (74.8)
Age at FBse
Mean age in years (SD) 71.6 (7.1) 70.2 (7.2) 73.0 (6.4) 74.1 (6.5) 75.6 (6.2)
< 70 874 (42.4) 638 (49.5) 156 (36.0) 50 (28.2) 30 (18.4)
70 - 79.99 947 (45.9) 532 (41.3) 219 (50.6) 98 (55.4) 98 (60.1)
≥ 80 240 (11.6) 118 (9.2) 58 (13.4) 29 (16.4) 35 (21.5)
Pigmentation status (based on eye, hair and skin color)
Dark 212 (10.3) 164 (12.7) 26 (6.0) 12 (6.8) 10 (6.1)
Medium 1,294 (62.8) 813 (63.1) 272 (62.8) 116 (65.5) 93 (57.1)
Light 385 (18.7) 201 (15.6) 92 (21.2) 39 (22.0) 53 (32.5)
Data missing 170 (8.2) 110 (8.5) 43 (9.9) 10 (5.6) 7 (4.3)
glogau scale
1 and 2 180 (8.7) 156 (12.1) 17 (3.9) 5 (2.8) 2 (1.2)
3 1,684 (81.7) 1,026 (79.7) 359 (82.9) 154 (87.0) 145 (89.0)
4 197 (9.6) 106 (8.2) 57 (13.2) 18 (10.2) 16 (9.8)
naevi
< 25 1,569 (76.1) 985 (76.5) 323 (74.6) 130 (73.4) 131 (80.4)
25 – 50 385 (18.7) 236 (18.3) 90 (20.8) 35 (19.8) 24 (14.7)
50 or more 107 (5.2) 67 (5.2) 20 (4.6) 12 (6.8) 8 (4.9)
Baldness1
No / almost no baldness 1,355 (65.7) 940 (73.0) 60 (13.9) 66 (37.3) 83 (50.9)
Mild baldness 389 (18.9) 240 (18.6) 86 (19.9) 35 (19.8) 28 (17.2)
Severe baldness 317 (15.4) 108 (8.4) 287 (66.3) 76 (42.9) 52 (31.9)
Tendency to develop sunburn
Low 1,330 (64.5) 873 (67.8) 275 (63.5) 108 (61.0) 74 (45.4)
High 607 (29.5) 330 (25.6) 129 (29.8) 64 (36.2) 84 (51.5)
Data missing 124 (6.0) 85 (6.6) 29 (6.7) 5 (2.8) 5 (3.1)
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Prevalence of actinic keratoses
Of 2,061 participants, 773 (37.5%) had at least one or more AK of which 56.0% had 1 to 
3 AK, followed by 4 to 9 (22.9%) and 10 or more (21.1%). Overall, the prevalence of one 
AK or more was 49.0% (95% CI 45.8–52.2%) for men and 28.1% (25.5–30.7%) for women 
(Table 2). AK prevalence increased with age in both men and women, but there was a 
small dip in age category 80 – 84 years compared to younger age–groups in men and 
women (Table 2 and Figure 2).
Table 1 (continued)
Characteristics
Total study
population
(n=2,061)
no Ak
(%)
(n=1,288)
1 - 3 Aks 
(%)
(n=433)
4 - 9 Aks 
(%)
(n=177)
≥ 10 Aks 
(%)
(n=163)
outdoor work history ≥ 25 years
No 334 (16.2) 220 (17.1) 51 (11.8) 21 (11.9) 42 (25.8)
Yes 151 (7.3) 105 (8.2) 21 (4.8) 14 (7.9) 11 (6.7)
Data missing 1,576 (76.5) 963 (74.8) 361 (83.4) 142 (80.2) 110 (67.5)
history of living in sunny country of > 1 year
No 1,730 (83.9) 1,064 (82.6) 367 (84.8) 163 (92.1) 136 (83.4)
Yes 213 (10.3) 145 (11.3) 37 (8.5) 9 (5.1) 22 (13.5)
Data missing 118 (5.7) 79 (6.1) 29 (6.7) 5 (2.8) 5 (3.1)
sun protective behavior2
Never / almost never 672 (32.6) 454 (35.2) 135 (31.2) 49 (27.7) 34 (20.9)
Often / not always 640 (31.1) 358 (27.8) 136 (31.4) 75 (42.4) 71 (43.6)
Always 631 (30.6) 397 (30.8) 133 (30.7) 48 (27.1) 53 (32.5)
Data missing 118 (5.7) 79 (6.1) 29 (6.7) 5 (2.8) 5 (3.1)
smoking history
Never 663 (32.2) 434 (33.7) 155 (35.8) 35 (19.8) 39 (23.9)
Ever 1,381 (67.0) 846 (65.7) 272 (62.8) 139 (78.5) 124 (76.1)
Data missing 17 (0.8) 8 (0.6) 6 (1.4) 3 (1.7) 0
education level3
Low 374 (18.1) 235 (18.2) 78 (18.0) 31 (17.5) 30 (18.4)
Medium 1,215 (59.0) 751 (58.3) 271 (62.6) 106 (59.9) 87 (53.4)
High 444 (21.5) 285 (22.1) 78 (18.0) 39 (22.0) 42 (25.8)
Data missing 28 (1.4) 17 (1.3) 6 (1.4) 1 (0.06) 4 (2.5)
Legend:
1Based on the Norwood – Hamilton scale for men and Luwdig scale for women.
2Wearing sunglasses and/or a rimmed hat in the sunshine.
3Low (primary education and primary education with a higher not completed education), medium (lower-
level secondary education, lower-level vocational education intermediate-level vocational education), and 
high (general secondary education, higher-level vocational education and university)
Abbreviations: AK, actinic keratoses; FBSE, full body skin examination; SD, standard deviation; n, number
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Table 2. Prevalence of actinic keratoses among 2061 participants of the Rotterdam Study
Age-
groups
in years
Total study population Men women
Total
n=2,061
Ak (%)
n=773
(95% Ci) Total
n=927
Ak (%)
n=454
(95% Ci) Total
n=1,134
Ak (%)
n=319
(95% Ci)
50 - 54 49 0,0 (0.0 - 0.0) 16 0,0 (0.0 - 0.0) 33 0.0 (0.0 - 0.0)
55 - 59 74 6.8 (1.0 - 12.5) 31 12.9 (1.1 - 24.7) 43 2.3 (-2.2 - 6.8)
60 - 64 108 19.4 (12.0 - 26.9) 38 23.7 (10.2 - 37.2) 70 17.1 (8.3 - 25.9)
65 - 69 643 32.7 (29.0 - 36.3) 302 41.1  (35.6 - 46.6) 341 25.2 (20.6 - 29.8)
70 - 74 674 41.1 (37.4 - 44.8) 306 52.9  (47.3 - 58.5) 368 31.3 (26.6 - 36.0)
75 - 79 273 50.5 (44.6 - 56.6) 127 70.9 (63.0 - 78.8) 146 32.9 (25.3 - 40.5)
80 - 84 146 41.1 (33.1 - 49.1) 71 54.9 (43.3 - 66.5) 75 28.0 (17.8 - 38.2)
≥ 85 94 66.0 (56.4 - 75.6) 36 72.2  (57.6 - 86.8) 58 62.1 (49.6 - 74.6)
overall 2,061 37.5  (35.4 - 39.6) 972 49.0 (45.8 - 52.2) 1,134 28,1  (25.5 - 30.7)
Abbreviations: AK, actinic keratoses, n, number
Figure 2. Prevalence of actinic keratoses among 2061 participants of the Rotterdam Study, stratified by sex
Abbreviations: AK, actinic keratoses; BCC, basal cell carcinoma; CI, confidence interval; SCC, squamous cell 
carcinoma
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Extrapolation to The Netherlands showed that 1,408,641 of the 5,985,164 Dutch 
citizens aged fifty years or older were affected by AK in 2011, of which 817,823 (58%) 
were men and 596,487 (42%) were women. This corresponds to an AK prevalence of 
23.5% (95% CI 21.7 – 25.3%) in the Dutch population aged 50 years or older; 28.8% 
(25.9–31.7%) for men and 19.0% (16.7–21.2%) for women.
Location of actinic keratoses
Overall, the face was the location most commonly affected by 1 to 3 (42.5%) and 4 to 9 
(33.4%) AK, while ≥ 10 AK were more frequently located on scalp with 36.2% (Table 3). 
Stratification by sex showed that extensive actinic damage (≥ 10 AK) was most often 
found on scalp (47.5%) in bald men, while this was 0.0% in women. In women, extensive 
actinic damage was most often located on the face followed by chest, respectively 
32.2% and 29.0% (Table 3).
Table 3. Anatomical location of actinic keratoses among 774 participants of the Rotterdam Study with 
actinic keratoses
number 
of Ak
study population Men women
1 to 3
n = 891
4 to 9
n = 290
≥ 10
n = 130
1 to 3
n = 506
4 to 9
n = 205
≥ 10
n = 99
1 to 3
n = 385
4 to 9
n = 85
≥ 10
n = 31
Localisation
scalp 117 (13.1) 84 (29.0) 47 (36.2) 109 (21.5) 82 (40.0) 47 (47.5) 8 (2.1) 2 (2.4) 0 (0.0)
Face 379 (42.5) 97 (33.4) 35 (26.9) 182 (36.0) 64 (31.2) 25 (25.3) 197 (51.2) 33 (38.8) 10 (32.3)
ears 83 (9.3) 11 (3.8) 0 (0.0) 71 (14.0) 10 (4.9) 0 (0.0) 12 (3.1) 1 (1.2) 0 (0.0)
neck 8 (0.9) 2 (0.7) 1 (0.8) 6 (1.2) 1 (0.5) 0 (0.0) 2 (0.5) 1 (1.2) 1 (3.2)
Back of 
hands
116 (13.0) 37 (12.8) 9 (6.9) 63 (12.5) 24 (11.7) 6 (6.1) 53 (13.8) 13 (15.3) 3 (9.7)
Forearms 76 (8.5) 30 (10.3) 12 (9.2) 34 (6.7) 12 (5.9) 7 (7.1) 42 (10.9) 18 (21.2) 5 (16.1)
Chest 72 (8.1) 18 (6.2) 14 (10.8) 26 (5.1) 4 (2.0) 5 (5.0) 46 (11.9) 14 (16.5) 9 (29.0)
elsewhere 40 (4.5) 11 (3.8) 12 (9.2) 15 (3.0) 8 (3.9) 9 (9.1) 25 (6.5) 3 (3.5) 3 (9.7)
Abbreviations: AK, actinic keratoses; n, number
Risk factors of actinic keratoses
Male sex, age of 70 years and older, medium and dark pigmentation status, Glogau 
score 3 and 4, high tendency for sunburn and often / not always use of sun protec-
tive measurements were all significantly associated with the three outcome groups 
in the univariate multinomial logistic regression analysis (Appendix Table 1). Medium 
baldness was associated with 4 to 9 (OR 1.8 [95% CI 1.2 – 2.8]) and ≥ 10 AK (OR 2.1 
[95% CI 1.3 – 3.4]), whereas severe baldness was associated with all three outcome 
groups in a linear manner up to an OR 13.9 (9.3 – 20.7) for >10 AKs compared to no or 
minimal hairloss. Naevi and educational level were not significantly associated with 
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AK, whereas ever smoking was associated with 4 to 9 and ≥ 10 AK (OR 2.0 [95% CI 1.4 
– 3.0] and OR 1.6 [95% CI 1.1 – 2.4], respectively). All variables remained significantly 
associated with AKs in the multivariate multinomial model (Table 4). After adjusting 
for the other risk factors, severe baldness remained the strongest risk factor for ≥ 10 
AK (adjusted OR 6.3 [95% CI 3.6– 1.0]; p-value for trend < 0.001). After stratification by 
sex (data not shown), severe baldness remained significantly associated with ≥10 AK in 
men (adjusted OR 7.0 [3.8–13.1]), but not in women (no OR could be calculated since 
only 8 women had severe baldness). Male sex, age of 70 years or older, Glogau 3 and 
4 and tendency to develop sunburn remained significantly associated with all three 
outcome groups. Light pigmentation status was associated with 1 to 3 (OR 2.3 [95% 
CI 1.3 – 3.8]) and ≥ 10 AK (OR 2.5 [95% CI 1.1 – 5.7]), but not with 4 to 9 AK. Always use 
of sun protective measurement was associated with ≥ 10 AK (adjusted OR 2.0 [95% CI 
1.2 – 3.4]).
Table 4. Multivariate multinomial logistic regression: risk factors associated with actinic keratoses among 
2,061 participants of the Rotterdam Study
Characteristics
1 - 3 Aks
adjusted odds 
ratio
(95% Ci)
4 - 9 Aks
adjusted odds 
ratio
(95% Ci)
≥ 10 Aks
adjusted odds 
ratio
(95% Ci)
P – value4
(based on 
ordinal logistic 
regression)
sex
Women 1.0 (ref ) 1.0 (ref ) 1.0 (ref )
Men 2.2 (1.6 -2.9) 2.5 (1.5 - 3.9) 3.2 (1.8 - 5.6) p < 0.001
Age at clinical examination
< 70 1.0 (ref ) 1.0 (ref ) 1.0 (ref )
70 - 79.99 1.6 (1.2 - 2.1) 2.0 (1.4 - 3.0) 3.7 (2.3 - 6.0) p < 0.001
≥ 80 1.7 (1.1 - 2.7) 2.7 (1.5 - 5.0) 6.5 (3.4 - 12.4) p < 0.001
Pigmentation status (based on eye, hair and skin color)
Dark 1.0 (ref ) 1.0 (ref ) 1.0 (ref )
Medium 1.7 (1.1 - 2.8) 1.5 (0.8 - 3.0) 1.3 (0.6 - 2.7) p = 0.05
Light 2.3 (1.3 - 3.8) 1.9 (0.9 - 4.1) 2.5 (1.1 - 5.7) p < 0.001
glogau
1 and 2 1.0 (ref ) 1.0 (ref ) 1.0 (ref )
3 3.7 (1.9 - 7.0) 4.1 (1.4 - 11.7) 8.0 (1.9 - 34.8) p < 0.001
4 5.5 (2.6 - 11.5) 4.9 (1.5 - 16.2) 6.0 (1.2 - 29.4) p < 0.001
naevi
< 25 1.0 (ref ) 1.0 (ref ) 1.0 (ref )
25 – 50 1.4 (1.0 - 1.9) 1.3 (0.8 - 2.0) 1.0 (0.6 - 1.8) p = 0.15
50 or more 1.3 (0.7 - 2.2) 1.6 (0.8 - 3.4) 1.3 (0.5 - 3.2) p = 0.29
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Table 4 (continued)
Characteristics
1 - 3 Aks
adjusted odds 
ratio
(95% Ci)
4 - 9 Aks
adjusted odds 
ratio
(95% Ci)
≥ 10 Aks
adjusted odds 
ratio
(95% Ci)
P – value4
(based on 
ordinal logistic 
regression)
Baldness1
No / almost no baldness 1.0 (ref ) 1.0 (ref ) 1.0 (ref )
Mild baldness 0.8 (0.6 - 1.1) 1.1 (0.7 - 1.8) 1.2 (0.7 - 2.0) p = 0.79
Severe baldness 1.2 (0.8 - 1.8) 4.1 (2.5 - 6.8) 6.3 (3.6 - 11.0) p < 0.001
Tendency to develop sunburn
Low 1.0 (ref ) 1.0 (ref ) 1.0 (ref )
High 1.4 (1.0 - 1.8) 2.0 (1.3 - 2.9) 3.3 (2.2 - 5.0) p < 0.001
Data missing
outdoor work history ≥ 25 years
No 1.0 (ref ) 1.0 (ref ) 1.0 (ref )
Yes 0.9 (0.5 - 1.7) 1.6 (0.7 - 3.5) 0.6 (0.3 - 1.5) p = 0.60
Data missing 1.0 (ref ) 1.0 (ref ) 1.0 (ref )
history of living in sunny country of > 1 year
No 0.8 (0.5 - 1.2) 0.3 (0.1 - 0.7) 0.7 (0.4 - 1.3) p = 0.01
Yes 1.0 (ref ) 1.0 (ref ) 1.0 (ref )
Data missing 1.3 (0.9 - 1.7) 1.9 (1.3 - 2.0) 2.5 (1.5 - 4.1) p < 0.001
sun protective behavior2
Never / almost never 1.2 (0.9 - 1.6) 1.2 (0.8 - 2.0) 2.0 (1.2 - 3.4) p = 0.02
Often / not always 1.0 (ref ) 1.0 (ref ) 1.0 (ref )
Always 0.7 (0.5 - 0.9) 1.3 (0.8 - 2.0) 0.9 (0.6 - 1.4) p = 0.4
Data missing
smoking history 1.0 (ref ) 1.0 (ref ) 1.0 (ref )
Never 1.1 (0.8 - 1.4) 1.1 (0.7 - 1.8) 0.9 (0.5 - 1.4) p = 0.84
Ever 0.8 (0.5 - 1.1) 1.0 (0.6 - 1.7) 0.9 (0.5 - 1.6) p = 0.27
Legend:
1 Based on the Norwood – Hamilton scale for men and Luwdig scale for women
2 Wearing sunglasses and/or a rimmed hat in the sunshine
3 Low (primary education and primary education with a higher not completed education), medium (lower-
level secondary education, lower-level vocational education intermediate-level vocational education), and 
high (general secondary education, higher-level vocational education and university)
4 P-value based on multivariate ordinal logistic regression
Abbreviations: AK, actinic keratoses; FBSE, full body skin examination; ref, reference group
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In line with the multinominal model, the multivariate binary logistic regression 
showed that men, older age (≥ 70 years), Glogau score 3, medium and severe baldness, 
high tendency to develop sunburn, and often /not always and always use of sun protec-
tive measurements were significantly associated with extensive actinic damage (>10 
AKs) (Table 5).
Table 5. Risk factors associated with extensive actinic damage (≥ 10 actinic keratoses) among 2061 partici-
pants of the Rotterdam Study
Characteristics
0 - 9 Ak
n =1,898
≥ 10 Ak
n = 163
≥ 10 Ak
crude odds ratio
(95% Ci)
≥ 10 Ak
adjusted odds 
ratio
(95% Ci)
sex
Women 1,093 (42.4) 41 (25.2) 1.0 (ref ) 1.0 (ref )
Men 805 (42.4) 122 (74.8) 4.0 (2.8 – 5.8) 2.3 (1.4 - 4.0)
Age at clinical examination
< 70 844 (44.5) 30 (18.4) 1.0 (ref ) 1.0 (ref )
70 - 79.99 849 (44.7) 98 (60.1) 3.2 (2.1 – 4.9) 2.9 (1.8 - 4.6)
≥ 80 205 (10.8) 35 (21.5) 4.8 (2.9 – 8.0) 4.7 (2.5 - 8.7)
Pigmentation status (based on eye, hair and skin color)
Dark 202 (10.6) 10 (6.1) 1.0 (ref ) 1.0 (ref )
Medium 1,201 (63.3) 93 (57.1) 1.6 (0.8 – 3.1) 1.0 (0.5 - 2.2)
Light 332 (17.5) 53 (32.5) 3.2 (1.6 – 6.5) 1.8 (0.8 - 4.1)
Data missing 163 (8.6) 7 (4.3)
glogau
1 and 2 178 (9.4) 2 (1.2) 1.0 (ref ) 1.0 (ref )
3 1,539 (81.1) 145 (89.0) 8.4 (2.1 - 34.1) 5.4 (1.3 - 22.9)
4 181 (9.5) 16 (9.8) 7.9 (1.8 - 34.7) 3.4 (0.7 - 16.4)
naevi
< 25 1,438 (75.8) 131 (80.4) 1.0 (ref ) 1.0 (ref )
25 - 50 361 (19.0) 24 (14.7) 0.7 (0.5 – 1.1) 1.1 (0.5 - 2.5)
> 50 99 (5.2) 8 (4.9) 0.9 (0.4 – 1.9) 0.9 (0.5 - 1.5)
Baldness1
No / almost no baldness 1,303 (68.7) 83 (50.9) 1.0 (ref ) 1.0 (ref )
Mild baldness 361 (19.0) 28 (17.2) 1.9 (1.2 – 3.1) 1.2 (0.7 - 2.1)
Severe baldness 234 (12.3) 52 (31.9) 8.9 (6.1 - 12.9) 4.5 (2.6 - 7.5)
Tendency to develop sunburn
Low 1,256 (66.2) 74 (45.4) 1.0 (ref ) 1.0 (ref )
High 523 (27.6) 84 (51.5) 2.7 (2.0 – 3.8) 2.7 (1.8 - 4.0)
Data missing 119 (6.3) 5 (3.1)
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skin cancer history and detection during FBse
In total, 238 (11.5%) participants had a history of BCC, 51 (2.5%) of SCC and 20 (0.5%) 
of melanoma. The risk of a history with one of these cutaneous malignancies increased 
across the AK severity strata (i.e. from none to >10 AKs). For BCC, SCC and melanoma, these 
risks increased respectively from 7.2 to 26.5%, 1.2 to 13.6% and 0.7 to 1.9% (Figure 3). 
Although these risks increased gradually for BCC and melanoma, a sharper increase was 
seen for SCC. Participants with >10 AKs (13.6%) had a three fold higher risk for having 
Table 5 (continued)
Characteristics
0 - 9 Ak
n =1,898
≥ 10 Ak
n = 163
≥ 10 Ak
crude odds ratio
(95% Ci)
≥ 10 Ak
adjusted odds 
ratio
(95% Ci)
outdoor work history ≥ 25 years
No 292 (15.4) 11 (6.7) 1.0 (ref ) 1.0 (ref )
Yes 140 (7.4) 42 (25.8) 0.5 (0.3 – 1.1) 0.6 (0.3 - 1.3)
Data missing 1,466 (77.2) 110 (67.5)
history of living in sunny country of > 1 year
No 1,594 (84.0) 136 (83.4) 1.0 (ref ) 1.0 (ref )
Yes 191 (10.1) 22 (13.5) 1.4 (0.8 – 2.2) 0.9 (0.5 - 1.6)
Data missing 113 (6.0) 5 (3.1)
sun protective behavior2
Never / almost never 638 (33.6) 34 (20.9) 1.0 (ref ) 1.0 (ref )
Often / not always 569 (30.0) 71 (43.6) 2.3 (1.5 – 3.6) 2.1 (1.3 - 3.3)
Always 578 (30.5) 53 (32.5) 1.7 (1.1 – 2.7) 1.9 (1.1 - 3.1)
Data missing 113 (6.0) 5 (3.1)
smoking history
Never 624 (32.9) 39 (23.9) 1.0 (ref ) 1.0 (ref )
Ever 1,257 (66.2) 124 (76.1) 1.6 (1.1 – 2.3) 0.9 (0.6 - 1.4)
Data missing 17 (0.9) 0 (0.0)
education level3
Low 402 (21.2) 30 (18.4) 1.0 (ref ) 1.0 (ref )
Medium 1,128 (59.4) 87 (53.4) 0.9 (0.6 – 1.4) 0.9 (0.5 - 1.7)
High 402 (21.2) 42 (25.8) 1.2 (0.7 – 2.0) 1.8 (0.4 - 8.5)
Data missing 24 (1.3) 4 (2.5)
Legend:
1 Based on the Norwood – Hamilton scale for men and Luwdig scale for women
2 Wearing sunglasses and/or a rimmed hat in the sunshine
3 Low (primary education and primary education with a higher not completed education), medium (lower-
level secondary education, lower-level vocational education intermediate-level vocational education), and 
high (general secondary education, higher-level vocational education and university)
Abbreviations: AK, actinic keratoses; FBSE, full body skin examination
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a SCC history compared to participants with 4 to 9 AKs (4.0%). Of the 2061 participants 
who received a FBSE during our study period, it was histologically confirmed that 59 
(2.9%) had a BCC, 11 (0.5%) had a SCC and 9 (0.4%) a melanoma (including 5 invasive 
and 4 in situ). Overall, the detection rate of these cutaneous malignancies in our study 
population was 4.0% (82 out of 2,061 participants).
disCUssion
In this Dutch population-based study among more than 2,000 people with a mean age 
of 72 years who were examined by trained physicians, almost 38% had one or more 
AK and 8% had 10 or more (age- and sex-adjusted 23% and 5%, respectively). This AK 
prevalence is the highest overall AK prevalence in people aged 50 years or older when 
Figure 3. Percentage of participants with and withouth actinic keratoses who have a history of squamous 
cell carcinoma (SCC), basal cell carcinoma (BCC) or melanoma
Abbreviations: AK, actinic keratoses; BCC, basal cell carcinoma; SCC, squamous cell carcinoma
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compared to previous European population-based studies and comparable or less to 
studies from the United States of America (USA) and Australia.7,9
In Europe, the South Wales Skin Cancer Study observed an AK prevalence of 23% (95% 
CI 19.5 – 26.5), unadjusted for age and sex, among 1,034 persons aged 60 years or more. 
The lower prevalence may be explained by the fact that skin examinations were limited 
to the head and neck, lower arms (until shoulders), lower legs and feet and performed 
by research registrars in dermatology. Recently, in the PRAKTIS study a representative 
sample of 12,483 people of the Italian population aged > 45 years were selected by a 
stratified random sampling design in which 1.4% was affected by AK.7 Again, skin exami-
nations were performed by ‘interviewers’ and limited to the face and upper extremities.7 
In addition, the distribution of phenotypic characteristics of the Dutch (i.e. light skin, hair 
and eyes) increase the risk for AK development when compared to the the distribution 
in the Italian population with slightly darker skin, hair and eyes. German studies using 
claims data estimated an AK prevalences ranging from 2 to 31%, but these data were not 
population-based and included dermatology patients25-26, patients without history of 
skin cancer who were invited to undergo skin examination when visiting their practice-
based physician16 or healthy workers who could undergo a voluntary FBSE at their 
work.27 Between 1971-1975, a population-based study across the USA8, in which 101 
dermatologists performed FBSE in more than 8,000 white participants aged between 25 
and 74 years, observed a crude AK prevalence of around 17%.8 More recently, the crude 
prevalence for AK in the USA was estimated to be 45% in men aged 65 years or older and 
35% in women.28 Two Australian studies from the eighties who screened 2,095 and 1,040 
people randomly selected from sample state electoral roll demonstrated that 40-60% of 
the participants had at least one AK.6,10
Risk factors and implications
Multiple risk factors were found to be associated with AK development confirming 
findings of previous studies assessing AK and SCC risk factors.29-30 In men, baldness was 
found to be the strongest risk factor for presence of AK and severe actinic skin damage, 
probably because it continuously exposes the scalp in a horizontal plane to UV radia-
tion resulting in high cumulative UV doses. In clinical practice, these patients with large 
cutaneous fields affected by AKs on the scalp are numerous and difficult to manage.
Patients possessing risk factors associated with extensive actinic damage such as 
severe baldness may require directed public health campaigns, a case-finding approach 
(i.e., inspection of the bald scalp during physician visits) including providing more infor-
mation on sun protection and behavior.
In the past decade, pharmaceutical companies have focused on AK treatments result-
ing in new treatments other than cryotherapy, namely fluorouracil, imiquimod, photo-
dynamic therapy and most recently Ingenol mebutate gel.31-32 Recently, topical tretinoin 
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failed to act as a chemopreventive agent for AK development33, whereas sunscreen use 
is effective in both AK and SCC prevention.34-35
Although it remains controversial whether or not to actively treat AKs (as not all will 
progress to SCC), people with multiple lesions (in this study defined as ≥10) are most 
likely to benefit from treatment and require a closer follow-up over time to prevent or 
detect the early development of SCC. Even this conservative approach is a health care 
challenge because it involves 5% of the Dutch 50-plus citizens (approximately 300,000 
people) and this proportion is likely to increase over time. This is confirmed by a quick 
review of the claims data demonstrating that dermatologist reported twice as many AK 
related visits and treatment between 2007 and 2011 (from 42,115 to 76,395) emphasiz-
ing the strain cutaneous (pre-)malignancies put on the health care system.36
strengths and limitations
The fact that FBSE were performed by a few trained physicians in more than 2,000 par-
ticipants from a population-based study makes the Dutch point prevalence highly ac-
curate. In general, AK have a typical presentation and are therefore clinically diagnosed 
by dermatologists and general practitioners. However AK can resemble keratinocyte 
carcinoma (including BCC and SCC), possibly leading to misclassification and an under 
or overestimation of AK in this study.5 Nevertheless, this possible non – differential 
misclassification is considered small as trained physicians performed FBSE and previous 
studies observed a positive predictive value for AK diagnosis ranging from 74 to 94%.37-38 
In this study, AK prevalence was determined cross-sectionally and it was unknown 
whether participants were previously treated for AK which also could have resulted in 
an underestimation of the Dutch AK prevalence. Unfortunately, the design of the study 
does not allow a longitudinal follow up of individual AK to study its natural course. The 
individual number of AK lesions within a participant was not counted; instead AK pres-
ence was divided into three categories (i.e., 1 to 3, 4 to 9, ≥ 10). Although categorical 
data is less precise than continuous, previous studies showed that the inter-observer 
variation between dermatologists was large when counting the individual number of 
AK lesions within a participant and using categorised data greatly reduced this varia-
tion.15 The population of the Rotterdam Study is 45 years and older and almost exclusive 
Caucasian possibly limiting the generalizibility of the findings. However, none of the 
participants aged below 55 years (n = 50) had AK and AKs are rare in people with darker 
skin suggesting that the extent of this limitation is rather small. At time of FBSE, only feet 
and areas covered by underwear were not examined because of practical and psycho-
logical reasons. It is unlikely that this restriction resulted in an underestimation of the AK 
prevalence because these areas are not chronically UV exposed.
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ConCLUsions
More than a quarter of people are affected by AK and 8% by 10 or more lesions em-
phasizing that cutaneous (pre)maligancies are an enormous burden for health care 
providers. Preventive measures including promoting sun protective behavior, and rais-
ing awareness on cutaneous keratinocyte carcinoma and persistent AKs, should focus in 
particular on elderly, bald men and those with photodamaged facial skin to reduce the 
number of SCC.
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ABsTRACT
Background
Cutaneous malignant melanoma causes the majority of skin cancer related deaths and 
features increasing incidence and mortality rates in the Netherlands. Conditional sur-
vival analysis is performed on patients who survived the preceding year(s).
Methods
Patients with invasive melanoma, as recorded in the population-based Netherlands 
Cancer Registry, were included. To assess prognosis of melanoma survivors according to 
gender and Breslow thickness, conditional five-year relative survival was calculated for 
lymph node negative melanoma patients and conditional one-year relative survival was 
analysed for melanoma patients with and without nodal involvement.
Findings
Between 1994 and 2008, 40,050 patients developed a melanoma (stage I-III, of whom 
6% with nodal involvement). Six to eight years after diagnosis, survival of patients with 
a 1-2 mm (T2) thick melanoma equalized the general population. Conditional five-year 
relative survival for patients with >4mm thick (T4) melanomas increased from about 
60% at diagnosis to 90% at 7 years after diagnosis. Largest improvements were found in 
patients with thick melanomas and female patients with nodal involvement.
interpretation
The prognosis for melanoma survivors improved with each additional year of survival 
after diagnosis, except for patients with a ≤1mm thick melanoma, who never had any 
excess mortality during follow-up. Conditional survival of melanoma was better among 
females, among those with lower Breslow thickness, and nodal stage.
Funding
This work was supported by the Dutch Cancer Society [Grant number IKZ 2009-4316], 
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inTRodUCTion
Cutaneous malignant melanoma encompasses a large variety of malignancies with 
different disease presentations and short-term outcomes. Cutaneous malignant mela-
noma causes the majority of skin cancer related deaths and is currently the sixth most 
common cancer in the Netherlands (excluding keratinocyte carcinomas of the skin) with 
continuously increasing incidence rates of 4% annually.1 Similar rising trends have been 
reported in most European countries, while Australia, New Zealand, North America, 
and Israel showed a stabilizing or declining trend (mainly youngest age groups).2 Nor-
way has decreasing incidence trends in young age groups and increasing trends in 
older patients.3 Mortality rates increased in the Netherlands1 and several other European 
countries,4 but remained stable or decreased in Scotland, the United Kingdom, Denmark 
(females), Iceland (males) the United States, and Australia.5-11
Survival estimates for cancer patients are traditionally reported from the time since 
cancer diagnosis and do not provide estimates for patients who have already survived 
a period of time after initial diagnosis and treatment. Patients diagnosed with nodal or 
distant metastases often die soon after diagnosis and negatively affect standard survival 
curves which are estimated at time of diagnosis. The right side of melanoma Kaplan-
Meier survival curves show that there is generally a proportion of patients that have 
a better survival. The increasing incidence and relatively good survival, mostly due to 
thin melanomas, have resulted in a growing group of melanoma survivors. At the same 
time, patients with early nodal metastases (i.e. Sentinel Node (SN) positive patients), 
who have survived for 2-3 years after initial surgery, have a large chance to survive for a 
longer period of time. Conditional survival analysis is a method to estimate the survival 
rate of patients who already survived a certain period of time, i.e. patients on the right 
side of Kaplan-Meier survival curves.
These estimates give important information to cancer patients, i.e. almost a third of 
cancer survivors in the Netherlands experienced either changes in their work situation, 
problems with life insurances and/or problems regarding house mortgages due to their 
cancer.12 These problems could decrease several years after diagnosis if conditional 
survival show trends to 100%.
Recent studies reported conditional survival estimates for melanoma in Europe10,13-15, 
Australia16, and the USA.17-20 In this study, we present conditional 5-year relative survival 
rates for Dutch melanoma patients without nodal involvement and conditional 1-year 
relative survival rates for patients with and without nodal involvement, stratified for 
gender and Breslow thickness. This stratification is useful for caregivers and patients to 
be informed on their prognosis years after their initial diagnosis.
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MeThods
data collection
For this study, population-based data was used from the nationwide Netherlands 
Cancer Registry (NCR), which was started in 1989 and is maintained and hosted by 
the Comprehensive Cancer Centres.1 The NCR is primarily based on notification of all 
newly diagnosed malignancies in the Netherlands by the automated pathology archive 
(PALGA).1 Information on patient characteristics such as gender and date of birth, as well 
as tumour characteristics such as date of diagnosis, location (International Classification 
of Diseases for Oncology (ICD-O-3)21), histology, Breslow thickness, stage, and grade, 
are routinely obtained from the medical records.1 The quality of the data is high, due to 
thorough training of the registrars and computerized consistency checks at regional and 
national levels. Completeness of the NCR is estimated to be at least 95%.22
For the present study, all cases with stage I-III histologically proven invasive melanoma 
(C44) without distant metastasis (M0) diagnosed in the period 1994-2008 in the Nether-
lands were included (n=40,050). This study focussed on stage I-III patients, since stage IV 
patients generally have a poor survival and the number of patients in this group is too 
low to calculate accurate conditional survival estimates. Follow-up of vital status was 
complete until January 2010. Patients younger than 15 years and older than 89 years at 
diagnosis were excluded from the analysis, as well as cases diagnosed by autopsy. Age 
was divided in three groups (15-44, 45-59, 60-89 years). Breslow thickness was divided 
into four groups (≤1.0 mm, 1.01-2.0, 2.01-4.0, and >4.0 mm) according to the 7th edition 
(2009) of the American Joint Committee on Cancer (AJCC) staging system (T1,T2,T3, 
and T4; www.cancerstaging.org). Nodal involvement was grouped in node-positive (N+, 
consisting of N1, N2 or N3) and node-negative (N0, consisting of N0 or unknown nodal 
stage). Full stage according to AJCC could not be used, because criteria changed during 
the study period and subgroups became too small. Melanoma localization was catego-
rized into head and neck (C44.0-C44.4), trunk (C44.5, C44.9), and extremities (arms and 
legs, C44.6, C44.7). Morphology was categorized into nodular melanoma (ICD-O3 8721), 
superficial spreading melanoma (ICD-O3 8742), and other melanoma subtypes (ICD-O3 
8720-8780 excluding 8721 and 8742).
statistical analyses
Conditional relative survival rates are relative survival rates for every additional year 
survived up to several years after diagnosis, conditional on being alive at the beginning 
of that year. Thus conditional five-year relative survival is the relative survival of patients 
alive five years after initial diagnosis.
Relative survival is the survival taking into account the background mortality of 
a population. It is calculated as the absolute survival among cancer patients divided 
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by the expected survival of a comparable group from the general population (same 
period, age, and gender). Expected survival was calculated from population life tables, 
according to Ederer II.23 To provide up-to-date survival estimates, period analysis24-26 was 
used. All observations included in the analysis are truncated (limited) at the beginning 
of the period of interest (e.g. one or five year(s) before the year of estimation) as well as 
censored at the end of follow-up.
Furthermore, to enable the estimation of even more up-to-date survival, hybrid 
analysis was used,27 since follow-up of the study population (mortality data) is available 
up to 2009, while incidence data are only available up to 2008. This means that for the 
estimation of 5-year relative survival for patients diagnosed in 2008 we included the 
follow-up of years 2004–2008 (Supplemental Figure 1).
Five-year relative survival rates were computed for every additional year survived up 
to 11 years after diagnosis, conditional on being alive at the beginning of that year (con-
ditional 5-year relative survival, 5-year CRS). Five-year CRS was computed according to 
Bres low thickness and gender. One-year CRS was analyzed for melanoma patients accord-
ing to nodal status up to 15 years after diagnosis to estimate the short-term prognosis for 
melanoma patients taking into account the time a patient has already survived. Estimates 
for N+ patients could only be presented for limited time after diagnosis up to maximal 
10 years due to relatively small groups of patients. It was not possible to calculate 5-year 
CRS for all N+ melanoma patients due to the small number of patients in the subgroups, 
stratified by Breslow thickness and gender, combined with the poor prognosis of many 
patients in this group. One-year and 5-year CRS analyses were also stratified for age 
groups, histological subtype, and tumour location to examine differences in survival. We 
presented only CRS estimates based on sufficiently large groups of patients. Therefore, 
CRS estimates were limited to results with a standard error ≤5% of the survival rate to 
avoid results based on chance. Minimal excess mortality was defined as a 5-year CRS 
which persistently reached 95% for a group of patients. Calculations were performed with 
SAS software (SAS system 9.2, SAS Institute, Cary, NC). This study was reported according 
to the STROBE criteria for cohort studies(http://www.strobe-statement.org).
ResULTs
A total of 40,050 patients (16,942 men and 23,108 women) were diagnosed with a 
stage I-III melanoma (N+ :6%, N0: 94%) between 1994 and 2010. The median ages of 
male and female patients were 56 (interquartile range (IQR): 44-67) and 52 (IQR: 40-
65). The median (IQR) follow-up time was 5.4 (IQR: 2.8-9.4) years (males: 4.8 [2.5-8.6] 
years, females: 5.8 [3.0-9.8] years). Female patients had more thin melanomas (T1, 
Breslow thickness ≤1.0 mm) compared to male patients (54% vs. 44%, p<0.0001). Thick 
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melanomas (T4, >4.0 mm) were diagnosed in 11% of the male patients and 6% of the 
female patients (Table 1).
Conditional 5-year relative survival in n0 patients
Five-year CRS remained almost 100% for both males and females with a melanoma of 
≤1.0 mm (T1), indicating that these patients experience the same survival as the general 
Dutch population with the same age and gender as the patients. (Figure  1a and 1b) 
Five-year relative survival at diagnosis for male patients with a melanoma with a higher 
Breslow thickness were significantly lower with a 5-year relative survival ranging from 
58% for >4.0 mm(T4) to 88% for 1.01-2.0 mm. For female patients this was higher with 
the 5-year relative survival ranging from 63% for >4.0 mm (T4) to 95% for 1.01-2.0 mm 
(T2). However, 5-year CRS for these Breslow categories quickly improved with time since 
Table 1. Characteristics of patients with stage I-III melanoma in the Netherlands, 1994-2008 (n=40,050)
Men (n=16,942) women (n=23,108) Total
n % n % n %
Age (yrs)
15-44 4,337 25 8,052 35 12,389 31
45-59 5,553 33 7,106 31 12,659 32
60-89 7,052 42 7,950 34 15,002 37
Breslow thickness (mm)
≤1.0 (T1) 7,534 44 12,534 54 20,068 50
1.01-2.0 (T2) 3,766 22 4,965 22 8,731 22
2.01-4.0 (T3) 2,798 17 2,707 12 5,505 14
>4.0 (T4) 1,804 11 1,412 6 3,216 8
Missing/unknown 1,040 6 1,490 6 2,530 6
n stage
N0 15,534 92 22,013 95 37,547 94
N+ 1,408 8 1,095 5 2,503 6
Morphology
Nodular melanoma 2,821 17 2,843 12 5,664 14
Superficial melanoma 9,968 59 14,658 64 24,626 61
Other 4,153 24 5,607 24 9,760 24
Location
Head and neck 2,793 16 2,449 11 5,242 13
Trunk 8,325 49 6,340 27 14,665 37
Extremities 5,817 34 14,313 62 20,130 50
Unknown 7 0 6 0 13 0
Abbreviations: N0, no nodal involvement; N+, nodal involvement; n, number. Source: Netherlands Cancer 
Registry.
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Figure 1a: 5-year relative survival at each time point after diagnosis for lymph node negative male patients 
who have already survived the previous year(s). E.g. male patients with Breslow thickness 2.01-4.0 mm at 
diagnosis who have already survived for 4 years, had a 80% chance to survive another 5 years (this means 
up to 9 years after diagnosis). When 5-year relative survival approached 100%, melanoma patients then 
alive had a prognosis similar to the background population (no excess mortality anymore). Source: Neth-
erlands Cancer Registry.
Figure 1b: 5-year relative survival at each time point after diagnosis for lymph node negative female pa-
tients who have already survived the previous year(s). Source: Netherlands Cancer Registry.
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Figure 2a: 1-year relative survival at each time point after diagnosis for lymph node positive male patients 
who have already survived the previous year(s). Source: Netherlands Cancer Registry.
Figure 2b: 1-year relative survival at each time point after diagnosis for lymph node positive female pa-
tients who have already survived the previous year(s). Source: Netherlands Cancer Registry.
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Figure 3a: 1-year relative survival at each time point after diagnosis for lymph node negative male patients 
who have already survived the previous year(s). Source: Netherlands Cancer Registry.
Figure 3b: 1-year relative survival at each time point after diagnosis for lymph node negative female pa-
tients who have already survived the previous year(s). Source: Netherlands Cancer Registry.
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diagnosis. Minimal excess mortality for melanomas with a Breslow thickness of 1.01-2.0 
mm (T2) was seen 8 and 6 years after diagnosis for males and females, respectively. For 
male patients with a 2.01-4.0 mm (T3) melanoma 5-year CRS increased from 70% (95%CI: 
68-73%) at diagnosis to 93% (95%CI: 84-102%) 10 years after diagnosis (Table  2a). 
Among female patients, 5-year CRS increased from 85% (95%CI: 82-87%) at diagnosis to 
98% (95%CI: 91-105%) 10 years after diagnosis. Minimal excess mortality was reached 
8 years after diagnosis (Table 2b). Five-year CRS for both male and female patients with 
thick melanomas (T4, >4.0 mm) increased from about 60% at diagnosis to about 90% 
after 7 years. An excess mortality of around 10% remained (Figure 1a and 1b).
In female N+ patients with a 1-2mm (T2) thick melanoma the 5-year CRS was 80% 
(95%CI: 74-86%) at diagnosis and 83% (95%CI: 75-91%) 4 years after diagnosis. The 
5-year CRS of female N+ patients with a 2-4 mm (T3) melanoma improved from 64% 
(95%CI: 58-70%) at diagnosis to 81% (95%CI: 74-89%) 3 years after diagnosis. The other 
subgroups with nodal involvement were too small for reliable 5-year CRS estimates.
Conditional 5-year relative survival analyses was also stratified for age groups, morphol-
ogy and tumour location. No large differences in estimates were observed (results not 
shown), although a better CRS of superficial spreading melanomas was found compared 
to nodular melanomas.
For male patients with a superficial spreading melanoma 5-year CRS increased from 
91% (95%CI: 90-92%) at diagnosis to 99% (95%CI: 97-100%) 10 years after diagnosis, in 
contrast with male patients with a nodular melanoma in which 5-year CRS increased 
from 67% (95%CI: 65-69%) at diagnosis to 93% (95%CI: 89-97%) 10 years after diagnosis. 
The 5-year CRS in female patients with a superficial spreading melanoma remained 
stable and comparable to the general population at diagnosis (97% [95%CI: 96-97%]) 
and 10 years after diagnosis (98% [95%CI: 97-99%]), in contrast with female patients 
with a nodular melanoma in whom 5-year CRS increased from 81% (95%CI: 79-83%) at 
diagnosis to 96% (95%CI: 93-99%) 10 years after diagnosis.
Conditional 1-year relative survival
A total of 2,503 patients (6%) had nodal involvement at diagnosis. The 1-year CRS at 
diagnosis for N+ male patients with a T1 melanoma of ≤1.0 mm (91%) and 1.01-2.0mm 
T2 melanoma (96%) was only slightly worse than N+ female patients with a melanoma 
of ≤2.0 mm (T1/2) where 1-year CRS at diagnosis was 98%. The short term prognosis 
fluctuated and improved slightly in male patients and remained stable in female pa-
tients. One-year CRS at diagnosis for N0 male and female patients with a melanoma of 
≤2.0 mm (T1/2) was 100% and remained comparable to the general population during 
follow-up (97-100%) (Figures 2ab and 3ab).
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In male N+ patients with melanomas with a Breslow thickness of >2.0 mm (T3/4) the 
1-year CRS initially decreased fast and then increased up to 93% 5 years after diagnosis, 
in contrast with female N+ patients with >2·0 mm (T3/4) thick melanomas where 1-year 
CRS decreased slightly and increased up to 97% 5 years after diagnosis (Figure 2ab). In 
male and female N0 patients with >2·0 mm (T3/4) thick melanomas a similar declining 
trend of 1-year CRS was observed in the first 3 years after diagnosis and then improved 
to respectively 97% and 99% 10 years after diagnosis (Figure 3ab).
disCUssion
Survival of patients with advanced melanoma was fairly good 5 years after diagnosis. 
To the best of our knowledge, this is the largest population-based study providing 
accurate conditional survival estimates for melanoma patients according to gender, 
Breslow thickness, and nodal status with 1-year and 5-year CRS estimates up to 15 and 
11 years after diagnosis, respectively. Dutch melanoma patients who are N0 at diagnosis 
and still alive 5 years after diagnosis have a high probability of surviving another 5 years 
(83-100%, depending on gender and Breslow thickness).
A large proportion of melanoma patients will survive their melanoma,28 thus 5-year CRS 
estimates are an indication of a new prognostic model for melanoma survivors during 
follow-up. Studies on conditional survival may provide useful prognostic information 
for both patients and caregivers. We feel conditional survival is more useful for clinicians 
wanting to inform patients on their actual prognosis than the usual 5-or 10-year relative 
survival rates that are extremely influenced by patients who die rapidly after diagnosis 
and are not representative for the majority of the melanoma patients when they have 
survived a significant time since diagnosis.1 The excess mortality function by time since 
diagnosis10 is a good measurement to show what the prognosis is of patients then alive 
and when they might be ‘cured’. In our study was shown that 5-year relative survival 
generally improved with time that patients have already survived. When such 5-year 
relative survival approaches 100%, that group of melanoma patients have a prognosis 
similar to the background population. The changing conditional 5-year relative survival 
rates for the various subgroups with time since diagnosis estimates accurately actual 
prognosis during follow-up. In this study estimates of excess mortality were only avail-
able for lymph node negative patients due to large enough sample size in this subgroup. 
To provide additional (short term) prognostic information to lymph node positive pa-
tients when they survived several years after the first melanoma diagnosis 1-year CRS 
was calculated.
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Melanoma survival is substantially better for women than for men.29-31 This was also re-
flected in the 1-year and 5-year CRS estimates for both N+ and N0 patients. We observed 
that minimal excess mortality was found in a later time period for men compared to 
women. In the short term prognosis curves of N+ T3/4 melanoma patients (2-4 mm/>4 
mm) a faster rise was shown in the prognosis of female patients compared to male 
patients. This is in line with a study that found that female melanoma patients have a 
lower risk of disease progression compared to males.30 The relatively good 5-year CRS of 
female N+ melanoma patients is a novel finding of major importance, which stresses the 
usefulness of CRS and could prevent long term anxiety amongst this group.
Three previous European studies provided CRS estimates for melanoma patients ac-
cording to gender and age groups or country.13-15 Gender and country influenced the 
estimates, while different age groups showed similar results in the different countries. 
Conditional relative survival was lower in countries with poorer survival rates.14 Breslow 
thickness or stage were not available in these studies, therefore the minimal excess 
mortality estimates in these studies (3-7 years after diagnosis15 and 5-7 years after 
diagnosis13) are rather negative for patients with thin melanomas, because N0 and N+ 
melanoma patients with varying tumour depths were analysed together.
A large U.S. study reported 5-year CRS for melanoma with local, regional, and distant 
disease at 0-5 years after diagnosis.20 The 5-year CRS in localized melanoma remained 
stable (98% at diagnosis and 99% 10 years after diagnosis), an increase was found in 
regional melanoma (63% at diagnosis and 87% 10 years after diagnosis) and distant 
melanoma (15% at diagnosis and 80% 10 years after diagnosis).20 The estimates of local-
ized and regional melanoma correspond well with the 5-year CRS estimates of respec-
tively T1(<1 mm) N0 melanoma in males and females, and T3(2-4 mm) N+ melanoma in 
females we found. Another U.S. study reported 5-year melanoma-specific and overall 
conditional survival estimates up to 5 years after diagnosis, which was stratified for 
stage, gender, and age groups.17 The 5-year CRS for stage I was stable and comparable 
to the general population (97% at diagnosis and 98% 5 years after diagnosis), for stage 
II, III and IV an increase in 5-year CRS was shown (stage II: 72% at diagnosis vs. 86% 5 
years after diagnosis, stage III: 51% vs. 87%; stage IV 19% vs. 84%).17 These results (stage 
I-III) are comparable with 5-year CRS of respectively T1 (<1 mm) N0, T3 (2.01-4.0 mm) N0 
in males or T3 (2.01-4.0 mm) N+ in females, and T4 (>4.0 mm) N0 in the present study. 
Patients younger than 50 years with stage II or III melanoma showed higher melanoma-
specific 5-year adjusted conditional survival estimates than patients aged 50 years or 
older only in the first 2-3 years after diagnosis.17
Five year conditional disease specific survival of stage IIIA melanoma in the U.S. 
population was 78% at time of lymphadenectomy and increased up to 90% for 5 year 
survivors, for stage IIIB from 54% to 79% and for stage IIIC from 39% to 78%.18 Another 
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U.S. study showed that 8 years after diagnosis no significantly different survival rates 
existed between high risk melanoma patients (T4N0M0 or T2-4N1-3M0) and low risk 
melanoma patients (T2-3N0M0)19, supporting the minimal excess mortality of 8 years 
after diagnosis in T2N0 males and T3N0 females in this study.
A recent study concerning 5-year CRS of Australian cancer patients presented esti-
mates for different stages of melanoma with results similar to ours.16 The Breslow thick-
ness categories and disease stages were grouped in four categories: localized, regional 
(Breslow thickness >2 mm (T3 and T4) were grouped with spread to regional lymph 
nodes), distant or unknown. The 5-year CRS in localized melanoma remained stable 
(99% at diagnosis and 99% 10 years after diagnosis), an increase was found in regional 
melanoma (74% at diagnosis and 99% 10 years after diagnosis) and distant melanoma 
(32% at diagnosis and 91% 10 years after diagnosis).16 The different age groups (15-49, 
50-69, and 70-89 years) in this study showed similar conditional survival.16 The trends 
of this study were similar to those of our study, but comparing these studies is difficult, 
because different stratification categories were used (i.e. stage or melanoma spread vs. 
Breslow thickness and nodal involvement).
Conditional survival gives a quantitative estimate of the possibility of local or distant 
recurrence or a second tumour. Most recurrences and second primary melanomas are 
found in the first five years after the first melanoma diagnosis. However, this effect is not 
clearly visible in the 5-year CRS curves, since these patients had no nodal involvement 
and might be a more ‘healthy’ patient group with a lower risk of disease progression in 
the years after the melanoma diagnosis. The effect of recurrence or disease progression 
might be visible in the short term prognosis 1-year CRS curves (where a decrease was 
shown in the first years after diagnosis in almost all subgroups indicating a decreased 
survival in this time period).
Changes in sentinel node (SN) procedures and lymph node surgery might be re-
sponsible for misclassification of a part of the lymph node negative (N0) patients, since 
SN staging was not yet common practice in the Netherlands in 1994. SN staging has 
become more or less routine practice nationwide during the first decade of the 2000’s. 
The NCR records N stage only at the time of first diagnosis. Thus, in the pre-SN era, it 
only recorded patients with simultaneous palpable (macrometastases) lymph node 
metastases. Therefore, a number of N0 patients was understaged, since occult (micro)
metastases were not detected, because no SN procedure was performed.
Strengths of this study are the size of the population-based cohort, completeness of the 
cancer registry data, length of follow-up time, and stratified CRS rates based on three 
important prognostic factors (gender, Breslow thickness, and nodal involvement). The 
better CRS of superficial spreading melanomas compared to nodular melanoma could 
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be explained by the fact that nodular melanomas have a higher Breslow thickness than 
superficial spreading melanomas. These results are reflected in the stratified Breslow 
estimates. Limitations are the lack of power to calculate 5-year CRS estimates for most 
subgroups of patients with nodal involvement and the merged group of lymph node 
positive patients (N1-N3) in the 1-year CRS estimates. The short term prognosis estimates 
of 1-year CRS showed fluctuations and had wide confidence intervals and is therefore 
more difficult to use in clinical practice than 5-year CRS estimates.
In conclusion, the prognosis for melanoma survivors improved with each additional year 
of survival after initial diagnosis (except for patients with ≤1 mm T1 melanomas who 
already showed minimal excess mortality at diagnosis). In the first years after diagnosis 
there were large improvements in conditional survival for melanoma patients, especially 
with a Breslow thickness of >2mm (T3/4) and female patients who were lymph node 
positive. Quantitative insight into conditional survival is useful for dermatologists, 
surgeons and oncologists to help planning optimal cancer surveillance. It gives a more 
optimistic message of their future to melanoma survivors than the traditional survival 
rates and could reduce anxiety concerning their melanoma diagnosis in the past.
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sUPPLeMenTAL dATA
Year of 
diagnosis 
Year of follow-up 
1994 1995 1996 1997 1998 1999 2000 2001 2002 2003 2004 2005 2006 2007 2008 2009 
1994 1 1/2 2/3 3/4 4/5 5/6 6/7 7/8 8/9 9/10 10/11 11/12 12/13 13/14 14/15 15/16 
1995  1 1/2 2/3 3/4 4/5 5/6 6/7 7/8 8/9 9/10 10/11 11/12 12/13 13/14 14/15 
1996   1 1/2 2/3 3/4 4/5 5/6 6/7 7/8 8/9 9/10 10/11 11/12 12/13 13/14 
1997    1 1/2 2/3 3/4 4/5 5/6 6/7 7/8 8/9 9/10 10/11 11/12 12/13 
1998     1 1/2 2/3 3/4 4/5 5/6 6/7 7/8 8/9 9/10 10/11 11/12 
1999      1 1/2 2/3 3/4 4/5 5/6 6/7 7/8 8/9 9/10 10/11 
2000       1 1/2 2/3 3/4 4/5 5/6 6/7 7/8 8/9 9/10 
2001        1 1/2 2/3 3/4 4/5 5/6 6/7 7/8 8/9 
2002         1 1/2 2/3 3/4 4/5 5/6 6/7 7/8 
2003          1 1/2 2/3 3/4 4/5 5/6 6/7
2004           1 1/2 2/3 3/4 4/5 5/6
2005            1 1/2 2/3 3/4 4/5
2006             1 1/2 2/3 3/4
2007              1 1/2 2/3
2008               1 1/2
supplemental Figure 1: Years of diagnosis and years of follow-up included in the calculations of hybrid es-
timates of 5-year relative survival of patients for the years 2004-2009. The numbers within the cells indicate 
the years following diagnosis.
See http://www.sciencedirect.com/science/article/pii/S095980491300957X.
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Multiple cutaneous (pre)-malignancies: old news or time for action, to treat or not to 
treat (in some cases), to follow or to not follow? In order to provide a contribution to 
these debates, this thesis provides insight into the occurrence and survival of multiple 
cutaneous (pre)-malignancies using several data sources and analyses. These include 
two systematic reviews and meta-analyses, five population based cohort studies and a 
population-based cross-sectional study. In this discussion chapter, I will first answer the 
research questions posed in the introduction of this thesis briefly and present the limita-
tions of the studies. Finally, I will discuss possible implications and recommendations for 
future perspectives.
Part i: what are the risks of developing multiple cutaneous (pre)- malignancies 
(melanoma, sCC and BCC)
a. in The netherlands, and
b. worldwide (europe, north America and Australia)?
The risks for the Netherlands were evaluated using data of the population-based Neth-
erlands Cancer Registry and Eindhoven Cancer Registry, which provided data of first and 
subsequent skin cancers of Dutch patients diagnosed with melanoma, SCC and BCC. 
These studies show that the risk of developing a subsequent skin cancer after a first 
melanoma, SCC or BCC is significantly elevated on the short- and long-term. The SIR 
of a subsequent different skin cancer ranged between 3 and 6 and SIR of a melanoma 
after melanoma ranged between 12 and 26. The 20-year cumulative risks varied largely 
between the different tumor combinations (1-28%).
To investigate the risks on a global level, an extensive systematic literature search was 
conducted (last performed on January 18, 2012). A history of a prior melanoma was 
shown to be a strong predictor for development of a subsequent melanoma (approxi-
mately 10-fold increased risk) and to a lesser extent SCC or BCC (3 to 5 fold increased 
risk). A history of a prior KC is a very strong predictor for developing a subsequent SCC 
and BCC (range pooled SIR 3-17, range pooled proportion 4-29%) and to a lesser extent 
melanoma (pooled SIR approximately 2.5 and pooled proportion 0.5%).
This information on risks for subsequent skin malignancies could serve as information 
for patients, doctors and health care systems in explaining the importance of skin self 
examination, and planning follow-up care, amongst others.
Part ii: a.) what are the trends in incidence of thin melanomas and b.) what is 
the prevalence of actinic keratosis in The netherlands?
To evaluate if there are indications of overdiagnosis, we investigated time trends of 
incidence of thin melanomas. The incidence rates of in situ, thin and thick melanomas 
increased in a similar pace between 1994 and 2010 (source data: Netherlands Cancer 
Registry). However, for in situ melanomas and thin melanomas, increases were more 
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marked in recent years, in men. These recent accelerations in the increasing trends for 
thin and in situ melanomas are most likely caused by a combination of increased ultra-
violet exposure, increased awareness, early detection and ‘overdiagnosis’ and therefore 
a mixture of an artificial and a true increase.
At the time of initiation of this thesis, there was no data available on the prevalence 
and risk factors of actinic keratoses in The Netherlands. The prevalence of actinic kerato-
sis is very high (49% for men and 28% for women), especially among elderly bald males 
(OR 6.3 in patients with >10 AK) (source data: Rotterdam Study). As AKs may progress 
to invasive SCC, the prevention and management of AK is a true challenge for patients, 
physicians, and health-care policymakers, particularly considering this very high preva-
lence in the population.
Part iii: what is the conditional survival of lymph node negative and positive 
melanoma patients and patients with multiple melanoma?
The increasing incidence and relatively good survival, have resulted in a growing group 
of melanoma survivors. Conditional survival is a method to estimate the survival rate 
of patients who already survived a certain period of time. I found that with each ad-
ditional year that Dutch melanoma patients survive after their diagnosis, their prognosis 
improves, except for patients with a melanoma thinner than one millimeter, who never 
had any excess mortality during follow-up. Six to eight years after diagnosis, survival 
of patients with a T2 melanoma was equal to that of the general population, and con-
ditional 5-year relative survival for T4 patients increased from 60% to 90% at 7 years 
after diagnosis. Conditional survival of melanoma was better amongst females (as 
expected1,2), amongst those with lower Breslow thickness and nodal stage. Conditional 
survival estimates generally give a more optimistic message to patients who have al-
ready survived a certain amount of time compared to the traditional survival rates.
Survival of multiple melanomas was better than single melanomas in regular Kaplan 
Meier curves and conditional survival estimates. If the time between melanomas was 
taken into account in a Cox proportional hazards model as a time dependent variable 
the hazard ratio of multiple versus single melanoma was higher.
MULTiPLe CUTAneoUs (PRe)-MALignAnCies
It is not new that the risk of developing a subsequent cutaneous malignancy after an 
initial skin cancer is increased. Fred Wise, professor of Dermatology and Syphilology, 
already discussed in 1929 that multiple epitheliomas (keratinocyte carcinoma and pre-
cursors) are certainly not relatively ‘benign’, and mentioned the metastatic potential of 
prickle cell growths and (more rarely) basocellular neoplasms3. Almost 100 years after 
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this observation, skin cancer has become a major public health problem due to increas-
ing incidence rates and occurrence of multiple cutaneous (pre)-malignancies. Recently, 
a U.S. study reported a substantial increase in average annual total cost for skin cancer 
from 3.6 billion dollar in the period 2002-2006 to 8.1 billion dollar between 2007 and 
2011, representing an increase of 126.2%, while the average annual total cost for all 
other cancers (excluding skin cancer) increased by 25.1%4. These findings emphasize the 
importance of skin cancer in (public) health policy, as well as the urge for effective pri-
mary and secondary prevention. Early detection and possible overdiagnosis will further 
increase the economic burden of skin cancer but should result in decreasing mortality 
rates. The recently stabilizing mortality rates of melanoma in The Netherlands5 indicate 
the first advantages of early detection and increased awareness, and less likely may also 
have been caused by new targeted therapies.
Skin cancer and premalignant skin lesions sometimes cause confusion to doctors and 
patients, because a (skin) cancer diagnosis might cause feelings of distress and anxiety 
among patients6 whereas doctors or dermatologists might explain their diagnosis rather 
casually because of the generally good prognosis. Doctors know some lesions (e.g. AK 
or BCC) are rather meaningless, but treat them anyhow because the course of the indi-
vidual lesion is unknown. Some patients are able to self-examine their skin and accept 
discharge from further clinical follow-up, other patients prefer a lifelong annual full body 
skin examination by their dermatologist. Aging of the population and lifestyle habits (e.g. 
sun seeking behavior) increases the number of patients, a proportion of them geriatric, 
with (extensive) actinic damage and (multiple) cutaneous (more advanced) malignancies. 
Dermatologists should be aware of the overall elderly patients’ general health status both 
physically and cognitively, and short-term as well as long-term goals. When it comes to 
patients’ autonomy, the ability of elderly patients to make their own decisions regarding 
their health care should be evaluated and, if needed, appropriate family members or care-
givers should be involved in the decision-making processes7. Less costly treatments (e.g. 
curettage or cryotherapy) with higher recurrence rates and a poorer cosmetical outcome 
may on the long term lead to higher health care costs (if the geriatric patient survives and 
Mohs’ micrographic surgery is required to treat of a recurrent skin cancer). On the other 
hand, if the remaining life expectancy of the patient is limited, watchful waiting without 
intervention may be appropriate. Of course, evaluation of the patients’ appearance and 
sense of well-being and attractiveness and potential limitations in application of topical 
treatments is needed equally for geriatric as other patients7. The rising group of ageing 
patients with a comorbidity interfering with surgery might indicate symptomatic treat-
ments of extensive BCCs, AKs, SCCs or lentigo maligna’s rather than curative treatments 
(palliative purposes versus curative care according to Internal Oncology); literature on 
this topic in the field of Dermato-Oncology is scarce.
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LiMiTATions oF The sTUdies wiThin This Thesis
The major limitation of the meta-analysis (chapter 2 and 3) was the lack of information 
of high quality risk estimates (SIR). We had to focus mostly on “proportion” as risk esti-
mate because the majority of studies investigating KC patients reported only propor-
tions. The preferable SIRs, which control for background incidence or cumulative risk, is 
time-specific and accounts for the competing risk ‘death’ were hardly reported in exist-
ing literature. Cancer registries mainly report the first histologically confirmed BCCs and 
SCCs. Therefore the risk of a subsequent BCC or SCC could only be calculated for very few 
populations using population-based data. Available data were primarily from smaller 
hospital-based studies, with shorter follow-up and a potential of selected populations, 
that may have underestimated the pooled proportions. A (relatively limited) part of the 
BCCs are clinically diagnosed (proportion in The Netherlands 7.1% vs. Scotland, Finland 
and Malta 0.7% - 24.1%8), which may further underestimate the pooled proportions and 
SIRs. Also, the on average younger age of melanoma patients compared to patients with 
a KC, together with limited follow-up time could have influenced the pooled BCC or SCC 
risk negatively.
Generally, as the number of follow-up visits increase, so does the number of subse-
quent skin cancers detected and therefore the proportion (i.e. surveillance bias). The 
averaged cumulative risks were based on a few studies and therefore external validity of 
these measurements is rather limited.
The high risks of subsequent melanoma, BCC or SCC in patients with melanoma or 
KC described in chapter 4 and 5 might be related to increased patients’ and doctors’ 
awareness illustrating selection bias and length-time bias9 (i.e. slowly growing tumours 
are more likely to be discovered). In the case of subsequent melanoma, some benign 
lesions that are misclassified as melanoma could result in some melanoma overdiagno-
sis, because of the difficult histological interpretation of very small melanocytic lesions 
from patients with a history of melanoma10. However, the main objective of increasing 
awareness is early detection and a decrease of melanoma mortality. Anyhow, increased 
surveillance and early detection will result in increasing numbers of melanoma with a 
good prognosis, and therefore the term overdiagnosis might be inappropriate. Recently 
the term indolent lesion of epithelial origin (IDLE) was introduced, and the need for a 
new terminology for several indolent (pre)-cancers was suggested11. The increased risk 
of a subsequent skin cancer, either of the same or a different type, might be caused by 
field cancerization and other shared risk factors, although individual effects are difficult 
to examine. Further limitations of these studies are the absence of information concern-
ing phenotypic characteristics of patients, lifestyle and behavior, medication use such as 
immunosuppressive drugs and genetic susceptibility, which are all related to individual 
risks of developing one or more skin cancers.
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A limitation of the study of trends in incidence of thin melanomas (chapter 7) is the 
proportion of patients with a missing Breslow thickness. As the regional comprehensive 
cancer center in Rotterdam began capturing information regarding Breslow thickness 
on a routine basis later than the other regional comprehensive cancer centers, we de-
cided to exclude this registry from the analyses. Further limitations are the unknown 
levels of a true increase, increased awareness, diagnostic drift and overdiagnosis. 
I believe all play a role to a certain extent but based on the available data we were not 
able to discern which proportion each effect contributed. The difficult interpretation 
of small melanoma simulators and small in situ or micro-invasive melanomas causes 
misinterpretation10 of indolent lesions. Diagnostic drift seems to have occurred, sup-
ported by the observation that a re-evaluation of biopsy specimens taken 20 years ago 
results in a higher number of melanoma diagnosis (approximately 25% of 29 dysplastic 
nevi diagnosed between 1988 and 1990 were diagnosed as melanoma between 2008 
and 2009) recently compared to 20 years ago12. The increased use of dermoscopy and 
identification of more atypical small lesions (which could be harmless and not affect life 
expectancy) might further increase the wanted early detection or possibly unwanted 
overdiagnosis.
The clinically diagnosed actinic keratoses in The Rotterdam Study (chapter 8) may 
have led to misclassification and an underestimation or overestimation, because AK 
can resemble keratinocyte carcinoma. However, nondifferential misclassification was 
estimated to be small, considering previously reported positive predictive values of a 
clinical AK diagnosis ranging from 74% to 94%13,14. Moreover, the use of categorized data 
(1-3, 4-9, ≥ 10 AKs) decreased the inter-observer variation15. The cross-sectional design 
and missing information concerning previous treatment of AK are further limitations to 
this study. However, prevalence data are by definition cross-sectional, and in a future 
measurement of the Rotterdam Study we can evaluate trends of the occurrence of AKs.
The lack of power to calculate 5-year conditional relative survival (CRS) estimates for 
most subgroups of patients with nodal involvement was a limitiation of the study in 
chapter 9. The fluctuations with wide confidence intervals in the short term prognosis 
estimates of 1-year CRS makes these numbers less appropriate for use in clinical practice. 
Limitations of the complex analysis of survival of multiple malignancies (chapter 10) 
are: the relatively small subgroup of patients with multiple melanomas, limiting stability 
of estimates and stratification of different subgroups with a different Breslow thickness. 
Particularly the fact that being classified as patient with multiple melanomas already 
implied that a patient survived the time between first and second melanoma diagnosis, 
caused methodological problems to circumvent in order to provide valid estimates and 
conclusions.
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PossiBLe iMPLiCATions And ReCoMMendATions FoR FUTURe 
PeRsPeCTiVes
i individual patient – Clinical relevance
The increasing number of (multiple) cutaneous (pre)-malignancies in The Netherlands 
requires improvements in primary and secondary prevention. Primary prevention of 
skin cancer is a challenge, because protection against exposure to ultraviolet radiation 
requires environmental changes (e.g. create shade by planting trees, reschedule work 
practices and sporting times), social changes (sun bathing habits and solarium use for 
a cosmetic tan) and most of all behavioural modification (sunscreen use, wearing hats 
and long-sleeved clothes) and policy changes (a sunbed ban). Even though instructions 
for behavioural modifications are clear, it is notoriously difficult to change these types 
of habits. Moreover, in practice, it seems that a proportion of the population uses sun-
screen in order to be able to stay in the sun for longer periods. The interaction of skin 
cancer and ultraviolet protection knowledge, attitudes towards tanning and ultraviolet 
protection behaviour needs further investigation16.
In 1989, a screening campaign for skin cancer was organized using a ‘freckle bus’ for skin 
examinations in four seaside resorts of The Netherlands. Much publicity was given to the 
campaign by the (inter)national media and it appeared that after the campaign there was 
an increase in the number of consultations and diagnoses of malignant lesions. A similar 
education and screening campaign was organized in Belgium in 1999 (‘Melanoma day’) 
and since 2000 it is active in a large and growing number of European countries under 
the name Euromelanoma17. Since 2013 a national skin cancer day is organized annually 
in May in The Netherlands (www.huidkanker.pro) to increase awareness and several hos-
pitals offer free skin examinations by dermatologists. To improve efficacy of prevention 
campaigns, high risk populations must be reached such as elderly men and people with 
lower socio-economic status that usually escape campaigns18. In Australia, since 1980 
many public health campaigns and environmental interventions were used to stimulate 
sun protection. These campaigns should have decreased the incidence of melanoma in 
younger populations that were born and raised during the active campaigns, however, 
the crude rate of melanoma in patients under 30 years of age in the susceptible popula-
tion (total number of Australians minus Australians born in Asia, the Pacific Islands, the 
Middle East, or sub-Saharan Africa; and Australian-born children whose parents were 
born in these regions) increased from 5.9 per 100,000 in 1982 to 6.3 in 200919. On the 
other hand, mortality rates are decreasing in younger patient groups. One of the secrets 
behind the relative success of this campaign is that prevention programmes are hosted 
by a stable and supportive organization with reliable funding for about 30 years20.
Secondary prevention of skin cancer consists of early detection and is obtained by 
increased surveillance by the population at risk and their physicians. Routine skin self-
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examination increases chances of early detection and treatment and may be the key to 
better survival, particularly in the case of melanoma. Sensitivity of skin self-examination 
(SSE) for melanoma is low (25-93%, patients are often unable to count the number of 
nevi or detect atypical nevi and changes in mole size on their own bodies correctly), 
specificity is higher (83-97%), future studies to improve its accuracy are needed, because 
SSE would be the easiest screening-tool21. Different types of images used in educational 
aids have improved the performance of skin self-examination and the accuracy of SSE 
and melanoma detection22. Several studies are underway using apps for the smart-
phone, either with or without tele-evaluation by experts23-25. Early detection by physi-
cians (other than dermatologists) may improve by optimizing skin cancer examination 
education at medical school and identifying curricular factors associated with medical 
students’ confidence, intent, and performance regarding the skin cancer examination26. 
Data concerning true effects on morbidity and mortality of self-examination and effects 
of regular examination of the skin by a general practitioner, nurse practitioner or by 
even the patients’ partner or significant other who has received a training is absent27. 
Most studies investigating mobile teledermoscopy have been small pilot cohort studies 
or trials, larger studies investigating a representative group of patients (including those 
with little technical skills) are needed to confirm the viability28.
Reasons for follow-up (or tertiary prevention) of skin cancer patients include detection 
of a recurrence, diagnosis of second primary skin cancers and provision of psychosocial 
support and/or information. The majority of recurrences of skin cancer are found in the 
first years after initial diagnosis, but as I have shown, the risk of subsequent skin cancers 
remains elevated lifelong. Skin cancer follow-up in The Netherlands is quite limited 
according to the guidelines29-31 and patients’ perspective has not been included in de-
termining the cut-off. Anyhow, patients with extensive actinic damage, high numbers of 
(atypical) moles and immune suppressed patients are advised annual follow-up visits. 
The subgroup with extensive actinic damage needs a more clear definition (e.g. >10 
actinic keratosis and/or >3 keratinocyte carcinomas in medical history). In patients with 
localized melanoma less intensive monitoring might lead to more efficient follow-up 
strategies32. A subset of patients with KC may not develop another KC, a better under-
standing of the course and frequency of subsequent KC might improve follow-up strate-
gies33. At this moment no evidence-based data is available concerning frequency and 
duration of follow-up of melanoma and keratinocyte carcinoma and I suggest a clinical 
trial comparing annual skin examinations of high risk populations by a dermatologist/
general practitioner versus skin cancer education of patients.
Large-scale skin cancer screening is not recommended by the US Preventive Ser-
vices Task Force34; modelling studies suggest that selective targeted screening might 
be a more cost-effective strategy35. The identification of high risk populations may be 
improved by risk prediction models. Recently, a systematic review was reported which 
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described and compared 25 risk prediction models for melanoma36. The 25 risk predic-
tion models considered 144 different possible risk factors, which included 18 measures 
of number of naevi, 26 of sun / ultraviolet exposure, 14 of history of sunburn and the 
risk factors which most likely remained in the final model were age, number of naevi, 
presence of freckles, history of sunburn, skin type, hair colour, skin colour and personal 
history of skin cancer. Fourteen studies provided discriminatory performance estimates 
with values for the area under the receiver operating curve (AUROC) of approximately 
0.76 with little difference between models for self-assessment and those requiring a 
health care professional; only two models have been validated in separate populations 
with AUROC values of 0.79 and 0.7036 . More studies validating existing models and de-
velopment of new risk models incorporating genetic information were suggested. Olsen 
et al37 recently assessed the performance of six melanoma risk prediction tools in two 
independent data sets, 762 melanoma cases and a population-based sample of 42,116 
people without melanoma, and found that most existing prediction models were poorly 
calibrated. However, most models had reasonable discriminatory accuracy (AUROC 0.73-
0.93)37. Problems to estimate cancer risk at the individual level are a) that the primary 
risk factors are common in the population, b) effects of risk factors are typically modest 
(relative risks < 5) and do not discriminate those who will develop cancer from those 
who will not, and c) most cancers have long latent periods and arise in individuals with a 
risk close to the general population38. The addition of integrating genetic risk profiles to 
models in breast cancer only modestly improved discrimination (AUROC for a risk model 
with age, study and entry year, and four traditional risk factors was 58.0%; AUROC with 
addition of 10 genetic variants was 61.8%)39.
Several studies suggested a chemopreventive effect of non-steroidal anti-inflammatory 
drugs (NSAIDs) for cancer, however a recent Dutch study40 and recent meta-analysis41 do 
not support these findings in the case of melanoma and keratinocyte carcinoma. Trans-
plant recipients showed a reduced risk of new keratinocyte carcinoma when acitretin 
was compared to placebo (relative risk 0.22) without significant differences in risks of 
adverse events and T4N5 liposome lotion significantly reduced the rate of new BCCs in 
xeroderma pigmentosum patients, however the number of trials is small and studies 
show inconsistent results42. Chemoprevention for (multiple) cutaneous (pre)-malignan-
cies is an interesting strategy that needs to be explored further in observational and 
interventional studies which investigate the risk-benefit ratio of the candidate drug43.
ii societal impact
The high incidence of (multiple) cutaneous malignancies combined with a relatively 
good prognosis (more than 90% of skin cancer patients survives) results in a large and 
growing group of skin cancer survivors. In 2005, the Institute of Medicine noted in a 
report that many cancer survivors become lost in the transition from cancer patient to 
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cancer survivor and recommended recognizing cancer survivorship as a distinct phase 
of cancer care that deserves ongoing attention from cancer and other health care 
providers, however, the specific challenges that individual survivors encounter vary 
widely44. The first step of a survivorship care plan is the treatment summary, the next step 
is the ongoing care plan for survivors with a clear plan for the patient and all involved 
health care providers including guidelines for surveillance of development of recurrence 
or new cancers, long-term and late effects of treatment (e.g. cosmetic scarring from 
surgery), noncancer health care and health maintenance (specific recommendations on 
lifestyle issues), psychosocial concerns (simple recognition and referral can be enough 
to improve psychosocial outcomes in many cases), employment/insurance/economic 
issues and identification of providers (which provider will be responsible for ongoing 
cancer monitoring)44. In the Netherlands melanoma survivors received more follow-up 
than recommended by the Dutch melanoma guideline45, which might be caused by pa-
tients’ need for additional care or doctors’ preferences. Future research should focus on 
the different elements of a proposed survivorship care plan (diagnosis, previous treat-
ments, plan for surveillance and monitoring, resources available, and correct providers 
for different problems), evaluating levels of satisfaction, variations in follow-up practice 
patterns and outcomes, testing the acceptability of survivors and providers who use 
different models or survivorship care and determining the current and optimal levels 
of involvement of different specialists and primary care physicians in the creation and 
execution of the survivorship care plan44. Cost and time restraints are major barriers 
for the creation and use of survivorship care plans, and the expectation that electronic 
medical records can simplify and accelerate survivorship care plan development is yet 
to be achieved46.
The high incidence of skin cancer also has imposed an increasing burden on primary 
health care in the Netherlands and most likely health care costs as well (total number of 
contacts for malignant skin lesions had an annual percent change of +11.8% between 
2001 and 201047). Since 2006, in 31.2% of 4,513 patients that had a first visit for a skin 
lesion suspected of malignancy, general practitioners performed minor surgery within 
one year after their first contact and in total 13.0% of the patients were referred for 
specialized care (data from general practice registration network in the northern part of 
the Netherlands with an average annual population of approximately 30,000 patients)47. 
A study in Australia investigated number of lesions needed to excise or biopsy (NNE) for 
1 melanoma or 1 nonmelanoma skin cancer to be detected and found that the NNE for 
melanoma and nonmelanoma skin cancer in primary care physicians were respectively 
1.5 and 19.6 with strong effects of clinical impressions and patients pressure to excise48. 
General practitioners and skin cancer clinic doctors in Queensland treat large numbers 
of melanomas and keratinocyte carcinoma and diagnose these skin cancers with high 
sensitivity49. At this moment the Dutch skin cancer guidelines are quite vague about the 
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different roles of health care providers (third line versus second line (and dermatologist 
versus [surgical] oncologist) versus first line/general practitioners) during follow-up29-31. 
Future research should evaluate the role and quality of dermatologists and general prac-
titioners in skin cancer diagnosis, treatment and follow-up. In 2013, a relatively small 
faculty of 538 dermatologists and a large faculty of 11,192 general practitioners were 
registered in the Netherlands50. Future research needs to focus on health care capacity 
and costs (available time dermatologists, general practitioners and nurse practitioners). 
Depending on offer and demand, a shift of a part of skin cancer care towards first line 
care might cause loss of income and employment of dermatologists. Such a shift may 
also lead to an improved quality of care and higher patient satisfaction if patients prefer 
to go to the GP and the dermatologist has more time for difficult cases. A high quality 
capacity, quality and cost-effectiveness study of skin cancer care should further investi-
gate this sensitive issue.
In the Skin Cancer Research to Provide Evidence for Effectiveness of Screening in 
Northern Germany SCREEN project (SCREEN), 360,288 inhabitants received at least one 
whole-body examination [participation rate women 27% and men 10%, 75% of screenees 
were women]. The examination was performed by general physicians, the screenee was 
referred to a dermatologist if a suspicious lesion was detected. Screenees were also free 
to consult a dermatologist for initial screening, but only 22.6% used that pathway. The 
study presented evidence that the skin cancer screening program produced a nearly 
50% reduction melanoma mortality in Schleswig-Holstein51,52. However, the fast decline 
in mortality rates could also be caused by increased awareness or diagnostic or treat-
ment effects. The SCREEN project had a substantial impact on melanoma incidence53 
and caused high numbers of excisions in the youngest screenees with an associated low 
yield54. Also a pronounced incidence increase was found for BCC and SCC which might 
improve early detection and treatment and hopefully reduce recurrences and costs, but 
it could not ruled out that screening might increase morbidity and costs (if detected 
lesions would otherwise not have been noticed during patient’s lifetime)55. Worldwide 
no other countries followed the German example of mass screening and the benefit-risk 
ratio of skin cancer screening remains unknown56. The small number of dermatologists 
in the Netherlands and shrinking health care budgets would never allow examination of 
all Dutch inhabitants similar to the German model. I therefore suggest validation studies 
of the previously mentioned risk prediction models to create possible (cost-effective) 
targeted screening strategies.
Information provision in the Netherlands needs a Dutch web-based tool/ a smart-
phone app and skin cancer patient brochure (for older patients) to better inform skin 
cancer survivors about the different aspects of skin cancer (risk of recurrence/second 
primary skin cancer, prognosis at time of diagnosis and during follow-up, monthly skin-
self-examinations and sun protection recommendations). Psychological distress should 
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be evaluated with a short questionnaire (or visual analogue scale) during a follow-up 
visit, if distress is high an educated nurse or general practitioner should be involved 
in distress management. I suggest lifelong annual follow-up visits for patients with >1 
melanoma (in situ), >3 keratinocyte carcinomas or >10 actinic keratosis, because of the 
high level of actinic damage and/or field cancerization. Skin cancer risk reduction (sun 
protection, ban solariums, education material with images of early signs of skin cancer 
vs. advanced skin cancer and benign lesions, skin self-examination instructions and 
awareness campaigns) needs to improve in The Netherlands.
ConCLUsion
The increasing incidence of multiple cutaneous (pre)-malignancies in The Netherlands 
is and remains a large burden for the current health care system and will only increase 
in the future. This thesis contributes to the current knowledge on the occurrence of 
multiple cutaneous malignancies and associated mechanisms of field cancerization 
and overdiagnosis and could therefore be used as material for patient education and 
follow-up strategies. More research is needed in the field of treatment choices and all 
stages of prevention to manage skin cancer optimally. Mechanistic studies investigat-
ing aetiology and genetics are needed to further reduce the burden of multiple skin 
cancers. Cost-effectiveness studies are required to reduce the pressure of skin cancer 
on the Dutch health care system and I suggest further studies investigating the role of 
different health care providers in the first, second and tertiary line in terms of diagnosis, 
treatment and follow-up.
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Summary
Chapter 1 is a general introduction to this thesis. Skin cancer, the most commonly 
occurring cancer in Caucasian populations, includes a large number of types of malig-
nancies deriving from a myriad of different cells. The three most common cutaneous 
malignancies are derived from melanocytes and keratinocytes (ordered in decreasing 
aggressiveness): melanoma, squamous cell carcinoma (SCC) and basal cell carcinoma 
(BCC). This thesis focuses only on these three types of cancer and their precursors. 
The incidence rates of the three most common skin cancers are rising and show large 
variations between countries. The majority of skin cancer patients have a relatively good 
prognosis, which has implications for treatment, follow-up strategies and risks of devel-
oping multiple cutaneous (pre)-malignancies. Important topics like follow-up and early 
detection of skin cancer remain a subject of debate. In this thesis I describe the burden 
of multiple cutaneous malignancies and their consequences for patients, doctors and 
health care systems.
In chapter 2 a systematic review and meta-analysis is performed to investigate risks 
(i.e. proportions, standardized incidence ratios [SIR] and cumulative risks) of develop-
ing a melanoma, basal cell carcinoma (BCC) or squamous cell carcinoma (SCC) after a 
melanoma. Fifty, of 233 fully read articles, met selection criteria. In melanoma patients, 
pooled proportions for a subsequent melanoma, BCC or SCC were respectively 3.8% 
(n=47), 2.8% (n=5) and 1.0% (n=6). The pooled SIRs for a subsequent melanoma, BCC 
or SCC in melanoma patients were respectively 10.4 (n=12), 4.6 (n=2) and 2.8 (n=2). 
Mean 20-year cumulative risks of a subsequent melanoma, BCC or SCC in melanoma 
patients were respectively 5.4% (n=3), 14.0% (n=1) and 4.0% (n=1). Subgroup analyses 
showed substantial differences in reported risks between continents and study design. 
In conclusion, a history of a prior melanoma is a strong predictor for development of 
a subsequent melanoma (approximately 10-fold increased risk) and to a lesser extent 
BCC or SCC. This information could serve as information for health care systems. Further, 
secondary prevention seems pivotal in this patient group.
In chapter 3 a systematic review and meta-analysis is performed to investigate the risk 
(i.e. proportions, cumulative risks or standardized incidence ratios [SIR]) of a subsequent 
basal cell carcinoma (BCC), squamous cell carcinoma (SCC) or melanoma in patients 
with a previous keratinocyte carcinoma (KC; including BCC and SCC). In total, 45 articles 
fulfilled the inclusion criteria. In BCC patients, the pooled proportion for a subsequent 
BCC, SCC or melanoma was respectively 29.2%, 4.3% and 0.5%. The pooled proportion 
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of a subsequent SCC, BCC or melanoma in SCC patients was respectively 13.3%, 15.9% 
and 0.5%. The pooled SIRs for a subsequent BCC, SCC or melanoma were respectively 
17.4, 3.2 and 2.4 in BCC and 4.2, 15.0 and 2.7 in SCC patients. In the subgroup analyses, 
strongest differences in risks were found in the continent strata (risks Australia>North 
America>Europe). A history of a prior KC is a very strong predictor for developing a 
subsequent BCC and SCC and to a lesser extent melanoma. Secondary prevention (early 
detection of subsequent episodes of the disease) is pivotal in patients with a prior KC. 
Patients should be well informed about future risk and require adequate follow-up by 
physicians.
In chapter 4 we estimate risks (cumulative risks, standardized incidence ratio [SIR] and 
absolute excess risk [AER] of developing a second primary in situ or invasive cutaneous 
melanoma after a first melanoma in The Netherlands, between 1989 and 2008. In total, 
10,765 in situ and 46,700 invasive melanoma patients were included (source: Nether-
lands Cancer Registry). Cumulative risks of a second invasive melanoma after a first in 
situ or invasive melanoma at 20 years of follow-up were 6.2% and 5.0%, respectively. 
Relative risk of developing any melanoma (in situ or invasive) after any first melanoma 
(SIR) was 12.4 (invasive after invasive melanoma) to 26.4 (in situ after in situ melanoma) 
fold increased compared to the general population. SIRs and AERs remained elevated up 
to 20 years after the first melanoma. This study shows significantly increased long-term 
risks (both relative and absolute) of developing a second invasive melanoma after a first 
melanoma (invasive and in situ) which might serve as a basis for follow-up guidelines.
Geurts et al estimated, in a commentary, the expected impact of prolonged follow-up 
of patients with a history of invasive melanoma on health care services. They concluded 
that extension of follow-up period will result in overdiagnosis, overtreatment, anxiety in 
patients and a tripled workload for dermatologists. In our rebuttal letter, we agree that 
prolonged follow-up may have negative side effects and associated costs. In our opinion 
the duration and frequency of follow-up visits remain debatable and more research is 
needed to clarify the influence of follow-up visit schemes on melanoma survival and 
quality of life of melanoma survivors.
In chapter 5 we describe the cumulative risk, Standardized Incidence Ratio and Ab-
solute Excess Risk of subsequent different skin cancers in The Netherlands. A total of 
50,510 melanoma patients and 64,054 patients with a squamous cell carcinoma of the 
skin were included (national data Netherlands Cancer Registry). The regional data of the 
Eindhoven Cancer Registry consisted of 5,776 melanoma patients, 5,749 SCC patients 
and 41,485 BCC patients. The 21-year cumulative risk of getting a subsequent melanoma 
after a first SCC or BCC was respectively 1.7% and 1.3% for males and 1.3% and 1.2% 
for females; SCC after melanoma or BCC was 4.6% and 9.3% (males) and 2.6% and 4.1% 
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(females); BCC after melanoma or SCC was respectively 13.2% and 27.8% (males) and 
14.9% and 21.1% (females). SIRs and AERs remained elevated up to 21 years after the 
first melanoma, SCC or BCC. This study shows significantly increased long-term risks of 
developing a subsequent different skin cancer after a first melanoma, SCC or BCC. These 
estimates can serve as a base for follow-up guidelines and patient education.
In chapter 6 we report a commentary on: Exclusive development of a single type of kera-
tinocyte skin cancer: evidence from an Australian population-based cohort study (Keim 
et al). Major strengths of this study are 16 years of follow-up time, a clear case definition 
(i.e., histopathologically confirmed KC), the performed full-body skin examinations 
and detailed information on clinical features. The main limitations of this study were 
the small sample of patients with multiple cutaneous malignancies and the relatively 
young study population (the majority of the included people had not yet reached the 
age in which KC incidence is highest). Investing in large cohort studies and consortia 
might increase the validity of observational findings and should stimulate scientists to 
investigate the underlying mechanisms in detail.
In chapter 7 we estimate trends in melanoma incidence by sex, Breslow thickness (thin 
melanomas subdivided into 4 subgroups: < 0.25 mm, 0.25-0.49 mm, 0.50-0.74 mm, and 
0.75-1.0 mm), age and location, and compare these with trends in subgroups of thicker 
melanomas (source: Netherlands Cancer Registry). Between 1994-2010, 34,156 persons 
were diagnosed with an in situ or thin melanoma. The European standardized rate 
(ESR) of in situ melanomas doubled for males and females with a recent steeper rise in 
incidence (EAPC 12.1% and 12.5%, respectively). ESR for thin melanomas amongst males 
approximately doubled with a steep, but non-significant acceleration compared to other 
thickness categories since 2006 for <0.25 mm melanomas (EAPC 26.3%). For female 
patients with thin melanomas the ESRs increased almost two-fold, except for <0.25 mm 
melanomas. The incidence rates of in situ, thin and thick melanomas increased similarly 
between 1994 and 2010. Recently steep increases were found for in situ melanomas and 
thin melanomas in men. A combination of increased ultraviolet exposure and therefore 
a ‘true’ increase, increased awareness, early detection, diagnostic drift and ‘overdiagno-
sis’ are likely causes for these rises.
In chapter 8 we investigate the prevalence of actinic keratosis (AK), its risk factors and 
association with skin cancer in an elderly population. Within the Rotterdam Study, a 
Dutch population-based cohort study, full body skin examinations were performed 
among 2,061 participants aged 45 years or older. Of these cohort members (mean age 
72 years), 21% had 1 to 3, 9% 4 to 9 and 8% ten or more AK. Prevalence of AK in the 
Rotterdam Study was 49% (95% CI 46%–52%) for men and 28% (26%–31%) for women. 
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Extrapolation suggested that approximately 1.4 of the 16 million Dutch citizens are 
affected with AK. Male sex, older age, light pigmentation status, severe baldness, skin 
wrinkling and high tendency for sunburn were significantly associated with number of 
AKs and extensive actinic damage (≥10 AKs) in the multivariate analyses. Especially bald 
males were at an increased risk of severe actinic skin damage (adjusted OR= 7.0). The 
group with no AKs had a lower positive history for skin cancer (including melanoma, 
SCC or BCC) than the group with 10 or more AKs. The prevalence of AK is very high, 
especially among elderly bald males, and the presence of severe actinic damage signifi-
cantly increases a history of skin cancer. The prevention and management of AK is a true 
challenge for patients, physicians, and health care policy makers.
In chapter 9 we describe conditional survival of melanoma in The Netherlands (source: 
Netherlands Cancer Registry). Conditional survival analysis is performed on patients who 
survived the preceding year(s). To assess prognosis of melanoma survivors according to 
gender and Breslow thickness, conditional five-year relative survival was calculated for 
lymph node negative melanoma patients and conditional one-year relative survival was 
analysed for melanoma patients with and without nodal involvement. Between 1994 
and 2008, 40,050 patients developed a melanoma (stage I-III, of whom 6% with nodal 
involvement). Six to eight years after diagnosis, survival of patients with a 1-2 mm (T2) 
thick melanoma equalized the general population. Conditional five-year relative survival 
for patients with >4mm thick (T4) melanomas increased from about 60% at diagnosis to 
90% at 7 years after diagnosis. Largest improvements were found in patients with thick 
melanomas and female patients with nodal involvement. The prognosis for melanoma 
survivors improved with each additional year of survival after diagnosis, except for pa-
tients with a ≤1mm thick melanoma, who never had any excess mortality during follow-
up. Conditional survival of melanoma was better among females, among those with 
lower Breslow thickness, and nodal stage. Quantitative insight into conditional survival 
is useful for dermatologists, surgeons and oncologists to help planning optimal cancer 
surveillance. It gives a more optimistic message of their future to melanoma survivors 
than the traditional survival rates and could reduce anxiety concerning their melanoma 
diagnosis in the past.
In chapter 10 we compared the survival probabilities of patients with multiple melano-
mas with the survival of patients with only one melanoma. We included data from the 
Netherlands Cancer Registry (NCR) of all patients with a diagnosis of invasive cutaneous 
melanoma between 1994 and 2009; these were followed until 2011. Cox proportional 
Hazard models, with time-varying covariates for multiple melanomas were used to il-
lustrate differences in survival of single melanoma and multiple melanoma patients. We 
showed that patients with multiple melanomas have a 50% worse survival, indicating 
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the importance of surveillance of melanoma patients in order to detect subsequent 
melanomas in early stages.
In chapter 11 the main findings of the studies presented in this thesis are discussed 
and placed into perspective. In addition, study limitations are described and recommen-
dations for future research are given. The increasing incidence of multiple cutaneous 
(pre)-malignancies in The Netherlands is and remains a large burden for the current 
health care system and will only increase in the future. This thesis contributes to the cur-
rent knowledge on the occurrence of multiple cutaneous malignancies and associated 
mechanisms of field cancerization and overdiagnosis and could therefore be used as 
material for patient education and follow-up strategies. More research is needed in the 
field of treatment choices and all stages of prevention to manage skin cancer optimally. 
Mechanistic studies investigating aetiology and genetics are needed to further reduce 
the burden of multiple skin cancers. Cost-effectiveness studies are required to reduce 
the pressure of skin cancer on the Dutch health care system and I suggest further studies 
investigating the role of different health care providers in the first, second and tertiary 
line in terms of diagnosis, treatment and follow-up.
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Samenvatting
hoofdstuk 1 is een algemene inleiding voor dit proefschrift. Huidkanker, de meest voor-
komende vorm van kanker onder de Kaukasische bevolking, omvat een groot aantal 
types maligniteiten en ontwikkelt zich uit diverse verschillende cellen. De drie meest 
voorkomende cutane maligniteiten ontwikkelen zich uit melanocyten en keratinocy-
ten (geordend in afnemende agressiviteit): melanoom, plaveiselcelcarcinoom (PCC) 
en basaalcelcarcinoom (BCC). Dit proefschrift focust zich alleen op deze vormen van 
kanker en hun voorlopers. De incidentie van de drie meest voorkomende huidkankers 
zijn nog steeds stijgende en per land bestaan er grote verschillen. De meerderheid van 
huidkankerpatiënten kent een relatief goede prognose en dit heeft daarom implicaties 
voor de behandeling, follow-up strategieën en risico’s op het ontwikkelen van multipele 
cutane (pre)-maligniteiten. Belangrijke onderwerpen zoals follow-up en vroegdetectie 
van huidkanker blijven een onderwerp van debat. In dit proefschrift beschrijf ik de 
impact van multipele cutane maligniteiten en de consequenties voor patiënten, artsen 
en het zorgstelsel.
In hoofdstuk 2 beschrijven we een systematische review met meta-analyse waarin de 
risico’s (proporties, gestandaardiseerde incidentie ratio’s [SIR] en cumulatieve risico’s) op 
het krijgen van een melanoom, basaalcelcarcinoom (BCC) of plaveiselcelcarcinoom (PCC) 
worden beschreven bij patiënten die eerder werden gediagnosticeerd met een mela-
noom. In totaal werden 50 van de 233 gelezen artikelen geïncludeerd. Voor melanoom-
patiënten was de ‘gepoolde’ proportie voor het krijgen van een nieuw melanoom, BCC 
of PCC, respectievelijk 3,8% (n=47); 2,8% (n=5) en 1,0% (n=6). De ‘gepoolde’ SIR voor het 
krijgen van een melanoom, BCC of PCC voor patiënten die eerder een melanoom hadden 
was achtereenvolgend 10,4 (n=12); 4,6 (n=2) en 2,8 (n=2). Bij melanoompatiënten was 
het gemiddelde 20-jaars cumulatieve risico op een nieuw melanoom, BCC of PCC respec-
tievelijk 5,4% (n=3); 14,0% (n=1) en 4,0% (n=1). Subgroep analyses toonden substantiële 
verschillen in de risico’s wanneer continenten en onderzoeksopzet werden vergeleken. 
Concluderend, een voorgeschiedenis met een melanoom geeft een hoog risico op het 
ontwikkelen van een opvolgend melanoom (ongeveer tienvoudig hoger risico), en in min-
dere mate op een opvolgend BCC of PCC. Secundaire preventie lijkt dus van groot belang 
te zijn bij deze patiëntengroep. Deze informatie kan gebruikt worden voor zorgstelsels.
In hoofdstuk 3 beschrijven we een systematische review met meta-analyse waarin de 
risico’s (proporties, gestandaardiseerde incidentie ratio’s [SIR] en cumulatieve risico’s) 
op het krijgen van een basaalcelcarcinoom (BCC), plaveiselcelcarcinoom (PCC) of me-
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lanoom worden beschreven bij patiënten die eerder werden gediagnosticeerd met 
een keratinocyt carcinoom (KC, inclusief BCC en PCC). In totaal werden 45 artikelen 
geïncludeerd. Voor BCC patiënten was de ‘gepoolde’ proportie voor het krijgen van 
een nieuw BCC, PCC of melanoom, respectievelijk 29,2%; 4,3% en 0,5%. De ‘gepoolde’ 
proportie voor het krijgen van een PCC, BCC of melanoom bij patiënten met een PCC 
in de voorgeschiedenis was achtereenvolgend 13,3%; 15,9% en 0,5%. De ‘gepoolde’ SIR 
voor het krijgen van een BCC, PCC of melanoom was 17,4; 3,2 en 2,4 voor patiënten die 
eerder een BCC hadden en 4,2; 15,0 en 2,7 voor patiënten die eerder een PCC hadden. 
In de subgroep analyses werden de grootste verschillen gevonden tussen de verschil-
lende continenten (risico’s Australië> Noord-Amerika>Europa). Concluderend, een 
voorgeschiedenis met een BCC of PCC geeft een hoog risico op het ontwikkelen van 
een opvolgend BCC of PCC, en in mindere mate op melanoom. Secundaire preventie 
(vroegdetectie van opvolgende episodes van de ziekte) lijkt dus van groot belang te zijn 
bij deze patiëntengroep. Zij dienen goed geïnformeerd te worden over hun toekomstig 
risico op meerdere huidtumoren.
In hoofdstuk 4 onderzoeken wij risico’s (cumulatieve risico’s, gestandaardiseerde inci-
dentie ratio’s [SIR] en absolute excess risico’s [AER]) op het ontwikkelen van een tweede 
primaire in situ of invasief cutaan melanoom bij Nederlandse melanoompatiënten 
tussen 1989 en 2008. In totaal werden er 10.765 in situ and 46.700 invasieve melanoom-
patiënten geincludeerd (bron: Nederlandse Kanker Registratie). Bij patiënten met een 
in situ of invasief melanoom was het 20-jaars cumulatieve risico op een tweede invasief 
melanoom respectievelijk 6,2% en 5,0%. Het relatieve risico (SIR) van het ontwikkelen 
van een melanoom na een melanoom was 12 tot 26 keer verhoogd ten opzichte van 
de algehele bevolking. Tot 20 jaar na het eerste melanoom bleven de SIR’s en AER’s 
verhoogd. Deze studie laat langdurig verhoogde risico’s zien op het ontwikkelen van 
een tweede melanoom na een eerste melanoom. Deze risico’s kunnen gebruikt worden 
als informatie voor follow-up richtlijnen.
Geurts et al beschreven in een commentaar wat de te verwachten impact op het zorg-
stelsel zou zijn van langdurige follow-up van melanoompatiënten. Zij concludeerden 
dat verlenging van follow-up zal resulteren in overdiagnose, overbehandeling, angst bij 
patiënten en een verdrievoudigde werklast voor dermatologen. In onze reactie geven 
wij aan dat wij het eens zijn met eventuele negatieve uitwerkingen van verlengde 
follow-up en de geassocieerde kosten. Wij zijn van mening dat de duur en frequentie 
van follow-up bezoeken nog steeds betwistbaar is en dat er meer onderzoek nodig is 
om te verhelderen wat de invloed van verscheidene follow-up schema’s is op de over-
leving van melanoompatiënten en de kwaliteit van leven van melanoompatiënten die 
nog in leven zijn.
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In hoofdstuk 5 onderzoeken wij risico’s (cumulatieve risico’s, gestandaardiseerde 
incidentie ratio’s [SIR] en absolute excess risico’s [AER]) op het ontwikkelen van een 
ander type huidkanker na een eerste huidkanker tussen 1989 en 2009. In totaal werden 
50.510 melanoom patiënten en 64.054 patiënten met een plaveiselcelcarcinoom (PCC) 
geïncludeerd (landelijke data Nederlands Kanker Registratie). De regionale data van 
de Eindhoven Kanker Registratie bestond uit 5.776 melanoom patiënten, 5.749 PCC 
patiënten en 41.485 basaalcelcarcinoom (BCC) patiënten. Bij patiënten met een eerste 
PCC of BCC waren de 21-jaars cumulatieve risico’s op een opvolgend invasief melanoom 
respectievelijk 1,7% en 1,3% voor mannen en 1,3% en 1,2% voor vrouwen; PCC na me-
lanoom of BCC: 4,6% en 9,3% (mannen) en 2,6% en 4,1% (vrouwen); BCC na melanoom 
of PCC: respectievelijk 13,2% en 27,8% (mannen) en 14,9% en 21,1% (vrouwen). SIR’s 
en AER’s bleven verhoogd tot 21 jaar na het eerste melanoom, PCC of BCC. Deze studie 
toont langdurige significant verhoogde risico’s op het ontwikkelen van een opvolgende 
ander type huidkanker na een eerste melanoom, PCC of BCC. Deze waarden kunnen 
gebruikt worden voor follow-up richtlijnen en patiënteneducatie.
In hoofdstuk 6 rapporteren wij een commentaar op een artikel van Keim et al over het 
ontwikkelen van multipele huidkankers van een type. De kracht van deze studie is de 16 
jaar aan follow-up tijd, een heldere definitie van de ziektegevallen (histopathologisch 
bevestigde keratinocyte carcinomen, de verrichte volledige huidinspecties en de ge-
detailleerde informatie over de klinische kenmerken van de patiënten. De belangrijkste 
beperkingen van de studie zijn de kleine aantallen patiënten met multipele cutane 
maligniteiten en de relatief jonge studie populatie (de meerderheid van de geïnclu-
deerde patiënten had nog niet de leeftijd bereikt waarop de incidentie van keratinocyt 
carcinomen het hoogst is). Investeringen in grote cohort studies en consortia kan de 
validiteit van observationele bevindingen vergroten en zou wetenschappers moeten 
stimuleren om de onderliggende mechanismen in detail te onderzoeken.
In hoofdstuk 7 onderzoeken wij incidentietrends van dunne melanomen in Nederland 
waarbij wij stratificeren voor geslacht, Breslow dikte (dunne melanomen onderverdeeld 
in 4 subgroepen: < 0,25 mm, 0,25-0,49 mm, 0,50-0,74 mm, and 0,75-1,0 mm), leeftijd 
en locatie en deze trends vergelijken met subgroepen van dikkere melanomen (bron: 
Nederlands Kanker Registratie). Tussen 1994 en 2010 werden er 34.156 mensen gediag-
nosticeerd met een in situ of dun melanoom. De naar de Europese standaardbevolking 
gestandaardiseerde incidentiecijfers (ESR) van in situ melanomen verdubbelden voor 
mannen en vrouwen met een recente steilere stijging in incidentie (de EAPC, de ge-
schatte jaarlijkse procentuele verandering van het incidentiecijfer berekend op basis 
van jaarlijkse incidentiecijfers in de desbetreffende periode, was respectievelijk 12,1% 
en 12,5%). De ESR voor dunne melanomen bij mannen verdubbelde en toonde sinds 
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2006 een niet-significante (vergeleken met andere Breslow dikte categoriën) steile ac-
celeratie voor melanomen dunner dan 0.25 mm (EAPC 26,3%). Voor vrouwen met dunne 
melanomen verdubbelden de ESR’s bijna, behalve voor de melanomen dunner dan 0,25 
mm. De incidenctiecijfers van in situ, dunne en dike melanomen stegen ongeveer gelijk 
tussen 1994 en 2010. Recent namen de incidentiecijfers van in situ melanomen en dunne 
melanomen bij mannen sterk toe. Een combinatie van verhoogde ultraviolet blootstel-
ling (en dus een ‘echte’ stijging), een verhoogd bewustzijn, vroegdetectie, diagnostische 
drift en ‘overdiagnose’ zijn mogelijke oorzaken van deze stijgingen.
In hoofdstuk 8 onderzoeken wij binnen een oudere populatie de prevalentie van ac-
tinische keratoses (AK’s), de hiermee geassocieerde risicofactoren en de associatie met 
huidkanker. Bij 2061 deelnemers van 45 jaar en ouder (gemiddelde leeftijd 72 jaar) van 
de Rotterdam Study werd een volledig huidonderzoek uitgevoerd. Hiervan bleek 21% 
1 tot en met 3 AK’s te hebben, 9% 4 tot en met 9 en 8% 10 of meer. De AK prevalentie 
binnen de Rotterdam Study was 49% (95%BI 46%-52%) voor mannen en 28% (26%-31%) 
voor vrouwen. Extrapolatie van deze data toonde aan dat bijna 1.4 van de 16 miljoen 
Nederlanders AK heeft. Mannen, oudere leeftijd, lichte pigmentatie status, kaalheid, 
rimpels in het gezicht en gevoeligheid voor zonnebrand waren allen significant geas-
socieerd met ernstige actinische schade (≥10 AK’s) in de multivariate analyses. Vooral 
kale mannen hadden een verhoogd risico op ernstige actinische schade (aangepaste 
odds ratio = 7,0 [3,8-13,1]). De groep deelnemers zonder AK’s hadden minder vaak een 
voorgeschiedenis met een BCC, PCC of melanoom vergeleken met de groep deelnemers 
met tien of meer AK’s. Concluderend kan er gezegd worden dat de prevalentie van AK’s 
erg hoog is, vooral bij oudere kale mannen, en dat de aanwezigheid van ernstige acti-
nische schade het risico op een huidkanker voorgeschiedenis verhoogd. De preventie 
en het management van AK’s is en zal een uitdaging worden voor patiënten, artsen en 
gezondheidszorg medewerkers.
In hoofdstuk 9 beschrijven wij de conditionele overleving van melanoom in Nederland 
(bron: Nederlandse Kanker Registratie). Conditionele overlevingsanalyse bepaalt de 
overleving van patiënten met een melanoom, naarmate zij langer leven na de diagnose. 
Alle patiënten die in de periode 1994-2008 de diagnose ‘invasief melanoom’ kregen, 
werden geïncludeerd. De prognose van melanoompatiënten werd berekend voor elk 
extra overleefd jaar na de diagnose, in de vorm van een conditionele relatieve 1- en 
5-jaarsoverleving (de laatste alleen voor lymfekliernegatieve patiënten). Er werd uitge-
splitst naar geslacht en Breslow-dikte. In de periode 1994-2008 werden 40.050 patiënten 
gediagnosticeerd met een melanoom (stadium I-III, 6% met lymfekliermetastasen). De 
overleving voor patiënten met een melanoom met een Breslow-dikte van ≤ 1,0 mm 
(T1) was op het moment van diagnose en gedurende de gehele follow-upperiode gelijk 
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aan die in de algehele bevolking. Zes tot acht jaar na diagnose werd de conditionele 
5-jaarsoverleving van patiënten met een 1-2 mm dik melanoom (T2) ongeveer gelijk 
aan die van de algehele bevolking. Hoewel de conditionele relatieve 5-jaarsoverleving 
van patiënten met een melanoom > 4 mm dik (T4) steeg van ongeveer 60% bij diagnose 
naar 90% na 7 jaar, bleef een oversterfte van ongeveer 10% bestaan. Naarmate de pati-
enten langer overleefden, werd de prognose van de Nederlandse melanoompatiënten 
beter, vooral bij lymfeklierpositieve vrouwen en patiënten met een dik melanoom. Bij 
patiënten met een T1-melanoom bleef de overleving vanaf diagnose gelijk aan die in de 
algehele bevolking. Deze cijfers geven een optimistischere en werkelijkheidsgetrouwere 
boodschap aan patiënten met een melanoom dan de traditionele relatieve overlevings-
cijfers, waardoor patiënten die overleven na de diagnose ‘melanoom’ misschien minder 
angst en praktische problemen ervaren.
In hoofdstuk 10 onderzoeken we de overleving van patiënten met multipele melano-
men in Nederland (bron: Nederlands Kanker Registratie). Wanneer er rekening wordt 
gehouden met de tijd tussen de melanomen in een Cox Proportional Hazards model 
in de vorm van een tijdsafhankelijke variabele dan wordt de hazard ratio van multi-
pele versus een enkel melanoom 50% hoger. Deze studie toont de complexiciteit van 
overlevingsanalyses van multipele kankers en illustreert het belang van surveillance bij 
patiënten met een melanoom om nieuwe melanomen vroegtijdig te ontdekken.
In hoofdstuk 11 worden de belangrijkste bevindingen van dit proefschrift besproken 
en in perspectief geplaatst. Daarnaast worden studie beperkingen beschreven en sug-
gesties voor toekomstig onderzoek gegeven. De stijgende incidentie van multipele 
cutane (pre)-maligniteiten is en zal een uitdaging worden voor het huidige zorgstelsel. 
Dit proefschrift draagt bij aan de huidige kennis over het voorkomen van multipele 
cutane maligniteiten en de geassocieerde mechanismen van veld transformatie tot kan-
ker en overdiagnose. Deze gegevens kunnen gebruikt worden voor patiënteneducatie 
en follow-up strategieën. Er is meer onderzoek nodig in het veld van behandelings-
keuzes en alle stadia van preventie om het steeds omvangrijkere maatschappelijke 
gezondheidsprobleem huidkanker aan te kunnen. Bovendien zijn er mechanistische 
studies nodig die de etiologie en genetica onderzoeken om de impact van multipele 
huidkankers verder te verminderen. Kosteneffectiviteitsanalyses zijn nodig om de druk 
van huidkanker op het Nederlandse zorgstelsel te verminderen en toekomstige studies 
zouden de rol van verschillende zorgverleners in de eerste, tweede en derde lijn moeten 
onderzoeken op het vlak van diagnose, behandeling en follow-up.
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List of abbreviations
AER absolute excess risk
AJCC American Joint Committee on Cancer
AK actinic keratosis
ALM acrolentiginous melanoma
BCC basal cell carcinoma
CI confidence interval
CR cumulative risk
CRS conditional relative survival
EAPC estimated annual percentage change
ECR Eindhoven Cancer Registry
ERGO Het Erasmus Rotterdam Gezondheid Onderzoek
ESR European standardized rate
F females
FBSE full body skin examination
HR hazard ratio
ICD-O International Classification of Diseases for Oncology
IQR interquartile range
KC keratinocyte carcinoma
LM lentigo maligna
M males
Mel melanoma
MMS Mohs’ micrographic surgery
N number
N+ nodal involvement
N0 no nodal involvement
NA not applicable
NCR Netherlands Cancer Registry
NM nodular melanoma
NMSC non-melanoma skin cancer
NOS Newcastle – Ottowa score
OR odds ratio
Ref reference group
RS Rotterdam Study
SCC squamous cell carcinoma
SD standard deviation
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SIR standardised incidence ratio
SN Sentinel Node
SSE skin self-examination
SSM superficial spreading melanoma
TNM tumor lymph node metastasis
USA United States of America
UV ultraviolet
WSR world standardized rate
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1ab Lentigo maligna / Melanoma in situ
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b
2a Melanoma in situ (6) 2b Dysplastic nevi (8, 9, 10 and 11)
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3 Superficial spreading melanoma (T1)
 
  
 
  
4 Nodular melanoma (T3)
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5 Acral melanoma (T3)
 
  
 
 
 
 
 
 
  
6ab Amelanotic nodular melanoma (T3)
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  7 Actinic Keratosis
 
  
8 Multiple Actinic Keratoses, ‘Field cancerization’
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9 Morbus Bowen, Squamous Cell Carcinoma in situ
   
10 ‘Cornu cutaneum’: Squamous Cell Carcinoma, 
well differentiated
11 Squamous Cell Carcinoma, moderately 
differentiated
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12 Squamous Cell Carcinoma, poorly differentiated
 
13 Superficial Basal Cell Carcinoma
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14 Nodular Basal Cell Carcinoma
 
15 Two synchronous Nodular Basal Cell Carcinoma
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16 Infiltrative Basal Cell Carcinoma treated with Mohs' Micrographic Surgery and a glabellar flap.
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